Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 447043 |
| CHEMBL ID | 529 |
| CHEBI ID | 2955 |
| SCHEMBL ID | 23481 |
| MeSH ID | M0027130 |
| Synonym |
|---|
| smr000471864 |
| MLS001066331 |
| AC-16014 |
| BIDD:GT0792 |
| AB00698251-10 |
| KBIO1_000233 |
| DIVK1C_000233 |
| zitromax avium 600 |
| sumamed |
| zmax sr |
| cp-62993-3 |
| zentavion |
| dch3 |
| xz-450 |
| zmax |
| zitromax |
| zithromac |
| SPECTRUM_000307 |
| SPECTRUM5_001867 |
| IDI1_000233 |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6 |
| zithromycin |
| AZM , |
| [2r-(2r*,3s*,4r*,5r*,8r*,10r*,11r*,12s*,13s*,14r*)]-13-[(2,6-dideoxy-3-c-methyl-3-o-methyl-.alpha.-l-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6- |
| cp-62993 |
| zithromax |
| cp62,993 |
| nsc643732 |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)13-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadec |
| MLS001332499 |
| CHEBI:2955 , |
| azitromicina |
| azifast |
| azitromin |
| MLS001332500 |
| azithromycine |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyr |
| azithromycinum |
| azigram |
| azimakrol |
| ZIT , |
| azithromycin (aids initiative) |
| NCGC00090753-01 |
| MLS001055353 |
| azenil |
| c38h72n2o12 |
| aziwok |
| ccris 1961 |
| 1-oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-, (2r-(2r*,3s*,4r*,5r*,8r |
| zithromax iv |
| azithromycin (anhydrous) |
| hemomycin |
| zitrim |
| hsdb 7205 |
| zmas |
| zeto |
| azasite |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-13-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentade |
| azithromycinum [latin] |
| aztrin |
| tobil |
| zifin |
| z-pak |
| azithromycine [french] |
| drg-0104 |
| 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
| zithrax |
| brn 5387583 |
| setron |
| zitrotek |
| azitrocin |
| aritromicina [spanish] |
| mixoterin |
| azithromycin |
| DB00207 |
| cp 62993 |
| azithromycin [usan:inn:ban] |
| cp-62,993 |
| KBIO3_001505 |
| KBIO2_000787 |
| KBIO2_005923 |
| KBIOGR_000731 |
| KBIOSS_000787 |
| KBIO2_003355 |
| SPECTRUM3_000653 |
| SPECTRUM2_001582 |
| NINDS_000233 |
| SPBIO_001544 |
| SPECTRUM4_000186 |
| SPECTRUM1503679 |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-d-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-c-methyl-3-o-methyl-a-l-ribo-hexopyranoside |
| BSPBIO_002285 |
| NCGC00090753-02 |
| MLS001304005 |
| MLS001201763 |
| HMS2094M11 |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-o |
| durasite |
| xz 450 |
| CHEMBL529 |
| aruzilina |
| azithromycin anhydrous |
| zythromax |
| macrozit |
| xithrone |
| azithrocin |
| aziwin |
| xz 405 |
| nsc-758625 |
| aziromycin |
| trozocina |
| anhydrous azithromycin |
| HMS500L15 |
| HMS1922G12 |
| NCGC00090753-03 |
| NCGC00090753-04 |
| HMS3259D10 |
| azitromicine |
| z-pak (azithromycin) |
| ec 617-500-5 |
| unii-j2klz20u1m |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-((2s,3r,4s,6r)- |
| 1-oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-, (2r,3s,4r,5r,8r,10r,11r |
| trulimax |
| nsc 758625 |
| j2klz20u1m , |
| NCGC00258564-01 |
| tox21_201011 |
| dtxsid8030760 , |
| cas-83905-01-5 |
| tox21_111008 |
| dtxcid6010760 |
| azithramycine |
| aritromicina |
| HMS2232M10 |
| CCG-39360 |
| bdbm50373918 |
| n-methyl-11-aza-10-deoxo-10-dihydroerythromycin a |
| azithromycin [inn] |
| azithromycin [hsdb] |
| azithromycin [usp monograph] |
| azithromycin [who-dd] |
| azithromycin [mi] |
| AKOS015895044 |
| N46072 |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one |
| gtpl6510 |
| HY-17506 |
| NC00712 |
| SCHEMBL23481 |
| azithromycin, antibiotic for culture media use only |
| A-9940 |
| azyter |
| 13-[(2,6-dideoxy-3-c-methyl-3-o-methyl-?-l-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-d-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-2-ethyl-3,4,10-trihydroxy-13-((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yloxy)-3,5,6,8,10,12,14-heptamethy... |
| AB00698251_11 |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan- |
| A-9941 |
| azithromycin, analytical standard |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-(((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-2-ethyl-3,4,10-trihydroxy-13-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptameth |
| azithromycin identity, united states pharmacopeia (usp) reference standard |
| sr-05000002067 |
| SR-05000002067-1 |
| SR-05000002067-2 |
| azithromycin, european pharmacopoeia (ep) reference standard |
| azithromycin for peak identification, european pharmacopoeia (ep) reference standard |
| azithromycin for system suitability, european pharmacopoeia (ep) reference standard |
| SBI-0206706.P001 |
| F94OW58Y8V , |
| azithromycin, unspecified hydration |
| azitromicina [spanish] |
| 13-[(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one |
| HB4336 |
| Z1558483766 |
| azithromycin (zithromax) |
| azithromycin,(s) |
| Q165399 |
| BRD-K74501079-001-18-1 |
| NCGC00090753-06 |
| A905251 |
| 13-[(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one |
| n-methyl-11-aza-10-deoxy-10-dihydroerythromycin a |
| (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-13- |
| s01aa26 |
| 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin a |
| j01fa10 |
| azithromycinum (latin) |
| azithromycin (usp monograph) |
| Excerpt | Relevance | Reference |
|---|---|---|
| "The chemistry, mechanism of action, antimicrobial spectrum, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of clarithromycin and azithromycin are described." | ( Clarithromycin and azithromycin: new macrolide antibiotics. Danziger, LH; Piscitelli, SC; Rodvold, KA, 1992) | 0.28 |
| " Trials were assessed by sample size, macrolide dosage regimen, and therapeutic response." | ( The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Bahal, N; Nahata, MC, 1992) | 0.28 |
| " The high tissue-to-serum level and extended elimination half-life of azithromycin allow for once-daily dosing and short-course therapy." | ( The new macrolide antibiotics. Azithromycin and clarithromycin. Havlichek, DH; Stein, GE, 1992) | 0.28 |
| " These properties allow novel dosing schemes for azithromycin, because a five-day course will provide therapeutic tissue concentrations for at least ten days." | ( Azithromycin and clarithromycin: overview and comparison with erythromycin. Tunkel, AR; Whitman, MS, 1992) | 0.28 |
| " Blood samples were drawn for AZM measurement over 72 and 360 h on the first and fifth AZM administrations, respectively, as well as before and 3 h after dosing on the second, third, and fourth AZM dosings." | ( Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Biollaz, J; Chatton, JY; Chave, JP; Dayer, P; Glauser, MP; Munafo, A, 1992) | 0.28 |
| " Oral drug administration was initiated 4 h after infection by various dosage regimens." | ( Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1992) | 0.28 |
| " However, the prolonged half-life and enhanced tissue penetration of azithromycin should allow for less frequent dosing and shorter duration of therapy than with erythromycin or clarithromycin." | ( In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Hammerschlag, MR; Qumei, KK; Roblin, PM, 1992) | 0.28 |
| "To discuss the chemistry, mechanism of action, spectrum of activity, pharmacokinetics, clinical trials, adverse-effect profile, drug interactions, and dosage guidelines of azithromycin, the first azalide antibiotic." | ( Azithromycin: the first azalide antibiotic. Amsden, GW; Ballow, CH, 1992) | 0.28 |
| " Azithromycin possesses key pharmacokinetic properties that are prerequisites for a convenient once-daily dosage schedule which may improve patient compliance." | ( Azithromycin pharmacokinetics and penetration to lymph. Bergan, T; Jørgensen, NP; Olszewski, W; Zhang, Y, 1992) | 0.28 |
| " In comparison to other new macrolides, azithromycin achieves higher tissue and intracellular concentrations and these concentrations are sustained for several days after dosing due to a long elimination half-life." | ( Azithromycin in lower respiratory tract infections. Lode, H; Schaberg, T, 1992) | 0.28 |
| " Although azithromycin has been shown to be effective in the treatment of erythema migrans, further studies will be needed to determine the optimal dosage and duration of therapy." | ( Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. Cimperman, J; Ruzic, E; Strle, F, 1992) | 0.28 |
| " or once daily dosage regimens, good intracellular and tissue penetration, better activity against gram-negative microorganisms (some) and a low rate of adverse reactions." | ( Clinical use of the new macrolides, azalides, and streptogramins in pediatrics. Adam, D, 1992) | 0.28 |
| " These pharmacokinetic properties imply that the dosing period for azithromycin can be greatly reduced while still achieving high antimicrobial activity at sites of infection." | ( Azithromycin in the treatment of uncomplicated genital chlamydial infections. Stamm, WE, 1991) | 0.28 |
| " Erythromycin's short half-life means that a four-times daily dosage schedule is required for effective treatment." | ( The pharmacokinetics of azithromycin and their clinical significance. Lode, H, 1991) | 0.28 |
| " Tissue concentrations were higher after multiple dosing and became greater as the dose was increased from 10 to 40 mg/kg." | ( Pharmacokinetics of azithromycin in rats and dogs. Falkner, FC; Shepard, RM, 1990) | 0.28 |
| " The high tissue concentrations suggest that proposed standard dosage regimens of 500 mg qds on day 1 followed by 250 mg qds for four days, or three daily dosages of 500 mg, will produce tissue concentrations above 3 mg/kg in a variety of tissues." | ( The pharmacokinetics of azithromycin in human serum and tissues. Foulds, G; Johnson, RB; Shepard, RM, 1990) | 0.28 |
| " Dosing with azithromycin eradicated Haemophilus influenzae from the bulla (middle ear) of gerbils, as was not the case with erythromycin and roxithromycin." | ( Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo. Girard, AE; Girard, D; Milisen, WB; Retsema, JA, 1990) | 0.28 |
| " influenzae with the drug dosage used in this study." | ( Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study. Davies, BI; Gubbelmans, R; Maesen, FP, 1989) | 0.28 |
| " Azithromycin was more potent than the other macrolides in experimental animal infection, eradicating the organism in all animals tested at a dosage of 8 mg/kg." | ( Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. Gross, B; Preac-Mursic, V; Schierz, G; Süss, E; Wilske, B, 1989) | 0.28 |
| " The drug dosage regimen used in this study should lead to tissue drug concentrations exceeding the MICs for common pathogens." | ( Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Foulds, G; Koranyi, KI; Luke, DR; Nahata, MC, 1995) | 0.29 |
| " A dosage of 15 mg/kg/day azithromycin was administered to rabbits with 24 h or 2 week old infected tissue cages and to uninfected controls." | ( Azithromycin in an experimental Staphylococcus aureus abscess model. Bamberger, DM; Herndon, BL; Suvarna, PR, 1995) | 0.29 |
| " Urine from mice dosed with up to 200 mg/kg of azithromycin also had no effect on the number of revertants in these same strains suggesting the absence of mutagenic excretory products following oral exposure." | ( Preclinical toxicology studies with azithromycin: genetic toxicology evaluation. Amacher, DE; Ellis, JH; Holden, HE; Joyce, AJ; Muehlbauer, PA; Ray, VA; Turner, GN; Wahrenburg, MG, 1993) | 0.29 |
| "Pharmacodynamic parameters have become increasingly important for the determination of the optimal dosing schedules of antibiotics." | ( Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Cars, O; Löwdin, E; Odenholt-Tornqvist, I, 1995) | 0.29 |
| "When macrolide antibiotics are administered according to the standard therapeutic regimens, the highest plasma concentrations of total drug, both during the first dosage interval and at steady state, are obtained with roxithromycin, followed by clarithromycin and azithromycin." | ( Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin. Nilsen, OG, 1995) | 0.29 |
| " This dosing convenience is an important consideration for the clinician; as shown by Nelson, patient compliance ranges from 95% with once-daily dosing to 58% with four-times-a-day dosing." | ( Azithromycin and clarithromycin. Schlossberg, D, 1995) | 0.29 |
| " Mice were dosed orally, commencing at 7 days after infection, with minocycline, doxycycline, or amoxicillin-clavulanate." | ( Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid, or azithromycin. Beale, AS; Upshon, PA, 1994) | 0.29 |
| " Azithromycin shows promise as an alternative agent for treatment of early syphilis; controlled trials and assessment of other dosage regimens are indicated." | ( Pilot study of azithromycin for treatment of primary and secondary syphilis. Handsfield, HH; Johnson, RB; Verdon, MS, 1994) | 0.29 |
| "-azithromycin dosage regime (83%) (95% CI = 52-98%) compared to the 250-mg-b." | ( Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. al-Assi, MT; Cole, RA; Genta, RM; Graham, DY; Karttunen, TJ, 1995) | 0.29 |
| " Azithromicin was administered at the increasing dosage of 100-200-300 and 400 mg every 2 days." | ( [Safety of azithromycin in patients allergic to penicillin and cephalosporin]. Biasi, D; Lunardi, C; Maleknia, T; Pacor, ML, 1994) | 0.29 |
| "025), so the dosage was lowered to 250 mg four times a day to complete the course." | ( Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Bush, MR; Rosa, C, 1994) | 0.29 |
| " This pilot study suggests that the combination of pyrimethamine and azithromycin may be further investigated and that the optimal dosage of azithromycin has yet to be determined." | ( Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Hazebroucq, V; Joly, V; Leport, C; Morlat, P; Raffi, F; Saba, J; Vildé, JL, 1993) | 0.29 |
| " The mean lung azithromycin concentration in infected animals was significantly higher than that in controls 48 h after dosing (12." | ( Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. Edelstein, MA; Edelstein, PH; Stamler, DA, 1994) | 0.29 |
| " Clinical and bacteriological efficacy, excellent tolerability, simplified dosage (single daily dose) and short-course (3 days) therapeutic regimen make azithromycin, in our experience, efficacious for the treatment of acute exacerbation of chronic bronchitis and community-acquired pneumonia." | ( Clinical efficacy of azithromycin in lower respiratory tract infections. Carnimeo, NS; Foschino, MP; Miragliotta, G; Morandini, G; Perduca, M; Zannini, G, 1993) | 0.29 |
| " The treatment-related differences seen in the plasma concentrations were as expected from the different dosage schedules." | ( Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine. Laufen, H; Leitold, M; Wildfeuer, A; Zimmermann, T, 1993) | 0.29 |
| " Therefore, no dosage modifications of azithromycin seem to be required for patients with class A or B liver cirrhosis." | ( Pharmacokinetics of azithromycin in patients with impaired hepatic function. Carlà, V; Crispo, A; Fallani, S; Mazzei, T; Novelli, A; Periti, P; Surrenti, C; Surrenti, E, 1993) | 0.29 |
| " Azithromycin (10 mg/kg/day) was administered as a single dose for three days and co-amoxiclav was given tid for ten days at a dosage according to the manufacturer's instructions for the country." | ( Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. Daniel, RR, 1993) | 0.29 |
| " The dosage schedule for azithromycin was 10 mg/kg/day, in a single daily dose, administered for three days." | ( Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children. Schaad, UB, 1993) | 0.29 |
| " Plasma protein binding is low, less than 50% at plasma concentrations obtained with the usual dosage regimen." | ( [Clinical pharmacokinetics of azithromycin]. Singlas, E, 1995) | 0.29 |
| " Different animal models allow to demonstrate the curative activity of the azithromycin administered as a single dose, at dosage regimen equivalent to those used in man, and a prophylactic activity on the salpingitis onset in provoked Chl." | ( [Azithromycin and genital infections]. Micoud, M; Pépin, LF, 1995) | 0.29 |
| " Equal clinical efficacy and tolerability were observed with the 3- and 5-day dosage regimen." | ( Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Culig, J; Kuzman, I; Schönwald, S; Soldo, I, 1995) | 0.29 |
| " Patients who received azithromycin also received a dummy placebo so that the dosing schedules were identical." | ( Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Bosler, EM; Dattwyler, RJ; Gadgil, SD; Grunwaldt, E; Johnson, RC; Luft, BJ; Luger, SW; Masters, EJ; Rahn, DW, 1996) | 0.29 |
| "Patients with histologically confirmed donovanosis were randomised to receive one of two open-label azithromycin dosage regimens: Regimen A--1." | ( Pilot study of azithromycin in the treatment of genital donovanosis. Bastian, I; Bowden, FJ; Mein, J; Plunkett, C, 1996) | 0.29 |
| " Thus the dosage regimen of azithromycin in renal impairment may (and should) be the same as in patients with normal renal function." | ( Pharmacokinetics of azithromycin in normal and impaired renal function. Höffler, D; Koeppe, P; Paeske, B, ) | 0.13 |
| " High tissue concentrations are maintained for prolonged periods because of azithromycin's long half-life, leading to once-daily dosing for 3 or 5 days." | ( Azithromycin--review of key chemical, pharmacokinetic and microbiological features. Borner, K; Koeppe, P; Lode, H; Schaberg, T, 1996) | 0.29 |
| " However, when the compound was given during a period of inflammation, considerably higher drug concentrations were found in infected sites than in non-infected sites at 5-24 h after dosing (0." | ( Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. Cimochowski, CR; Faiella, JA; Girard, AE, 1996) | 0.29 |
| " Thus, azithromycin tablets, suspension and sachet may be given without regard to meals, further enhancing the convenience of once-daily, short-duration dosing regimens." | ( The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. Curatolo, WJ; Foulds, G; Friedman, H; Luke, DR; Teng, R; Willavize, SA, 1996) | 0.29 |
| " Children (6 months-16 years of age) had been treated with an oral suspension of azithromycin (10 mg/kg given once daily for 3 consecutive days) or with the approved oral dosing regimen of the comparator (amoxycillin, co-amoxiclav, cefixime, cefaclor, clarithromycin, erythromycin, penicillin V, cloxacillin, or roxithromycin)." | ( Paediatric safety of azithromycin: worldwide experience. Pontani, D; Treadway, G, 1996) | 0.29 |
| " As a result of its pharmacokinetic profile azithromycin is unique among these alternative antimicrobials in allowing once daily dosing and shorter duration of treatment." | ( Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group. Heynen, G; Schaad, UB, 1996) | 0.29 |
| " Pharmacokinetics of azithromycin permits a reduction in dosage frequency and duration while maintaining efficacy comparable to that of conventional 7- to 10-day three or four times daily regimens." | ( Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Powers, JL, 1996) | 0.29 |
| "The efficacy and safety of azithromycin in otitis media and streptococcal pharyngitis, the simple dosing regimen and a highly palatable oral suspension formulation should increase compliance among pediatric patients and thereby improve clinical outcomes." | ( Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Powers, JL, 1996) | 0.29 |
| " The pharmacokinetic profile of dirithromycin offers the advantages of once-daily dosing and high and prolonged tissue concentrations; dosing adjustments are not needed in the elderly or in patients with renal or mild hepatic impairment." | ( Dirithromycin: a new macrolide. Abdel-Rahman, SM; Nahata, MC; Wintermeyer, SM, 1996) | 0.29 |
| " The long elimination half-life of dirithromycin allows once-daily dosing and higher and more prolonged tissue concentrations than are achievable with erythromycin." | ( Dirithromycin: a new macrolide. Abdel-Rahman, SM; Nahata, MC; Wintermeyer, SM, 1996) | 0.29 |
| " Because of the standardized 1-mg/ml infusates, all subjects in the 4-g dosing group complained of an urgent need to urinate." | ( Safety, toleration, and pharmacokinetics of intravenous azithromycin. Cohen, SF; Foulds, G; Levy, B; Luke, DR, 1996) | 0.29 |
| " Although the clinical significance of antibiotic concentrations in these compartments is nuclear, the sustained lung tissue penetration and extensive phagocytic accumulation demonstrated in this study support the proven efficacy of azithromycin administered on a 5-day dosage schedule in the treatment of extracellular or intracellular pulmonary infections." | ( Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Campbell, GD; Gann, LP; Gubbins, PO; Halinski, DM; Olsen, KM; San Pedro, G, 1996) | 0.29 |
| " Azithromycin in a dosage of 10 or 20 mg/kg/day one daily for three days was as safe and effective as penicillin V administered four times daily in the treatment of paediatric patients with acute pharyngitis/tonsillitis." | ( Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. O'Doherty, B, 1996) | 0.29 |
| "53 micrograms/ml, respectively, and urinary excretion rate in 120 hours after the first dosing was 10." | ( [Clinical study of a macrolide antibiotic, azithromycin, in pediatric patients]. Harada, Y; Higashino, H; Kawamura, Y; Kawasaki, H; Kino, M; Kobayashi, Y; Nagao, Y; Takaya, J, 1996) | 0.29 |
| "5%, and 1% (total, 15%) after intravenous dosing and 47%, 13%, and 2% (total, 62%) after oral dosing." | ( Disposition of oral azithromycin in humans. Foulds, G; Luke, DR, 1997) | 0.3 |
| " Azithromycin was discontinued and the theophylline dosage reduced by 33%." | ( Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction. Pollak, PT; Slayter, KL, ) | 0.13 |
| " The efficacy and safety of azithromycin suspension (10 mg/kg), dosed orally once daily for 3 days, was compared with that of co-amoxiclav (10 mg/kg in a 4:1 ratio), dosed orally three times daily for 5-10 days." | ( An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children. The Paediatric Azithromycin Study Group. Lauvau, DV; Verbist, L, ) | 0.13 |
| " pylori, the propensity to develop resistance in a high proportion of strains has a clear impact on the choice of the right combinations of macrolides with other agents as well as the dosage of the macrolide antibiotics." | ( Helicobacter pylori: in vitro induction of resistance to azithromycin. Dominis, M; Kalenić, S; Katicić, M; Kresić, S; Plecko, V; Presecki, V; Tripković, V; Zele-Stracević, L, ) | 0.13 |
| "5 mg/L (maximum serum concentration achieved by azithromycin after the usual dosing regimen)." | ( [The postantibiotic effect of azithromycin on respiratory pathogens]. Andrews, JM; Boswell, FJ; Diculencu, D; Wise, R, ) | 0.13 |
| "In this study, we determined the efficacy of various dosing regimens for erythromycin and azithromycin against four pneumococci with different susceptibilities to penicillin in an in vitro pharmacokinetic model and in a mouse peritonitis model." | ( Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. den Hollander, JG; Espersen, F; Frimodt-Møller, N; Fuursted, K; Knudsen, JD; Mouton, JW; Verbrugh, HA, 1998) | 0.3 |
| ") have been progressively employed for the design of dosing schedules of antimicrobial agents." | ( Postanitbiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli. Fuentes, F; Gomez-Lus, ML; Izquierdo, J; Martín, MM; Prieto, J, 1998) | 0.3 |
| "The relative in-vivo intracellular concentration of various macrolides in phagocytes cannot be directly extrapolated from in-vitro experiments that use a fixed and constant extracellular concentration for all compounds, since this fails to consider different rates of intracellular penetration, dosage regimens and pharmacokinetic data." | ( Computer-aided prediction of macrolide antibiotic concentrations in human circulating polymorphonuclear leucocytes. Bouvier d'Yvoire, MJ; Dresco, IA; Tulkens, PM, 1998) | 0.3 |
| " Azithromycin was as effective, and as well tolerated as co-amoxiclav, and its shorter simpler dosing regime may offer advantages in compliance and cost." | ( A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults. Clement, PA; de Gandt, JB, ) | 0.13 |
| " A better knowledge of the pharmacodynamic properties of macrolides and streptogramins is essential for definition of proper dosing regimens." | ( Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Carbon, C, 1998) | 0.3 |
| " These attributes, combined with its once-daily dosing schedule, make azithromycin suitable for the treatment of many types of bacterial infection." | ( Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. Rapp, RP, ) | 0.13 |
| " Azithromycin was also as effective as either phenoxymethylpenicillin (penicillin V), erythromycin, clarithromycin or cefaclor against streptococcal pharyngitis or tonsillitis in children, but appears to result in more recurrence of infection than phenoxymethylpenicillin in this indication, necessitating a dosage of 12 mg/kg/day for 5 days." | ( Azithromycin. A review of its use in paediatric infectious diseases. Balfour, JA; Langtry, HD, 1998) | 0.3 |
| "Azithromycin levels measured throughout the 144 h after dosing were consistently above the minimum inhibitory range (MIC) for Chlamydia trachomatis (0." | ( Pharmacokinetics of azithromycinin rabbit lacrimal glands and conjunctiv a. Ahmed, WS; El-Yazigi, A; Karcioglu, ZA; Raines, D, 1999) | 0.3 |
| " Results showed that SBA was maintained for 100% of the dosing interval for clarithromycin and 50-100% for azithromycin regardless of PCN susceptibility when standard doses were employed." | ( Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae. Lacy, MK; Nicolau, DP; Nightingale, CH; Owens, RC; Quintiliani, R; Xu, X, 1998) | 0.3 |
| " A significantly simpler dosage regimen and faster clinical effect were the advantages of azithromycin." | ( Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis. Culig, J; Klapan, I; Matrapazovski, M; Oresković, K; Radosević, S, ) | 0.13 |
| " Current dosing guidelines for intravenous azithromycin can result in much higher serum concentrations than is seen with oral administration." | ( Intravenous azithromycin-induced ototoxicity. Bizjak, ED; Dresing, JM; Haug, MT; Sarodia, BD; Schilz, RJ, 1999) | 0.3 |
| " Its spectrum of activity, unique pharmacokinetics, and high and sustained tissue penetration allow for once-daily dosing with monotherapy in many cases." | ( Intravenous azithromycin. Amsden, GW; Garey, KW, 1999) | 0.3 |
| " This allows for monotherapy and once-daily intravenous dosing for mild-to-moderate community-acquired pneumonia or pelvic inflammatory disease in many instances." | ( Intravenous azithromycin. Amsden, GW; Garey, KW, 1999) | 0.3 |
| " Further study may permit development of optimal once-daily dosing and enhance eradication rates." | ( Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. Cheybani, K; Estrada, R; Laine, L; Neil, G; Smith, S; Trujillo, M; Yeramian, P, 1999) | 0.3 |
| " In the case of clarithromycin, concentrations in both monocytes and granulocytes fluctuate between peaks of approximately 22-25 mg/l and troughs of approximately 5 mg/l during a standard dosing interval." | ( Pharmacological considerations in the emergence of resistance. Amsden, GW, 1999) | 0.3 |
| " Middle ear fluid was extracted by tympanocentesis 4, 12 and 24 h after dosing and divided into two fractions: with cells (as collected) (C+) and cell-free (C-)." | ( Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin. Arcidiacono, MM; Demartini, G; Dugnani, S; Fraschini, F; Pintucci, JP; Scaglione, F, 1999) | 0.3 |
| " Azithromycin and clarithromycin have pharmacokinetics that allow shorter dosing schedules because of prolonged tissue levels." | ( The macrolides: erythromycin, clarithromycin, and azithromycin. Alvarez-Elcoro, S; Enzler, MJ, 1999) | 0.3 |
| " Close monitoring of INR is recommended, and warfarin dosage adjustment may be necessary." | ( Potential interaction between azithromycin and warfarin. Foster, DR; Milan, NL, 1999) | 0.3 |
| "The high concentrations of azithromycin observed in gastric tissue of patients with gastritis on a 5-day dosage regimen point to a favorable pharmacokinetic basis for a role of azithromycin as a component of the eradication therapy of Heliobacter pylori." | ( Determination of azithromycin in gastric biopsy samples. Gallo, E; Kirchhoff, G; Krichhoff, RM; Laufen, H; Schäcke, G, 1999) | 0.3 |
| " Our data support the proven efficacy of these agents for MAC prophylaxis since clarithromycin and azithromycin displayed sustained intracellular concentrations which exceeded their MICs for MAC throughout the dosing periods." | ( Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. Bui, KQ; Li, C; McNabb, J; Nicolau, DP; Nightingale, CH, 1999) | 0.3 |
| "The newer macrolide antibiotics offer the advantage of fewer adverse gastrointestinal effects than erythromycin and dosing regimens of only once or twice a day." | ( Dental therapeutic indications for the newer long-acting macrolide antibiotics. Moore, PA, 1999) | 0.3 |
| "Owing to azithromycin's prolonged half-life, shorter and shorter dosage regimens are being studied for treatment of respiratory tract infections." | ( Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. Amsden, GW; Gray, CL, 2001) | 0.31 |
| " During one dosing arm, subjects received a single 1200 mg oral dose of azithromycin." | ( A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. Amsden, GW; Cabelus, LJ; Foulds, G; Nafziger, AN, 2000) | 0.31 |
| " The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine." | ( Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients. Amsden, G; Flaherty, J; Luke, D, 2001) | 0.31 |
| " To simplify training and logistics, it may be better to base dosage schedules on height rather than weight for those taking tablets, which included most people aged four years or more in the population studied." | ( Pilot study of the use of community volunteers to distribute azithromycin for trachoma control in Ghana. Abugri, P; Akudibillah, J; Bailey, RL; Foster, A; Hagan, M; Mabey, DC; Solomon, AW, 2001) | 0.31 |
| " Azithromycin, the first azalide antibiotic, presents pharmacokinetics and pharmacodynamics that allow for a simple dosing regimen with minimal side effects." | ( Azithromycin: indications for the future? Amsden, GW; Duran, JM, 2000) | 0.31 |
| " azithromycin was given at a dose of 10 mg/kg once a week, whereas amoxicillin was administered daily as a single intake of one third of the therapeutic dosage (20 mg/kg per day)." | ( Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media. Alfonso, C; De Diego, JI; Gavilan, J; Prim, MP; Rabanal, I; Sastre, N, 2001) | 0.31 |
| " Daily dosing with the combination of azithromycin and rifabutin was poorly tolerated, primarily because of gastrointestinal symptoms and neutropenia." | ( Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. Bethel, J; Cohn, DL; Drusano, G; Follansbee, S; Hafner, R; Kumar, P; Mole, L; Mushatt, D; Polk, RE; Raasch, R; Standiford, HC, 2001) | 0.31 |
| " Using serum and ELF concentrations after standard dosing, we calculated the proportion of isolates against which it would be possible to obtain a ratio of azithromycin area under the curve to MIC > or =25 and clarithromycin concentrations that exceeded the MIC for > or =40% of the dosing interval." | ( In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. Denys, GA; Kays, MB, 2001) | 0.31 |
| "A study concluded that for the prevention of disseminated Mycobacterium avium complex in patients with advanced HIV infection once-weekly dosing of azithromycin is a simpler and more effective regimen than daily rifabutin." | ( Azithromycin effective in preventing MAC. , 1996) | 0.29 |
| " These pharmacological and pharmacokinetic properties were reflected in good clinical results for the treatment of respiratory infections and other infections with once daily dosing for 3 days." | ( [Pharmacological and pharmacokinetic properties of azithromycin (Zithromac), a novel 15-membered ring macrolide antibacterial agent]. Matsunaga, T, 2001) | 0.31 |
| " This allows once-daily dosing for 3 days in the treatment of respiratory tract infections, in contrast to longer dosage periods required for erythromycin, clarithromycin, roxithromycin and agents belonging to other classes of antibiotics." | ( Advanced-generation macrolides: tissue-directed antibiotics. Amsden, GW, 2001) | 0.31 |
| " Convenience of dosing should be balanced against the increased cost of this regimen for the treatment of these common infections, where often no antibiotic may be indicated at all." | ( Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. Chew, P; Contopoulos-Ioannidis, DG; Ioannidis, JP; Lau, J, 2001) | 0.31 |
| " His oral cyclosporine dosage for the past 2 years was stabilized at 100 mg twice/day; his cyclosporine whole blood trough levels 15 days earlier and on the day he was admitted were both 178 ng/ml." | ( Possible interaction between intravenous azithromycin and oral cyclosporine. Fish, D; Lapointe, M; Page, RL; Ruscin, JM, 2001) | 0.31 |
| " Further studies are required to define frequency of dosing and duration of benefit." | ( Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Bell, S; Bowler, S; Masel, P; McCormack, J; Seeney, S; Wolter, J, 2002) | 0.31 |
| "Repeated dosing with erythromycin caused statistically significant increases in the AUC and Cmax of sildenafil (2." | ( The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Faulkner, S; Harness, JA; Muirhead, GJ; Taubel, J, 2002) | 0.31 |
| " Azithromycin did not affect the pharmacokinetics of sildenafil; therefore, no adjustment in dosage is necessary for patients receiving these drugs concomitantly." | ( The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Faulkner, S; Harness, JA; Muirhead, GJ; Taubel, J, 2002) | 0.31 |
| " These findings give pharmacokinetic support to the suggestion that increments of azithromycin dosing might ensure enhanced therapeutic levels at infective sites of the upper respiratory tract." | ( Improved tonsillar disposition of azithromycin following a 3-day oral treatment with 20 mg kg(-1) in paediatric patients. Baschiera, F; Blandizzi, C; Bruschini, P; del Tacca, M; Fornai, M; Lazzeri, G, 2002) | 0.31 |
| " Dosage of azitromycin was 10 mg/kg per day for 3 days and cefaclor 40 mg/kg per day for 10 days." | ( Etiology of acute otitis media in childhood and evaluation of two different protocols of antibiotic therapy: 10 days cefaclor vs. 3 days azitromycin. Dündar, G; Erdamar, B; Katircioğlu, S; Oğuz, F; Sidal, M; Süoğlu, Y; Unüvar, E, 2003) | 0.32 |
| " On the basis of plasma pharmacokinetics and tissue concentration data, we suggest an azithromycin dosage in ball pythons of 10 mg/kg, orally, every 2 to 7 days, depending upon the site of infection and susceptibil ity of the infective organism." | ( Pharmacokinetics and tissue concentrations of azithromycin in ball pythons (Python regius). Carpenter, JW; Coke, RL; Goatley, MA; Hunter, RP; Isaza, R; Koch, DE, 2003) | 0.32 |
| " Paediatric trachoma is treated with azithromycin according to weight at a target dosage of 20 mg/kg." | ( Height as a proxy for weight in determining azithromycin treatment for paediatric trachoma. Basilion, EV; Kilima, PM; Mecaskey, JW; Turner, VM, ) | 0.13 |
| " The purposes of this study were to determine whether an accurate dose could be determined by using height as a surrogate for weight and whether a single model of height-based dosage would be applicable in more than one setting." | ( Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. Bailey, R; Barwick, R; Burton, M; Foster, A; Mabey, D; Muñoz, B; Solomon, AW; West, SK; Zingeser, J, 2003) | 0.32 |
| " Dosage by height resulted in more than 97% of children receiving doses within the tolerance limits." | ( Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. Bailey, R; Barwick, R; Burton, M; Foster, A; Mabey, D; Muñoz, B; Solomon, AW; West, SK; Zingeser, J, 2003) | 0.32 |
| "Height-based determination of dosage of azithromycin in trachoma control programs appears to be feasible, using the height-based schedule proposed." | ( Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. Bailey, R; Barwick, R; Burton, M; Foster, A; Mabey, D; Muñoz, B; Solomon, AW; West, SK; Zingeser, J, 2003) | 0.32 |
| "Nineteen cases were treated with monotherapy and once-daily intravenous dosing of azithromycin injection." | ( [Clinic efficacy of treating chronic prostatitis caused by Neisseria gonorrhoeae with azithromycin aspartic-acid injection]. Gao, JP; Ge, JP; Ma, HQ; Sang, H; Wei, W; Zhang, ZY; Zhou, WQ, 2003) | 0.32 |
| "A prospective study was performed on 47 patients, 31 females and 16 males, aged 19-77 (median 52) years, treated with azithromycin (total dosage 3 g, divided over 5 days) for typical solitary erythema migrans." | ( Is azithromycin treatment associated with prolongation of the Q-Tc interval? Maraspin, V; Strle, F, 2002) | 0.31 |
| " It is concluded that azithromycin (500mg/dayx3 days) does not alter the disposition kinetics of CSA in a clinically significant way, and that CSA dosage adjustments are not warranted in renal transplant patients taking these two drugs together." | ( Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. Bachmann, K; Chandra, R; Jauregui, L; Thakker, K, 2003) | 0.32 |
| "We now report significant delirium associated with conventional dosing of azithromycin in two geriatric patients who were being treated for lower respiratory tract infection." | ( Delirium in the elderly resulting from azithromycin therapy. Cone, LA; Padilla, L; Potts, BE, 2003) | 0.32 |
| " The procedure was successfully applied for assay of the drug in the pharmaceutical dosage forms." | ( Voltammetric assay of azithromycin in pharmaceutical dosage forms. Nigović, B; Simunić, B, 2003) | 0.32 |
| " Clinical cure rates for patients infected with Streptococcus pneumoniae (67 of 76; 88%) and Haemophilus influenzae (28 of 44; 64%) were consistent with historical rates for the 5-day dosing regimen." | ( Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis. Arrieta, A; Aspin, M; Blatter, M; Blumer, JL; Chow, J; Dunne, MW; Ehrlich, GD; Emparanza, P; Fernandez, P; Gooch, WM; Khurana, C; Krogstad, JA; McLinn, S; Mohs, AA; Podgore, J; Rodriguez, A; Roine, I; Schwartz, R; Vargas, SL, 2003) | 0.32 |
| "Compared with 5 days of dosing, a 3 day dosing regimen of azithromycin for treatment of acute otitis media (AOM) may improve compliance, will simplify therapy for the caregiver and, by giving the same total dose as the 5 day regimen, provide more drug when the bacterial burden is highest." | ( Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media. Aoki, J; Boettger, D; Bottenfield, G; Dunne, MW; Garrett, A; Latiolais, T; Lewis, B; Moore, WH; Pistorius, B; Shemer, A; Spiegel, C; Stewart, TD, 2003) | 0.32 |
| " Recent anecdotal evidence, supported by its efficacy in the treatment of Chlamydia trachomatis infection in humans, has suggested that azithromycin may offer an alternative by allowing less frequent dosing for a shorter duration." | ( Efficacy of azithromycin for the treatment of feline chlamydophilosis. Egan, K; Gruffydd-Jones, TJ; Harbour, DA; Owen, WM; Sturgess, CP, 2003) | 0.32 |
| " Newer macrolides such as azithromycin have the advantage of improved tolerability and a prolonged intracellular half-life requiring an infrequent dosing regimen." | ( Macrolides in cystic fibrosis: is there a role? McCormack, JG; Seeney, SL; Wolter, JM, 2002) | 0.31 |
| " However, there are drawbacks to penicillin V therapy, including the length of the dosing regimen, which are leading to decreasing penicillin prescription rates in many countries." | ( Defining the optimum treatment regimen for azithromycin in acute tonsillopharyngitis. Cohen, R, 2004) | 0.32 |
| "To determine the steady-state, extracellular, and intracellular pulmonary disposition of moxifloxacin (MXF), levofloxacin (LEVO), and azithromycin (AZI) relative to that of the plasma over a 24-h dosing interval." | ( Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C, 2004) | 0.32 |
| "0 micro g/mL) throughout the dosing interval." | ( Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C, 2004) | 0.32 |
| " The azithromycin dosage ranged from 250 mg 3 times weekly to 500 mg daily." | ( Azithromycin for improving pulmonary function in cystic fibrosis. Carr, RR; Nahata, MC, 2004) | 0.32 |
| " Further research is needed to determine an optimal dosage regimen, duration of treatment, effects on quality of life, and cost-effectiveness of azithromycin therapy." | ( Azithromycin for improving pulmonary function in cystic fibrosis. Carr, RR; Nahata, MC, 2004) | 0.32 |
| " The detection of these drugs in commercial dosage formulations is reported." | ( Identification of 5-aminosalicylic acid, ciprofloxacin and azithromycin by abrasive stripping voltammetry. Komorsky-Lovrić, S; Nigović, B, 2004) | 0.32 |
| "Corneal concentrations of azithromycin increased with drug dosage and duration of application." | ( Corneal pharmacokinetics of topically applied azithromycin and clarithromycin. Giese, MJ; Holland, GN; Kuehne, JJ; Mondino, BJ; Ramaswamy, A; Rayner, SA; Taban, R; Yu, AL; Yu, F, 2004) | 0.32 |
| " Current recommended dosing intervals for mass azithromycin treatment for trachoma are based on a mathematical model." | ( Mass treatment with single-dose azithromycin for trachoma. Aguirre, A; Alexander, ND; Bailey, RL; Courtright, P; Foster, A; Holland, MJ; Mabey, DC; Massae, PA; Molina, S; Natividad-Sancho, A; Peeling, RW; Safari, S; Shao, JF; Solomon, AW; West, SK, 2004) | 0.32 |
| "7% of children aged 60 months to 15 years receiving tablets would have received treatment within a dosage range of 20-40 mg/kg." | ( Simplification and improvement of height-based azithromycin treatment for paediatric trachoma. Basilion, EV; Kilima, PM; Mecaskey, JW, 2005) | 0.33 |
| " From the dosage regimen proposed by the user, the model simulates a plotting of antibiotic plasma concentrations vs." | ( [An example of simulation for a better understanding of PK/PD relationship of antibiotics]. Abbas, S; Drugeon, H; Ganiere-Monteil, C; Kergueris, MF; Le Normand, Y; Mazeas, M, 2004) | 0.32 |
| " administration, principally its long half-life and high bioavailability, could provide an alternative to the oral route of administration in goats, although more studies are needed to establish a suitable pharmaceutical formulation, propose optimun dosage regimens, investigate clinical efficacy and study the tolerability of repeated doses." | ( Pharmacokinetics of azithromycin after intravenous and intramuscular administration to goats. Cárceles, CM; Escudero, E; Espuny, A; Fernández-Varón, E; Font, A; Serrano, JM, 2005) | 0.33 |
| "This analysis suggests that azithromycin administered at a dosage of 60 mg/kg in children or administered for 3 days at a dosage of 500 mg/day in adults is more effective than other treatment regimens in producing eradication and clinical cure of GAS tonsillopharyngitis." | ( Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Casey, JR; Pichichero, ME, 2005) | 0.33 |
| "A large dosage pediatric formulation of amoxicillin/clavulanate with an improved pharmacokinetic/pharmacodynamic profile was developed to eradicate many penicillin-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae (including beta-lactamase-producing strains)." | ( Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children. Bandekar, R; Dagan, R; Hoberman, A; Huff, A; Johnson, CE; Leibovitz, E; Rosenblut, A; Wynne, B, 2005) | 0.33 |
| "The anti-inflammatory potential of azithromycin in chronic obstructive pulmonary disease (COPD) patients was explored following a standard oral dosing regimen." | ( Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Barisić, K; Bosnar, M; Brajsa, K; Cepelak, I; Culić, O; Cuzić, S; Eraković, V; Glojnarić, I; Manojlović, Z; Munić, V; Novak-Mircetić, R; Oresković, K; Parnham, MJ; Pavicić-Beljak, V; Popović-Grle, S; Radosević, S; Sucić, M, 2005) | 0.33 |
| "As a result of the prolonged half-life and unique pharmacokinetic and pharmacodynamic (PK-PD) characteristics of azithromycin, shorter dosing regimens are being evaluated for the treatment of community-acquired infections." | ( Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. Dunne, MW; Finegan, SM; Girard, D; Lame, ME, 2005) | 0.33 |
| " Thirty patients were randomly assigned to three groups and treated for 3 days, before impacted lower third molar removal, as follows: (1) sublingual piroxicam-FDDF (fast dissolving dosage formulation) 20 mg/day; (2) oral azithromycin 500 mg/day; (3) piroxicam-FDDF 20 mg/day plus azithromycin 500 mg/day." | ( Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction. Antonioli, L; Blandizzi, C; Cei, S; Colucci, R; Corsi, L; Del Tacca, M; Fornai, M; Gabriele, M; Graziani, F; Tonelli, M, 2005) | 0.33 |
| " Adverse reactions are few and generally self-limited when used at the recommended dosage for immunomodulation." | ( Macrolides and airway inflammation in children. Rubin, BK; Shinkai, M, 2005) | 0.33 |
| " injection at a single dosage of 20 mg/kg bodyweight was studied in sheep." | ( Pharmacokinetics of azithromycin after i.v. and i.m. administration to sheep. Cárceles, CM; Escudero, E; Espuny, A; Fernández-Varón, E; Font, A; Marín, P, 2005) | 0.33 |
| " This allows once-daily administration for 3-5 days of treatment compared with traditional multi dosing 7-10-day treatment regimens." | ( Azithromycin and lower respiratory tract infections. Aliberti, S; Allegra, L; Blasi, F; Cazzola, M; Cosentini, R; Santus, P; Tarsia, P, 2005) | 0.33 |
| " These results indicate no alteration in dosage of azithromycin is necessary in patients with CF taking pancreatic enzymes." | ( Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Beringer, P; Bi, L; Gill, M; Han, E; Hoem, N; Hsu, D; Huynh, KM; Kriengkauykiat, J; Louie, S; Nguyen, T; Rao, PA; Shapiro, B, 2005) | 0.33 |
| " For these reasons, and because of convenience of dosing (QD for 3 days), azithromycin is widely used in Mexico." | ( Bioavailability of two oral formulations of azithromycin 500 mg: a randomized, open-label, two-period crossover comparison in healthy Mexican adult subjects. de Lago, A; Gómez Silva, M; González-de la Parra, M; Namur, S; Pineyro-Garza, E; Piñeyro-López, A; Rangel, RL; Reyes-Araiza, R; Torres-Alanís, O; Wacksman, N, 2005) | 0.33 |
| " They include updated information on macrolide agents other than erythromycin (azithromycin and clarithromycin) and their dosing schedule by age group." | ( Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. Moran, J; Murphy, TV; Tiwari, T, 2005) | 0.33 |
| " Adherence to the prescribed regimen is affected by a number of variables including dosing interval, treatment duration, adverse effects, and palatability in pediatric patients." | ( Value of short-course antimicrobial therapy in community-acquired pneumonia. Blasi, F; Tarsia, P, 2005) | 0.33 |
| " Azithromycin dosage is variable, based on published studies, and not supported by pharmacokinetic data." | ( Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Heijerman, HG; Touw, DJ; Wilms, EB, 2006) | 0.33 |
| " Azithromycin at a dosage of 1 g was administered at monthly intervals over 3 months in Khammouane province, on days 1, 30, and 90 in Oudomxai and days 1, 60, and 90 in Savannakhet." | ( Periodic presumptive treatment for cervical infections in service women in 3 border provinces of Laos. Morison, L; O'Farrell, N; Oula, R; Van, CT, 2006) | 0.33 |
| " The method was applied successfully for the assay of azithromycin dihydrate in pure and pharmaceutical dosage forms as tablets, capsules and suspensions." | ( Degradation studies of azithromycin and its spectrophotometric determination in pharmaceutical dosage forms. Arayne, MS; Fatima, A; Hussain, F; Sultana, N, 2006) | 0.33 |
| " From the results of the single administration in this study an IM dosage regimen can be proposed that achieves minimum concentrations over 2mg/L in rabbits: three doses of 4-5mg/kg/day would provide suitable therapeutic concentrations in pulmonary tissues over seven days." | ( Tissue disposition of azithromycin after intravenous and intramuscular administration to rabbits. Cárceles, CM; Escudero, E; Fernández-Varón, E; Marín, P, 2007) | 0.34 |
| " Due to its twice daily dosing regimen for 3 days, azithromycin represents a step forward in the management of purulent bacterial conjunctivitis, especially in children." | ( 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Amraoui, A; Bourcier, T; Cochereau, I; Delval, L; Garg, P; Goldschmidt, P; Khairallah, M; Meddeb-Ouertani, A; Pop, M; Pouliquen, P; Tandon, R; Zaghloul, K, 2007) | 0.34 |
| " Serial blood samples were collected up to 5 days after the start of dosing for both regimens." | ( Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Allaudeen, H; Breen, JD; Chandra, R; Jungnik, A; Liu, P; Phillips, K; Sharma, A, 2007) | 0.34 |
| " Applications of these pharmacokinetic/pharmacodynamic models will eventually provide a tool for rational antibiotic dosing regimen decisions." | ( Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Derendorf, H; Rand, KH; Schmidt, S; Suvanakoot, U; Treyaprasert, W, 2007) | 0.34 |
| "A simple, novel, sensitive, and specific spectrophotometric method was developed and validated for the determination of azithromycin (AZ), clarithromycin (CLA), and roxithromycin (ROX) in bulk powders and their dosage forms." | ( Development and validation of a spectrophotometric method for the determination of macrolide antibiotics by using 2,4-dinitrophenylhydrazine. Abdelmageed, OH, ) | 0.13 |
| " Lung function, BHR expressed as the dose-response slope (DRS) of forced expiratory volume in 1 second (FEV1) fall after hypertonic saline inhalation (DRS), and induced sputum were evaluated at baseline and after treatment." | ( Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Bodini, A; Boner, AL; Costella, S; Loiacono, A; Peroni, DG; Piacentini, GL; Pigozzi, R, ) | 0.13 |
| "Patients with a history of three or more episodes of furuncles were assigned to receive 12 weeks of suppressive treatment with azithromycin at a weekly dosage of 500 mg." | ( Prevention of chronic furunculosis with low-dose azithromycin. Aminzadeh, A; Demircay, Z; Ocak, K; Soyletir, G, 2007) | 0.34 |
| "In this study we examined pharmacokinetics, systemic exposure and sputum penetration of azithromycin (AZM) in CF patients on chronic daily AZM therapy after changing to a once weekly dosing scheme." | ( Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. Heijerman, HG; Touw, DJ; Wilms, EB, 2008) | 0.35 |
| " The aim was to identify the optimum azithromycin dose in the treatment of acne vulgaris through monitoring the efficacy and safety of three dosage regimens." | ( A dose-finding study of azithromycin in the treatment of acne vulgaris. Andjelinović, D; Basta-Juzbasić, A; Brajac, I; Cvitković, L; Gruber, F; Herceg-Harjacek, L; Kotrulja, L; Lipozencić, J; Marasović, D; Oremović, L, 2007) | 0.34 |
| " Multivariate analysis demonstrated that lack of downward dosage adjustment based on creatinine clearance (odds ratio [OR] 10." | ( Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. LaPlante, KL; Mersfelder, TL; Quilliam, BJ; Ward, KE, 2008) | 0.35 |
| " Lack of downward fluoroquinolone dosage adjustment for renal function, presence of diabetes, and treatment with insulin or sulfonylureas each independently increased the risk of dysglycemia." | ( Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. LaPlante, KL; Mersfelder, TL; Quilliam, BJ; Ward, KE, 2008) | 0.35 |
| " Azithromycin extended release (azithromycin-ER) formulation was developed to enable a higher dosage of 2 g to be administered as a single oral dose without decreasing the safety profile." | ( Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin. Damle, B; de Caprariis, PJ; Del Tacca, M; Fang, A; Lucchi, M; Mussi, A; Pasqualetti, G; Sanchez, SP, 2008) | 0.35 |
| "Both dosage regimens resulted in adequate and long-lasting azithromycin levels in the conjunctiva, the ocular target tissue relative to the expected therapeutic indication in man (bacterial conjunctivitis), and also in the cornea and tears." | ( Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits. Amar, T; Caillaud, T; Elena, PP, 2008) | 0.35 |
| " Azithromycin use was associated with more nausea in the 30 min after dosing (azithromycin group, 8% of patients; levofloxacin group, 1% of patients; Pp." | ( Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. Frenck, RW; Johnston, JR; Monteville, MR; Putnam, SD; Riddle, MS; Rockabrand, DM; Sanders, JW; Tribble, DR; Ulukan, S, 2007) | 0.34 |
| " Although nausea after dosing is uncommon, it is more frequently associated with azithromycin than with levofloxacin." | ( Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. Frenck, RW; Johnston, JR; Monteville, MR; Putnam, SD; Riddle, MS; Rockabrand, DM; Sanders, JW; Tribble, DR; Ulukan, S, 2007) | 0.34 |
| " So far there is no pharmacokinetic and clinical data on once-weekly dosage of AZM in CF patients." | ( Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Beck, G; Döring, G; Pfründer, D; Schmitt-Grohe, S; Schubert, R; Staab, D; Steinkamp, G; Zielen, S, 2008) | 0.35 |
| " Except for maximum observed concentration during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on average, there were no statistically significant differences in mean plasma concentrations in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone." | ( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008) | 0.35 |
| " Of the 9 patients with specimens obtained before and after treatment, only 2 had an initial specimen in which the mutation was present, indicating that drug resistance was induced as the result of an inappropriate dosage of azithromycin." | ( Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Bradshaw, CS; Fairley, CK; Hamasuna, R; Jensen, JS; Tabrizi, SN, 2008) | 0.35 |
| " Drug concentration analysis at various time points following instillation allows interpretation of the residence time and a rationale for dosing frequency." | ( Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. O'Brien, TP; Torkildsen, G, 2008) | 0.35 |
| ", 100-, 200-, 400-, 800-, or 1,200-mg dosing groups) consisting of eight subjects (six active and two placebo) each." | ( Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. Jiang, LJ; Or, YS; Wang, M, 2009) | 0.35 |
| " These results indicated that AZI has good penetration into sinus tissue regardless of formulation; however, dosing of AZI-ER (2 g) increased AZI exposure within the first 24 h compared with the Day 1 dose of 500 mg IR regimen." | ( Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis. Blumer, JL; Campbell, MD; Chiu, AG; Crownover, PH; Damle, BD; Fang, AF; Palmer, JN, 2009) | 0.35 |
| " Dosing was weight-based and observed." | ( Randomized trial of high dose azithromycin compared to standard dosing for children with severe trachoma in Tanzania. Campbell, JP; Mkocha, H; Munoz, B; West, SK, ) | 0.13 |
| " The most important PK features of EDP-420 observed in these clinical studies are its long half-life of 17 to 18 h and its high systemic exposure, which support once-daily dosing and treatment durations potentially shorter than those of most other macrolide antibiotics." | ( Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study. Jiang, LJ; Or, YS, 2009) | 0.35 |
| " In case of macrolides higher dosage is indicated, because there is a risk of clinical failure at lower doses." | ( [Voice on the treatment of ureaplasmas infections]. Biernat-Sudolska, M; Drzewiecki, A; Rojek-Zakrzewska, D, 2009) | 0.35 |
| " Sufficient dosage might control early formation of biofilms." | ( Activity of ciprofloxacin and azithromycin on biofilms produced in vitro by Haemophilus influenzae. Liu, YN; Wang, D; Wang, Y, 2009) | 0.35 |
| " Also included are human pharmacokinetic studies with prototype CR dosage forms for CJ-13,610 and CP-424,391." | ( The use of gastrointestinal intubation studies for controlled release development. Sutton, SC, 2009) | 0.35 |
| " Previous concomitant dosing studies in rats using rifamycin SV, a general organic anion-transporting polypeptide (OATP) inhibitor, suggested that the high oral absorption of azithromycin and clarithromycin may be caused by facilitative uptake by intestinal Oatps." | ( Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Davis, CB; Dawson, PA; Garver, E; Han, C; Haywood, J; Lan, T; Rao, A, 2009) | 0.35 |
| " Individualized dosage regimen design incorporating such information may improve the efficacy of the drug while reducing adverse reactions." | ( Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. He, XJ; Li-Ling, J; Qiu, F; Sun, YX; Zhao, LM, ) | 0.13 |
| "The dosage form discussed in this article employed a melt-congealing process to produce matrix microspheres with a 3-hour, first-order release." | ( Formulation design and pharmaceutical development of a novel controlled release form of azithromycin for single-dose therapy. Appel, LE; Herbig, SM; Lo, JB; McCray, SB; Thombre, AG, 2009) | 0.35 |
| " Twenty-eight healthy Japanese male subjects who never smoked were randomly allocated to seven groups of four subjects each who underwent bronchoalveolar lavage (BAL) at different times after dosing (2, 4, 6, 8, 10, 12, or 24 h)." | ( Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. Furuie, H; Saisho, Y; Shimada, J; Yoshikawa, T, 2010) | 0.36 |
| " Dose-response curves and the corresponding inhibitory potencies (IC(50)) of azithromycin, hydrocortisone, and dexamethasone were evaluated in a fluorescence assay using A549 cells." | ( Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity. Cheung, PS; Hosseini, K; Si, EC, 2010) | 0.36 |
| " Azyter, with its convenient dosing (bid for 3 days), is a step forward in the management of purulent bacterial conjunctivitis." | ( [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis]. Amraoui, A; Bhagat, Y; Bourcier, T; Cochereau, I; Khairallah, M; Meddeb-Ouertani, A; Pop, M; Robert, PY; Zaghloul, K, 2010) | 0.36 |
| " The remaining 20 patients received a vitamin C tablet (non-chewable) in the same dosage schedule." | ( Long-term oral azithromycin in chronic plaque psoriasis: a controlled trial. Dogra, J; Saxena, VN, ) | 0.13 |
| "Healthy volunteers were dosed with azithromycin tablets and capsules, fasted and fed, in a four-way randomized crossover study." | ( Mechanistic study of the azithromycin dosage-form-dependent food effect. Curatolo, W; Foulds, G; Labadie, R, 2010) | 0.36 |
| "When capsules were dosed to fed subjects, the systemic AUC for DCA was 243% of the value observed after fasted-state dosing, and the DCA C(max) was 270% of the value observed after fasted-state dosing." | ( Mechanistic study of the azithromycin dosage-form-dependent food effect. Curatolo, W; Foulds, G; Labadie, R, 2010) | 0.36 |
| "5% throughout the 7-day dosing period and for at least 7 days thereafter." | ( Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Brubaker, K; Crean, CS; Haque, RM; Hwang, DG; Stewart, WC; Zink, RC, 2010) | 0.36 |
| "Azithromycin 1% demonstrated high, therapeutic levels in the conjunctiva that were maintained up to 7 days after completion of a 1-week dosing regimen." | ( Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Brubaker, K; Crean, CS; Haque, RM; Hwang, DG; Stewart, WC; Zink, RC, 2010) | 0.36 |
| "A population pharmacokinetic study of orally dosed azithromycin was conducted in order to determine if the antibiotic usage in clinical practice is reasonable and individualized." | ( Population pharmacokinetics study of azithromycin oral formulations using NONMEM. Lu, W; Wang, YR; Zhang, Q; Zhang, XY, 2010) | 0.36 |
| " The other group of 61 subjects received azithromycin and dosed with 1 drop twice daily (BID) for 2 days followed by once daily (QD) dosing for 12 days." | ( Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Cockrum, P; Hammonds, WM; Meier, E; Silverstein, B; Silverstein, S; Torkildsen, GL, 2011) | 0.37 |
| " A novel controlled release suspension dosage form was designed to meet these constraints, and was shown to deliver the desired systemic dose with acceptable toleration." | ( Interdisciplinary science and the design of a single-dose antibiotic therapy. Curatolo, W, 2011) | 0.37 |
| "Commercial azithromycin gelatin capsules (Zithromax®) are known to be bioequivalent to commercial azithromycin tablets (Zithromax®) when dosed in the fasted state." | ( Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules. Chandra, R; Curatolo, W; Foulds, G; Hausberger, A; Johnson, BA; Liu, P; Quan, E; Vatsaraj, N; Vendola, T; Vincent, J, 2011) | 0.63 |
| "Healthy volunteers were dosed with these dosage forms under fasted and fed conditions; pharmacokinetics were evaluated." | ( Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules. Chandra, R; Curatolo, W; Foulds, G; Hausberger, A; Johnson, BA; Liu, P; Quan, E; Vatsaraj, N; Vendola, T; Vincent, J, 2011) | 0.37 |
| "When the two fast-dissolving capsule formulations were dosed to fed subjects, the azithromycin AUC was 38." | ( Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules. Chandra, R; Curatolo, W; Foulds, G; Hausberger, A; Johnson, BA; Liu, P; Quan, E; Vatsaraj, N; Vendola, T; Vincent, J, 2011) | 0.37 |
| " Capsules can provide a useful and elegant dosage form for almost all drugs, but may result in a negative food effect for drugs as acid-labile as azithromycin." | ( Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules. Chandra, R; Curatolo, W; Foulds, G; Hausberger, A; Johnson, BA; Liu, P; Quan, E; Vatsaraj, N; Vendola, T; Vincent, J, 2011) | 0.37 |
| " We discuss optimal dosing for ABCs and their likely protection against several sexually transmitted and reproductive tract infections." | ( Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. Chandramohan, D; Chico, RM, 2011) | 0.37 |
| " Oral azithromycin dosing 500 mg/day for 2 weeks is effective for treatment of intractable rosacea." | ( Oral azithromycin for treatment of intractable rosacea. Choi, EH; Kim, JH; Oh, YS, 2011) | 0.37 |
| " A range of antibiotic effectiveness was displayed in this cell association assay, providing data that may be considered in addition to traditional testing when determining therapeutic dosing regimens." | ( A novel cell-associated protection assay demonstrates the ability of certain antibiotics to protect ocular surface cell lines from subsequent clinical Staphylococcus aureus challenge. Bilonick, RA; Kowalski, RP; Ling, Y; Mah, FS; Romanowski, EG; Shanks, RM; Wingard, JB, 2011) | 0.37 |
| " We found that in primary human macrophages, concentrations of azithromycin achieved during therapeutic dosing blocked autophagosome clearance by preventing lysosomal acidification, thereby impairing autophagic and phagosomal degradation." | ( Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. Basaraba, RJ; Bowden, AR; Brown, K; Cooper, J; Coulter, S; Cusens, D; DeGroote, MA; Floto, RA; Grimsey, NJ; Haworth, CS; Hegyi, K; Helm, J; Jones, A; Kampmann, B; Newton, SM; Ordway, DJ; Renna, M; Rubinsztein, DC; Schaffner, C; Shang, S; Tamayo, MH, 2011) | 0.37 |
| " The method was successfully applied assay of the drug in the pharmaceutical dosage forms." | ( Electrochemical behavior of azithromycin at graphene and ionic liquid composite film modified electrode. Hou, CT; Hu, XY; Li, HB; Liu, XX; Peng, JY, 2011) | 0.37 |
| "To determine whether 2-day dosing of azithromycin may improve the efficacy of azithromycin dosing in children with severe trachoma." | ( Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in Tanzania. Campbell, JP; Mkocha, H; Munoz, B; West, SK, 2012) | 0.38 |
| " However, optimal duration and dosing of macrolide prophylaxis for AECOPD remains uncertain." | ( Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease. Mammen, MJ; Sethi, S, 2012) | 0.38 |
| " In azithromycin maintenance therapy, several dosing schemes are applied." | ( Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects. Heijerman, HG; Touw, DJ; van der Ent, CK; Wilms, EB, 2012) | 0.38 |
| " We speculate that appropriate antibiotic selection and dosing are required for effective treatment of Ureaplasma sepsis in neonates, and this model could be used to further evaluate these relationships." | ( Appropriate antibiotic therapy improves Ureaplasma sepsis outcome in the neonatal mouse. Kong, L; Leeming, AH; Weisman, LE, 2012) | 0.38 |
| " In the etiotropic therapy azithromycin was used in the standard dosage (1." | ( [Efficacy of azithromycin and its impact on cytokine system in urogenital infections]. Khrianin, AA; Kulikova, NB; Reshetnikov, OV; Safronov, ID; Trunov, AN, 2012) | 0.38 |
| " This dosage is more effective for common pharyngeal infections than the previously recommended dose of 125 mg." | ( Diagnosis and management of gonococcal infections. Mayor, MT; Roett, MA; Uduhiri, KA, 2012) | 0.38 |
| "The primary objective was to assess warfarin dosage adjustments and their effect on the INR after treatment with azithromycin." | ( Effect of azithromycin on anticoagulation-related outcomes in geriatric patients receiving warfarin. Krajewski, MP; Mattappallil, A; Mergenhagen, KA; Olbrych, PM; Ott, MC, 2013) | 0.39 |
| "The addition of azithromycin to a stable warfarin regimen resulted in a significant change in the INR and warfarin dosage alteration without an increase in bleeding." | ( Effect of azithromycin on anticoagulation-related outcomes in geriatric patients receiving warfarin. Krajewski, MP; Mattappallil, A; Mergenhagen, KA; Olbrych, PM; Ott, MC, 2013) | 0.39 |
| " Only clarithromycin and the combination clarithromycin-rifampin were predicted to achieve concentrations in bronchoalveolar cells and pulmonary epithelial lining fluid above the MPC for the entire dosing interval." | ( Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi. Berghaus, LJ; Giguère, S; Guldbech, K, 2013) | 0.39 |
| " Dosing of AZCQ was approximately 30 mg/kg AZ and 10 mg/kg CQ once daily for 3 days (for ≥20 kg weight: AZ/CQ 300/100 mg per tablet; 5 to <20 kg weight: AZ/CQ 150/50 mg per tablet)." | ( Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets. Chandra, R; Mould, DR; Tensfeldt, TG; Zhao, Q, 2014) | 0.4 |
| " Assuming equivalent dosing (mg/kg), AZ and CQ exposure in children would be expected to be lower than that in adults, suggesting that children may require a higher dose (mg/kg) than adults to achieve the same AZ and CQ exposure." | ( Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets. Chandra, R; Mould, DR; Tensfeldt, TG; Zhao, Q, 2014) | 0.4 |
| " Clearance (CL0-24/F) was similar in both dosing groups (1." | ( Azithromycin pharmacokinetics in the serum and its distribution to the skin in healthy dogs and dogs with pyoderma. Britzi, M; Lavy, E; Perry, E; Soback, S; Weiss, Y; Zur, G, 2014) | 0.4 |
| "3% eye drops in the treatment of purulent bacterial conjunctivitis in children, with a more convenient twice-a-day dosing regimen." | ( Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. Bianchi, PE; Bremond-Gignac, D; Chiambaretta, F; Delval, L; Hartani, D; Kaercher, T; Kocyla-Karczmarewicz, B; Lazreg, S; Messaoud, R; Murta, J; Nezzar, H; Renault, D; Speeg-Schatz, C; Voinea, L, 2014) | 0.4 |
| "According to label claims, in commercial solid dosage forms, azithromycin (AZI) exists either as a monohydrate (MH) or as a dihydrate (DH)." | ( Azithromycin hydrates-implications of processing-induced phase transformations. Sundaramurthi, P; Suryanarayanan, R, 2014) | 0.4 |
| " AZ dosing yields substantial fetal tissue uptake, although fetal plasma drug levels remain low; (ii) transfer of AZ from the amniotic fluid is less than transplacental transfer; and (iii) exposure to high concentrations of AZ did not elicit overt changes in fetal white blood cell counts, amniotic fluid monocyte chemoattractant protein 1 concentrations, or hepatotoxicity, all consistent with an absence of fetal injury." | ( Maternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy. Clarke, M; Hahne, D; Ireland, DJ; Jobe, AH; Kallapur, SG; Keelan, JA; Kemp, MW; Miura, Y; Newnham, JP; Payne, MS; Rodger, J; Saito, M; Spiller, OB; Stock, SJ; Yaegashi, N, 2014) | 0.4 |
| " It is a major determinant of half-life and dosing frequency of a drug." | ( Volume of Distribution in Drug Design. Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015) | 0.42 |
| " However, excellent adherence (defined as no tablets missed) was better in single dosing arm (98." | ( Comparative evaluation of 2 g single dose versus conventional dose azithromycin in uncomplicated skin and skin structure infections. Das, AK; Dey, SK; Hazra, A; Sen, S, ) | 0.13 |
| "Single 2 g azithromycin dose achieved the same result as conventional azithromycin dosing in uSSSI with comparable tolerability but with the advantage of assured adherence." | ( Comparative evaluation of 2 g single dose versus conventional dose azithromycin in uncomplicated skin and skin structure infections. Das, AK; Dey, SK; Hazra, A; Sen, S, ) | 0.13 |
| " Increasing the dosage regimen can be applied to ceftriaxone and azithromycin, but the emergence of high-level resistance has already been reported." | ( New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae. Chong, Y; Lee, H; Lee, K, 2016) | 0.43 |
| " The treatment dose of azithromycin has mostly been borrowed from that used to treat other bacterial pneumonias; there are no formal dose-response studies in pulmonaryM." | ( Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. Deshpande, D; Gumbo, T; Pasipanodya, JG, 2016) | 0.43 |
| " High dosage and repeated ingestion of antibiotics in the treatment of pneumonia leads to undesirable effects and inappropriate disposition of the drug." | ( High azithromycin concentration in lungs by way of bovine serum albumin microspheres as targeted drug delivery: lung targeting efficiency in albino mice. Boggarapu, PR; Kapanigowda, UG; Nagaraja, SH; Ramaiah, B; Subramanian, R, 2016) | 0.43 |
| " Beyond the neonatal period, acyclovir is more safely dosed by body surface area (not to exceed 500 mg/m(2)/dose) than by weight." | ( Optimizing antimicrobial therapy in children. Long, SS, 2016) | 0.43 |
| " Omadacycline offers once daily oral and IV dosing and a clinical tolerability and safety profile that compares favorably with contemporary antibiotics used across serious community-acquired infections where resistance has rendered many less effective." | ( Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Steenbergen, J; Tanaka, SK; Villano, S, 2016) | 0.43 |
| "A single oral dose of azithromycin, at a dosage of 30mg/kg, was non-inferior to a single dose of intramuscular benzathine penicillin for the treatment of early yaws among Ghanaian patients, and provides additional support for the WHO policy for use of oral azithromycin for the eradication of yaws in resource-poor settings." | ( A Single Dose Oral Azithromycin versus Intramuscular Benzathine Penicillin for the Treatment of Yaws-A Randomized Non Inferiority Trial in Ghana. Adu-Sarkodie, Y; Agana, N; Aryee, E; Asiedu, K; Ballard, R; Binka, F; Gyapong, J; Kwakye-Maclean, C; Nortey, P, 2017) | 0.46 |
| "The EC 50 of the dose-response curves correlated well with Etest MIC values (Pearson's r = 0." | ( A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae. Althaus, CL; Desilvestro, V; Foerster, S; Hathaway, LJ; Unemo, M, 2017) | 0.46 |
| "Initially, dosing regimen following ICV administrations of AZM at different post-natal days and concentrations was determined by their impact on SMN levels in disease-relevant tissues." | ( Analysis of Azithromycin Monohydrate as a Single or a Combinatorial Therapy in a Mouse Model of Severe Spinal Muscular Atrophy. Greif, H; Lorson, CL; Megiddo, D; Osman, EY; Simon, ME; Washington, CW, ) | 0.13 |
| " The formation of biofilms at the disease sites makes the treatment more complicated by protecting bacteria from antimicrobial agents and thus necessitating a much higher dosage of antibiotics to eradicate the biofilms." | ( Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the treatment of pneumonia. Hickey, D; Li, Y; Mi, G; Shen, Y; Tu, J; Wang, Q; Webster, TJ, 2018) | 0.48 |
| " However, based on our data, one cannot rule out suboptimal dosing in our study; attempts to study azithromycin at a different mode of application might be warranted in the future." | ( Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial. Dolak, W; Kiesewetter, B; Lagler, H; Lamm, WW; Lukas, J; Mayerhoefer, ME; Neuper, O; Obermueller, M; Raderer, M; Simonitsch-Klupp, I, 2019) | 0.51 |
| "Our findings showed that NPs gave sustained release of drugs inside plasma and organs, thus decreasing dosage frequency, and their weekly dosage had therapeutic efficacy equivalent to daily dosage of free drugs." | ( Therapeutic implications of nano-encapsulated rifabutin, azithromycin & ethambutol against experimental Grewal, TK; Majeed, S; Sharma, S, 2018) | 0.48 |
| " Trials were heterogenous in terms of dosing of interventions and outcome measures." | ( Antibiotics for treating scrub typhus. El Sayed, I; Hine, P; Liu, Q; Wee, I, 2018) | 0.48 |
| " Serial blood samples for the determination of venetoclax concentrations were collected after dosing in both periods." | ( Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. Agarwal, SK; Bueno, OF; Menon, RM; Salem, AH; Tong, B, 2018) | 0.48 |
| " The dosage regimen was further estimated based on Monte Carlo simulation and the area under the curve/minimal inhibitory concentration." | ( Population Pharmacokinetic Modeling of Azithromycin Eyedrops in Tears Following Single-Dose Topical Administration in Healthy Volunteers. Cui, Y; Li, X; Wu, F; Zhao, X, 2019) | 0.51 |
| "The study aimed to mask and evaluate the unpleasant bitter taste of azithro-mycin (AZ) in the dry suspension dosage form by physisorption technique." | ( A new strategy for taste masking of azithromycin antibiotic: development, characterization, and evaluation of azithromycin titanium nanohybrid for masking of bitter taste using physisorption and panel testing studies. Alsaid, MS; Amin, F; Hussain, Z; Khan, S; Rahim, H; Shah, SMH; Shahat, AA; Sohail, M; Ullah, R, 2018) | 0.48 |
| " The optimized nanohybrid was blended with other excipients to get stable and taste masked dry suspension dosage form." | ( A new strategy for taste masking of azithromycin antibiotic: development, characterization, and evaluation of azithromycin titanium nanohybrid for masking of bitter taste using physisorption and panel testing studies. Alsaid, MS; Amin, F; Hussain, Z; Khan, S; Rahim, H; Shah, SMH; Shahat, AA; Sohail, M; Ullah, R, 2018) | 0.48 |
| " Suggestions are also provided on possible dosing regimens when using extended and/or higher doses of azithromycin, which appropriately balance efficacy and side effects." | ( Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. Hocking, JS; Horner, P; Kong, FYS; Unemo, M, 2019) | 0.51 |
| " In addition, studies remain insufficient to establish the optimal dosage and duration of azithromycine." | ( [Azithromycine and chronic bronchial diseases: For which patients? For which benefits? With what modalities?] Pronost, P; Tromeur, C, 2019) | 0.51 |
| "The objective of the study was to evaluate whether there are differences in the latency from preterm premature rupture of membranes to delivery in patients treated with different dosing regimens of azithromycin vs erythromycin." | ( Azithromycin vs erythromycin for the management of preterm premature rupture of membranes. Bachilova, S; Berghella, V; Heidari, P; Hoffman, MK; Navathe, R; Roman, A; Schoen, CN; Smith, S; Tepper, J; Visintainer, P; Ward, A, 2019) | 0.51 |
| "There was no difference in latency to delivery, incidence of chorioamnionitis, or neonatal outcomes when comparing different dosing regimens of the azithromycin with erythromycin, with the exception of respiratory distress syndrome being more common in the 5 day azithromycin group." | ( Azithromycin vs erythromycin for the management of preterm premature rupture of membranes. Bachilova, S; Berghella, V; Heidari, P; Hoffman, MK; Navathe, R; Roman, A; Schoen, CN; Smith, S; Tepper, J; Visintainer, P; Ward, A, 2019) | 0.51 |
| " However, any further trials with longer dosing need to consider the potential risk of gastrointestinal effects and liver enzyme elevations." | ( Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial. Avery, A; Bradshaw, CS; Chen, MY; Das, AF; Donovan, B; Fairley, CK; Hardy, D; Hocking, JS; Howden, BP; McNulty, A; Nenninger, A; Oldach, D; Tabrizi, SN; Whiley, D, 2019) | 0.51 |
| " Here, we examined the appropriate dosage of oral AZM for human epididymal tissue by site-specific pharmacokinetic/pharmacodynamic (PK/PD) analysis." | ( Clinical pharmacokinetics of oral azithromycin in epididymal tissue. Araki, M; Fujiyoshi, M; Ikawa, K; Ishii, A; Mitsui, M; Morikawa, N; Nasu, Y; Sadahira, T; Wada, K; Watanabe, M; Watanabe, T, 2019) | 0.51 |
| " Treatment duration with AZM ranged from 3 to 5 days with a maximum dosage of 500 mg/day, gingival response was measured by using various scoring systems." | ( Does systemically administered azithromycin have an effect on gingival overgrowth? A systematic review. Fuchs, MD; Mendes, S; Schmidt, JC; Signer-Buset, SL; Walter, C, 2019) | 0.51 |
| "The effectiveness of azithromycin combined with full-mouth scaling procedures was compared to quadrant-wise scaling combined with the same dosage of azithromycin when treating periodontitis patients over a 6-month period." | ( Azithromycin and Full-Mouth Scaling For the Treatment of Generalized Stage III and IV Periodontitis: A 6-Month Randomized Comparative Clinical Trial. Aquino, DR; Cortelli, JR; Cortelli, SC; Costa, FO; Miranda, TB; Nogueira, LMR; Oliveira, AMSD; Oliveira, PAD, 2019) | 0.51 |
| " Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination." | ( A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020) | 0.56 |
| " In an era of increasing antimicrobial resistance, further studies are required to define appropriate azithromycin dosing regimens for enteric fever and to assess novel treatment strategies, including combination therapies." | ( Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model. Aljayyoussi, G; Angus, B; Ardrey, A; Biagini, GA; Feasey, NA; Gibani, MM; Jin, C; Liu, X; Moore, M; Parry, CM; Pennington, SH; Pollard, AJ, 2019) | 0.51 |
| " There are significant differences in the dosing of azithromycin and results of treatment of non-gonococcal urethritis among doctors with different professional titles, but not in the other aspects." | ( [Diagnosis and treatment of male urethritis in urology and andrology: A status survey]. Cai, J; Li, CD; Wu, ZG; Xiao, YB; Zhou, CF, 2019) | 0.51 |
| "The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir." | ( Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. Albuquerque, BC; Alexandre, MAA; Baía-da-Silva, D; Balieiro, AAS; Bassat, Q; Borba, MGS; Brito, M; Brito-Sousa, JD; Croda, J; Daniel-Ribeiro, CT; Fontes, CJ; Guerra, MVF; Hajjar, LA; Lacerda, MVG; Melo, GC; Monteiro, WM; Mourão, MPG; Naveca, FG; Nogueira, ML; Pacheco, AGF; Pinto, RC; Romero, GAS; Sampaio, VS; Santos, JDO; Schwarzbold, A; Siqueira, AM; Val, FFA; Xavier, MS, 2020) | 0.56 |
| " Although a number of different dosage regimens were assessed, the purpose of our study was not to provide recommendations for a dosing strategy, but to demonstrate the utility of a physiologically-based pharmacokinetic modeling approach to estimate lung concentrations." | ( Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling. Almond, LM; Ban Ke, A; Jones, HM; Pan, X; Rowland Yeo, K; Wesche, D; Zhang, M, 2020) | 0.56 |
| " The long-acting injectable preparation of doxycycline was well tolerated by koalas when administered via the subcutaneous route, and the weekly dosing requirement is a major advantage when treating wild animals." | ( Clinical comparison of five anti-chlamydial antibiotics in koalas (Phascolarctos cinereus). Booth, R; Nyari, S, 2020) | 0.56 |
| " In their study they conclude that prolonged treatment with azithromycin (at least 3 months) reduces the number of asthma exacerbations; however, the conclusions of this review should be interpreted carefully as the included studies vary in study design, dosing schedule and severity of the asthma." | ( [Azithromycin to prevent asthma exacerbations: only for patients with non-eosinophilic asthma]. Braunstahl, GJ, 2020) | 0.56 |
| " Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens." | ( An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria inf Bennett, J; Cicatelli, S; DeLuca, J; Duncan, EH; Hamer, M; Hutter, J; Kreishman-Deitrick, M; Lee, C; Livezey, J; Mills, K; Moon, JE; Morrison, M; Oliver, T; Poon, L; Sedegah, M; Selig, D; Sikaffy, A; Sousa, J; Tosh, D; Twomey, P; Vuong, C; Waterman, P, 2020) | 0.56 |
| " The choice of (typically subtherapeutic) dosing regimens, influenced partly by "QT-phobia," varied widely and seems anecdotal without any pharmacologically reliable supporting clinical evidence." | ( Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. Shah, RR, 2021) | 0.62 |
| " We may also need to examine other dosage regimens for azithromycin." | ( Azithromycin in the treatment of rectogenital Hammerschlag, MR; Sharma, R, 2021) | 0.62 |
| "Overuse or abuse of antibiotics has undoubtedly accelerated the increasing prevalence of global antibiotic resistance crisis, and thus, people have been trying to explore approaches to decrease dosage of antibiotics or find new antibacterial agents for many years." | ( The Synergistic Effect of Mud Crab Antimicrobial Peptides Sphistin and Sph Chen, F; Liu, J; Peng, H; Wang, KJ; Wang, X; Zhang, H, 2020) | 0.56 |
| "7%)) and incorrect dosing (n=6 (10." | ( Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital. Belmas, AS; Danion, F; Fourtage, M; Gourieux, B; Michel, B; Nai, T; Nivoix, Y; Reisz, F; Reiter-Schatz, A; Ruch, Y; Walther, J, 2021) | 0.62 |
| " For the lack of efficacy, we discuss the fundamental differences of treatment initiation between in vitro and in vivo studies, the pitfalls of the pharmacological calculations of effective blood drug concentrations and related dosing regimens, and the possible negative effect of HCQ on the antiviral type-I interferon response." | ( It is time to drop hydroxychloroquine from our COVID-19 armamentarium. Kashour, T; Tleyjeh, IM, 2020) | 0.56 |
| "This guideline included eighteen recommendations that covered four domains: (a) Indications: the treatment of pneumonia caused by atypical but common pathogens, such as Mycoplasma pneumoniae, Chlamydia trachomatis or Chlamydophila pneumoniae and Legionella pneumophila, more typical bacteria as well as the treatment of bronchitis of presumed bacterial aetiologies; (b) Usage and dosage: administration route, infusion concentrations, treatment duration, course of sequential treatment, and dosage stratified by age; (c) Adverse reactions and treatment: the management of gastrointestinal reactions, arrhythmias, pain or phlebitis at the infusion site, and anaphylaxis; and (d) Special population: children with renal or liver dysfunction, congenital heart disease, and obesity." | ( Recommendations on off-label use of intravenous azithromycin in children. Shen, K; Tong, X; Wang, X; Xu, B; Zhai, S; Zhang, X; Zhou, P; Zhou, W, 2021) | 0.62 |
| "Our findings support extended azithromycin dosing as an alternative treatment option for symptomatic LGV proctitis and provides the rationale for future randomized trials." | ( Effective Treatment of Lymphogranuloma venereum Proctitis With Azithromycin. Alsina-Gibert, M; Blanco, JL; Blanco-Arevalo, A; Bosch, J; Cranston, RD; De Lazzari, E; Estrach, T; Fuertes, I; Gatell, JM; Gonzalez-Cordón, A; Inciarte, A; Martinez, E; Mayans, J; Vergara, A, 2021) | 0.62 |
| " Further research is required to establish an optimal dosage regimen of azithromycin in OAD." | ( Patterns of azithromycin use in obstructive airway diseases: a real-world observational study. Gibson, PG; Gupta, S; Majellano, E; McDonald, VM; Simpson, JL; Smith, A; Thomas, D, 2022) | 0.72 |
| " Clinicians should consider efficacy with convenience of dosing regimen, medication compliance, and sexual behavior risks when treating chlamydia infections." | ( Challenges in Treating Kang-Birken, SL, 2022) | 0.72 |
| " However, previous studies have used different dosing regimens, and the efficacy of these regimens has not been compared." | ( Efficacy of Low-Dose versus High-Dose Continuous Cyclic Azithromycin Therapy for Preventing Acute Exacerbations of COPD. Casabella, A; Cuevas, E; Huertas, D; Marín, A; Martí, S; Montón, C; Oliva, JC; Pomares, X; Santos, S, ) | 0.13 |
| "In this cluster-randomized controlled trial, children aged 1 to 10 years in rural communities in the Goncha Seso Enesie district of Ethiopia were randomized to either no treatment or treatment with a single dose of oral azithromycin (height-based dosing to approximate 20 mg/kg) every 3 months for 1 year." | ( Effect of Azithromycin on the Ocular Surface Microbiome of Children in a High Prevalence Trachoma Area. Ayele, B; Chen, C; Doan, T; Emerson, PM; Gebre, T; Hinterwirth, A; Keenan, JD; Lietman, TM; Porco, TC; Ruder, K; Zerihun, M; Zhong, L; Zhou, Z, 2022) | 0.72 |
| " Age, weight or body-mass-index had no significant influence on plasma levels and thence should not be considered in dosage finding." | ( Azithromycin concentrations during long-term regimen, a pilot study in patients with MALT lymphoma. Lagler, H; Lamm, WW; Neuper, O; Obermüller, M; Raderer, M; Reznicek, G; Scheibenpflug, R, 2021) | 0.62 |
| " In 2 patients the pyridostigmine dosage had to be increased." | ( Myasthenia gravis and covid-19 in pregnancy: a review of the literature and case series report. Ignatov, PN; Milanova, M; Neykova, KK, 2022) | 0.72 |
| " Although azithromycin may have advantages over amoxicillin in terms of dosing and administration for uncomplicated severe acute malnutrition, it may not yield additional benefit for malaria outcomes." | ( Azithromycin versus Amoxicillin and Malarial Parasitemia among Children with Uncomplicated Severe Acute Malnutrition: A Randomized Controlled Trial. Arnold, BF; Arzika, AM; Boudo, V; Dah, C; Lebas, E; Nyatigo, F; O'Brien, KS; Oldenburg, CE; Ouédraogo, M; Ourohiré, M; Sié, A, 2021) | 0.62 |
| " He was treated with azithromycin, isoprinosine, lopinavir, and fondaparinux with thromboprophylaxis dosage since admission." | ( The Challenging Anticoagulant Therapy in COVID19 Patient with Associated Coagulopathy. Airlangga, MP; Fatimah, FN; Miftahussurur, M; Pradana, AD; Rianda, RA; Rianda, RV; Subkhan, M, 2021) | 0.62 |
| " There was substantial heterogeneity in the diagnostic methods used, treatment administered (including dosing and duration), and outcome assessed across studies." | ( Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform. Day, NPJ; Guérin, PJ; Maguire, BJ; McLean, ARD; Newton, PN; Ngu, RC; Saraswati, K; Singh-Phulgenda, S, 2021) | 0.62 |
| " Azithromycin indications, timing, and dosing varied significantly, and 37 (36%) reported inconsistency even within their center." | ( Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community. Goss, CH; Hachem, RR; Kapnadak, SG; Merlo, CA; Morrell, ED; Ramos, KJ; Shah, PD; Wai, TH, 2022) | 0.72 |
| " Dose-response curves in single-molecule assays with hydroxychloroquine were created for isolates with suspected reduced susceptibility." | ( Heterogeneity in susceptibility to hydroxychloroquine of SARS-CoV-2 isolates. Aherfi, S; Andreani, J; Bideau, ML; Boschi, C; Colson, P; Delerce, J; Gendrot, M; Jardot, P; La Scola, B; Levasseur, A; Pradines, B, 2021) | 0.62 |
| " The dose-response model showed a decrease in susceptibility of these three strains to hydroxychloroquine." | ( Heterogeneity in susceptibility to hydroxychloroquine of SARS-CoV-2 isolates. Aherfi, S; Andreani, J; Bideau, ML; Boschi, C; Colson, P; Delerce, J; Gendrot, M; Jardot, P; La Scola, B; Levasseur, A; Pradines, B, 2021) | 0.62 |
| " An observational assessment of MDA for trachoma was conducted to determine the frequency with which children aged 6 mo through 14 y received the recommended dose and form of azithromycin according to current dosing guidelines and to assess risk factors for choking and adverse swallowing events (ASEs)." | ( An observational assessment of the safety of mass drug administration for trachoma in Ethiopian children. Addiss, DG; Alemu, M; Ciciriello, AM; Emerson, PM; Gebre, T; Hooper, PJ; Kebede, F; Kiflu, G; LaCon, G; Seid, M; Seife, F; Sormolo, MJ; Tadesse, G; Teferi, T; West, SK, 2022) | 0.72 |
| "There is a high level of adherence to the revised azithromycin dosing guidelines and low incidence of choking and ASEs." | ( An observational assessment of the safety of mass drug administration for trachoma in Ethiopian children. Addiss, DG; Alemu, M; Ciciriello, AM; Emerson, PM; Gebre, T; Hooper, PJ; Kebede, F; Kiflu, G; LaCon, G; Seid, M; Seife, F; Sormolo, MJ; Tadesse, G; Teferi, T; West, SK, 2022) | 0.72 |
| " Almost all were willing to retake the same dosing for gonorrhoea in the future: 97% for 1 g single; 94% for 2 g single; and 97% for 2 g split dose." | ( Comparison of gastrointestinal side effects from different doses of azithromycin for the treatment of gonorrhoea. Aguirre, I; Chen, MY; Chow, EPF; Fairley, CK; Hocking, JS; Kong, FYS; Ly, J; Ong, JJ; Tieosapjaroen, W; Unemo, M, 2022) | 0.72 |
| " Azithromycin and doxycycline demonstrated MICs and MBCs equal or below their peak serum concentrations (PSC) after standard dosing in both cell types." | ( Clearing Chlamydia abortus infection in epithelial cells and primary human macrophages by use of antibiotics and the MDM2-p53-inhibitor nutlin-3. Diensthuber, D; Essig, A; Hagemann, JB; Peters, S; Simnacher, U; Walther, P, 2022) | 0.72 |
| " In the study, the within-subject standard deviation for area under the serum concentration-time profile from time 0 to 72 hours after dosing in the fasted condition was <0." | ( A Reference-Scaled Average Bioequivalence Study of Azithromycin Tablets Manufactured in China and the United States: An Open-Label, Randomized, Single-Dose, 3-Way Crossover Study in Healthy Chinese Subjects Under Fasted and Fed Conditions. Ding, Y; Ge, B; Li, C; Liu, Y; Peng, A; Wei, H; Wu, M; Zhang, K, 2022) | 0.72 |
| " However, the optimal dosing regimens of macrolides have not been determined, and its efficacy in Chinese NCFB population has not been validated." | ( Daily versus three-times-weekly azithromycin in Chinese patients with non-cystic fibrosis bronchiectasis: protocol for a prospective, open-label and randomised controlled trial. Chen, F; Chen, L; Fan, B; Fu, W; He, T; Li, F; Li, J; Mao, Y; Ni, W; Xiao, W; You, H; Zou, A, 2022) | 0.72 |
| " Blood culture reports were collected from microbiology departed and clinical data were assessed regarding the choice of antibiotics, frequency, dosage and clinical outcome." | ( A clinical audit to evaluate antibiotic prescribing practice in pediatric patients admitted for enteric fever. Rationalizing antibiotic stewardship program. Ali, I; Asghar Gill, I; Asghar, U; Hassan, MN; Hussain, A; Naheed, F; Numan Zahid, M; Shahid, A; Shahid, M, 2022) | 0.72 |
| " All cases received either oral clarithromycin at 500 mg twice-daily dosage or oral azithromycin at 500 mg daily." | ( Outcomes of Nontuberculous Mycobacterial Keratitis After Clear Corneal Incision Phacoemulsification Surgery: A Case Series of 6 Eyes in South Florida. Chhaya, N; Koo, EH; Miller, D; Shaik, N; Tonk, RS; Weiss, M; Zhu, A, 2022) | 0.72 |
| " The dosage of AZI prescribed was 250 mg three times per week." | ( Early onset of azithromycin to prevent CLAD in lung transplantation: Promising results of a retrospective single centre experience. Alonso Lecue, P; Cifrián Martínez, JM; Cristeto Porras, M; Iturbe Fernández, D; Izquierdo Cuervo, S; Miñambres García, E; Mora Cuesta, VM; Naranjo Gozalo, S; Sánchez Moreno, L; Tello Mena, S, 2023) | 0.91 |
| " Given the low plasma concentrations of azithromycin achieved in the study, it is not surprising that half the animals succumbed to anthrax during the dosing period; the animals that survived beyond the time during which placebo control animals succumbed survived to the end of the observation period." | ( Determination of the Postexposure Prophylactic Benefit of Oral Azithromycin and Clarithromycin Against Inhalation Anthrax in Cynomolgus Macaques. Crumrine, M; Hewitt, JA; Slay, RM, 2022) | 0.72 |
| " Height-based dosing was evaluated against the existing trachoma dosing pole and with a similar exhaustive search." | ( Simplified dosing of oral azithromycin for children 1-11 months old in child survival programmes: age-based and height-based dosing protocols. Abdou, A; Arzika, AM; Bamba, I; Boudo, V; Bountogo, M; Brogdon, J; Emerson, P; Hooper, PJ; Hu, H; Knirsch, C; Lebas, E; Lietman, TM; Maliki, R; Mankara, AK; Nyatigo, F; O'Brien, KS; Oldenburg, CE; Outtara, M; Sie, A; Yago-Wienne, F, 2022) | 0.72 |
| " The optimisation identified height-based dosing options with 95% accuracy, although this would require changes to the existing dosing pole as well as additional training to measure infants lying flat." | ( Simplified dosing of oral azithromycin for children 1-11 months old in child survival programmes: age-based and height-based dosing protocols. Abdou, A; Arzika, AM; Bamba, I; Boudo, V; Bountogo, M; Brogdon, J; Emerson, P; Hooper, PJ; Hu, H; Knirsch, C; Lebas, E; Lietman, TM; Maliki, R; Mankara, AK; Nyatigo, F; O'Brien, KS; Oldenburg, CE; Outtara, M; Sie, A; Yago-Wienne, F, 2022) | 0.72 |
| "Azithromycin eye drops with a bioadhesive ocular drug-delivery system can offer a simplified dosing regimen." | ( A Bioequivalence Study With Pharmacokinetic Endpoints for Azithromycin Eye Drops. Dai, Y; Guo, S; Han, Y; Ma, K; Ni, S; Wang, Y; Wu, F; Zhao, X, 2023) | 0.91 |
| " The reduced dosing and potentially fewer gastrointestinal AEs associated with azithromycin support its use as an alternative to doxycycline for at least 6 weeks." | ( Pulsed Oral Azithromycin vs 6-Week Oral Doxycycline for Moderate to Severe Meibomian Gland Dysfunction: A Randomized Clinical Trial. Phinyo, P; Tangmonkongvoragul, C; Upaphong, P, 2023) | 0.91 |
| " The final developed pediatric PBPK model was used to evaluate optimal dosing for children of different developmental ages." | ( Develop adult extrapolation to pediatrics and pediatric dose optimization based on the physiological pharmacokinetic model of azithromycin. Li, D; Li, W; Liang, L; Pu, S; Xiang, R; Zhai, F; Zhang, Z, 2023) | 0.91 |
| " Few serious adverse events occurred for ALIS users; however, reduction of dosing to three times weekly was common (52%)." | ( Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. Brown-Elliott, BA; Brunton, AE; Fuss, C; Griffith, DE; Philley, JV; Siegel, SAR; Strnad, L; Sullivan, PE; Wallace, RJ; Winthrop, KL, 2023) | 0.91 |
| " The most apparent changes might be in high-dose, mid-pregnancy, multi-course, and female, while there was no typical rule for a dose-response relationship." | ( Azithromycin exposure during pregnancy disturbs the fetal development and its characteristic of multi-organ toxicity. Ao, Y; Dai, Y; Li, X; Lu, X; Mao, T; Wang, H; Zhu, L, 2023) | 0.91 |
| " With various dosing devices being designed for manufacture by 3D printing, 3D-printed ophthalmic formulations to release drugs have been one such target of investigation." | ( Fabrication of 3D-Printed Contact Lens Composed of Polyethylene Glycol Diacrylate for Controlled Release of Azithromycin. Goto, E; Ogawa, K; Ozeki, T; Tagami, T, 2023) | 0.91 |
| "Amoxicillin, ceftriaxone, several oral cephalosporins, tedizolid, and dalbavancin exhibited anti-treponemal activity at concentrations achievable in human plasma following regular dosing regimens." | ( Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study. Canut, A; Giacani, L; González-Beiras, C; González-Candelas, F; Greninger, AL; Lieberman, NAP; Mitjà, O; Mueller, J; Pérez-Mañá, C; Rodríguez-Gascón, A; Suñer, C; Tantalo, LC; Tapia, K; Ubals, M; Vall Mayans, M, 2023) | 0.91 |
| " Azithromycin is currently used for the treatment of acne, with different dosing regimens for patients who cannot receive traditional treatment based on practice guidelines." | ( Azithromycin Treatment for Acne Vulgaris: A Case Report on the Risk of Clostridioides difficile Infection. Alasqah, MA; Alhubaishi, AA; Alkahtani, RM; Almuwinea, AI; Alnajjar, LI; Bakkari, S, 2023) | 0.91 |
| Role | Description |
|---|---|
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| environmental contaminant | Any minor or unwanted substance introduced into the environment that can have undesired effects. |
| xenobiotic | A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| macrolide antibiotic | A macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Azithromycin Action Pathway | 1 | 4 |
| Interferon 1 pathway (COVID-19 Disease Map) | 5 | 1 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| interleukin 8 | Homo sapiens (human) | Potency | 66.8242 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| PPM1D protein | Homo sapiens (human) | Potency | 20.8212 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| TDP1 protein | Homo sapiens (human) | Potency | 23.1093 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 18.9811 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259369; AID1259392 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 7.9433 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 36.6948 | 0.0123 | 7.9835 | 43.2770 | AID1346984; AID1645841 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 28.7014 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 15.0362 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 51.0391 | 0.0015 | 30.6073 | 15,848.9004 | AID1224849 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 0.0952 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 25.8040 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| IDH1 | Homo sapiens (human) | Potency | 5.8048 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 10.1836 | 0.0016 | 28.0151 | 77.1139 | AID1224895 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 0.1000 | 9.1916 | 31.6228 | AID1346983 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 31.9063 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 51.0391 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
| geminin | Homo sapiens (human) | Potency | 10.6505 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.6310 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Interferon beta | Homo sapiens (human) | Potency | 20.8212 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 33.4915 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 4.4668 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.1100 | 7.1903 | 10.0000 | AID1473738 |
| 30S ribosomal protein S6 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S7 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L15 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0001 | 1.7536 | 10.0000 | AID696099; AID696100 |
| 50S ribosomal protein L10 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L11 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L7/L12 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L19 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L1 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L20 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L27 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L28 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L29 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L31 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L31 type B | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L32 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L33 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L34 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L35 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L36 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S10 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S11 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S12 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S13 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S16 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S18 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S19 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S20 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S2 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S3 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S4 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S5 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S8 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S9 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L13 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L14 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L16 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L23 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S15 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L17 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L21 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L30 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L6 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S14 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S17 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S1 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L18 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L2 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L3 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L24 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L4 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L22 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L5 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 30S ribosomal protein S21 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L25 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| 50S ribosomal protein L36 2 | Escherichia coli K-12 | IC50 (µMol) | 0.3000 | 0.0089 | 1.2035 | 5.0000 | AID431505 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| Protein-arginine deiminase type-4 | Homo sapiens (human) | IC50 (µMol) | 10,000.0000 | 2.5000 | 4.2000 | 5.9000 | AID320706 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 0.0600 | 0.0600 | 8.9128 | 130.5170 | AID1902 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| twin arginine protein translocation system - TatA protein | Escherichia coli str. K-12 substr. MG1655 | AC50 | 29.3410 | 0.7070 | 10.9151 | 45.8560 | AID504941 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1055343 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 09-6 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID425571 | Antibacterial activity against penicillin-, macrolide-susceptible and quinolone-resistant Streptococcus pneumoniae HMC 1074 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutat | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID519203 | Antibacterial activity against Streptococcus pneumoniae assessed as susceptible isolates by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
| AID508402 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3665 harboring mef(A) gene after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID642859 | Antibacterial activity against efflux mediated macrolide resistant Streptococcus pneumoniae by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID428890 | Bactericidal activity against stationary-phase Pseudomonas aeruginosa PT1308 culture expressing Clostridium perfringens 23S rRNA methylase ErmBP assessed as effect on cell viability at 1 to 16 ug/ml after 22 hrs by plating serial dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID1549366 | Antibacterial activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID508412 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after 14 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID545938 | Ratio of MIC for Enterobacter cloacae ATCC 23355 to MIC for Enterobacter cloacae ATCC 23355 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID1487247 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mefA gene | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID279866 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM prochlorperazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID558630 | Antimicrobial activity against Streptococcus pneumoniae isolate 4747 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID573427 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB selected at 4 ug/ml of compound after 6 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1487245 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes isolate R2 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID1326851 | Antibacterial activity against Enterococcus faecalis MB5407 by broth microdilution technique | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | A Gestalt approach to Gram-negative entry. |
| AID470194 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID520409 | Antimicrobial activity against macrolide-susceptible Streptococcus sp. 'group A' by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID565308 | Antibacterial activity against Mycoplasma genitalium by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID498874 | Antimicrobial activity against Neisseria meningitidis M7tolC::Kan by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli. |
| AID558085 | Antimicrobial activity against Mycoplasma fermentans isolated from human by two fold serial dilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. |
| AID529898 | Antimicrobial activity against Leptospira weilii isolate 6 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID565331 | Antibacterial activity against Mycoplasma genitalium M6287 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID85944 | The compound was tested in vitro for antibacterial activity against 47 strains of Haemophilus influenza AmpS; Value is 0.15/1.2 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID559078 | Antibacterial activity against Klebsiella oxytoca by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID428897 | Ratio of bactericidal activity against Pseudomonas aeruginosa PT712 harboring mutation in bacterial rhlA protein to bactericidal activity against wild type Pseudomonas aeruginosa PAO1 PT5 | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID559055 | Antibacterial activity against Lancefield Streptococcus sp. 'group C' by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1691400 | Antibacterial activity against MLSB/methicillin-resistant Staphylococcus aureus 15B196 assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID422661 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 15 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID529304 | Antimicrobial activity against Acinetobacter baumannii isolate Ac058 expressing beta-lactamase Oxa-58 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. |
| AID735591 | Antibacterial activity against methicillin-susceptible, MLS-resistant (inducible) Staphylococcus epidermidis E1 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID535567 | Antibacterial activity against Salmonella enterica serovar blockley harboring G235A mutation in rlpD gene by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID483696 | Antimicrobial activity against inducible macrolide and constitutive lincosamide, streptogramin-resistant Streptococcus pneumoniae 4636 | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID285523 | Antibacterial activity against Moraxella catarrhalis after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID533856 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium mucogenicum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID423237 | Antibacterial activity against beta lactamase-positive Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID724185 | Antibacterial activity against erythromycin susceptible Streptococcus pneumoniae SP 030 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID508386 | Antibacterial activity against macrolide-resistant Streptococcus pyogenes harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID575944 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. |
| AID499551 | Antibacterial activity against constitutive macrolide-lincosamide-streptogramin B-resistant Staphylococcus aureus B0330 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID571450 | Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of 2 ug/ml NAB7062 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1498158 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes R1 after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID522360 | Antimicrobial activity against Neisseria gonorrhoeae isolate 3783 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. |
| AID559044 | Antibacterial activity against Listeria monocytogenes by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559066 | Antibacterial activity against Streptococcus oralis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1720814 | Bactericidal activity against violacein-negative Chromobacterium violaceum CV026 mini-Tn5 mutant at 400 uM by resazurin dye based assay relative to control | 2020 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16 | Chloroquine fumardiamides as novel quorum sensing inhibitors. |
| AID574693 | Enhancement of biofilm formation Staphylococcus epidermidis SW067 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID1459116 | Antibacterial activity against Haemophilus influenzae by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID416428 | Antimicrobial activity in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene infected in ftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse lung assessed as debris-like granular material surrounding polymorphonuc | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID279210 | Antibacterial activity against Streptococcus pneumoniae 2527 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID559042 | Antibacterial activity against vancomycin- resistant Enterococcus faecalis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425339 | Antibacterial activity against azithromycin-resistant Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1055344 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID99722 | Antibacterial activity against Legionella; More active | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | New directions in antibacterial research. |
| AID576339 | Antimicrobial activity against Chlamydia trachomatis serovar I infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID554653 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA20 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID571928 | Ratio of MIC for Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB mutant gene to MIC for Escherichia coli K-12 3-AG300 | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID83640 | The compound has been evaluated for the antibacterial activity against Haemophilus influenzae 351HT3 (beta-lactamase +) | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID207841 | Minimum inhibitory concentration against macrolide susceptible strain of Staphylococcus aureus (MB2865) | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: I. 4", 11 and 12-OMe derivatives via direct methylation. |
| AID663037 | Antimalarial activity against mefloquine-resistant Plasmodium falciparum TM91C235 assessed as [3H]hypoxanthine incorporation after 48 hrs | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID1754233 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID559576 | Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Acanthamoeba castellanii amoeba cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID508381 | Antibacterial activity against macrolide-susceptible Streptococcus pyogenes after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID554658 | Antimicrobial activity against Ureaplasma parvum isolate UHWP2 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID1241210 | Binding affinity to 5'-FAM-pre-miR-17 (unknown origin) after 4 hrs by fluorescence assay | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID502238 | Antibacterial activity against efflux-mediated macrolide-resistance Staphylococcus aureus PK1 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and properties of macrolones characterized by two ether bonds in the linker. |
| AID608736 | Antibacterial activity against efflux-mediated macrolide-resistant Staphylococcus aureus PK1 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID416247 | Toxicity in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as growth rate at 2 to 12 ug/mL after 14 hrs by molecular technology relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID696132 | Cmax in lung cancer patient epithelial lining fluid at 2 gram, po qd | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID577209 | Antimicrobial activity against Escherichia coli C600::933W in logarithmic phase encoding Stx-2 gene by broth macrodilution assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID508367 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID208127 | In vitro inhibitory activity against Streptococcus pneumoniae (EryRi 030SJ5i) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1180565 | Antimicrobial activity against vancomycin-resistant Enterococcus faecalis by broth microdilution/CLSI method | 2014 | Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14 | Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). |
| AID425338 | Antibacterial activity against azithromycin-susceptible Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID556350 | Antimicrobial activity against Mycoplasma pneumoniae clinical isolate harboring point mutations in 23S rRNA at positions 2063 and 2064 isolated from human respiratory tract by microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. |
| AID559515 | Antibacterial activity against Streptococcus pyogenes assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573417 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB selected at 4 ug/ml of compound after 1 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID539508 | Antibacterial activity against constitutive macrolide-lincosamide-streptogramin B-resistant Staphylococcus aureus B0330 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID531109 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa TNP090 mutant harboring las and rhl gene at 1 ug/ml after 7.5 hrs by Cat-2,3-diO reporter gene assay relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID1647107 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID573412 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA selected at 4 ug/ml of compound after 5 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID535360 | Antimicrobial activity against Haemophilus influenzae clinical isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID209282 | Compound was evaluated for antibacterial activity against Streptococcus pyogenes (MB2874) sensitive strain | 1998 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. |
| AID547543 | Antimicrobial activity against invasive Streptococcus constellatus obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on brain heart infusion agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID508467 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1511335 | Bactericidal activity against serine beta-lactamase producing Moraxella catarrhalis incubated in MH broth for 24 to 48 hrs by microbroth dilution method | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | C4-Phenylthio β-lactams: Effect of the chirality of the β-lactam ring on antimicrobial activity. |
| AID24865 | The negative logarithm of the fraction of singly charged molecules. | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID1238010 | Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as inhibition of bacterial growth after 18 hrs in presence of 50% bovine serum by liquid microdilution method | 2015 | Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16 | Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel. |
| AID548255 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID539504 | Antibacterial activity against efflux-resistant Streptococcus pneumoniae B0326 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID559080 | Antibacterial activity against Legionella pneumophila by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID548474 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID1488456 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID767505 | Antibacterial activity against Escherichia coli ATCC 25922 by standard dilution assay | 2013 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18 | Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents. |
| AID208125 | In vitro inhibitory activity against Streptococcus pneumoniae (032UC1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1549376 | Antibacterial activity against MLS-resistant Streptococcus pyogenes 01-968 expressing inducible ermB gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID571925 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-G616N mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID279273 | Antibacterial activity against Streptococcus pneumoniae assessed as period of suppression of bacterial growth | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID508391 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 43 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID422462 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as decrease in maximum thickness of biofilm in 2 days established biofilm at 0.125 ug/mL after 4 days using flow cell cu | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID595942 | Antiparasitic activity against yellow fluorescent protein expressing Toxoplasma gondii 2F-1 treated immediately after infection for 48 hrs followed by reinoculated into fresh HFF monolayers measured after 48 hrs | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID520016 | Antimicrobial activity against Staphylococcus epidermidis A8934 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID423104 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID1326852 | Antibacterial activity against Escherichia coli MB2884 by broth microdilution technique | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | A Gestalt approach to Gram-negative entry. |
| AID121253 | Survival rate of mouse inoculated intraperitoneally with 5.05*10e7 CFU of erythromycin-susceptible strain Streptococcus pneumoniae IID553 after treatment with 3 mg of compound | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID520236 | Antimicrobial activity against Enterococcus faecium A6349 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1055340 | Antibacterial activity against methicillin-resistant Staphylococcus aureus R6101 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID501675 | Antimicrobial activity against Streptococcus pneumoniae 58 spain by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID519999 | Antimicrobial activity against Streptococcus pyogenes harboring mef(A) gene | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID208618 | The compound was tested in vitro for antibacterial activity against 40 strains of constitutively erythromycin resistant Streptococcus pneumoniae; Value is 40/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID529904 | Antimicrobial activity against Leptospira interrogans serovar Canicola isolate 11 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID529897 | Antimicrobial activity against Leptospira interrogans serovar Pyrogenes isolate 5 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID372549 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID1417280 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID554656 | Antimicrobial activity against Ureaplasma parvum isolate UHWJM after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID372553 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene assessed as susceptibility rate by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID533853 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium chelonae after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID550375 | Antimicrobial activity against Enterococcus faecalis ATCC 29212 after 16 to 22 hrs by broth microdilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2 | Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae. |
| AID543819 | Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID279904 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM chlorpromazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID550376 | Antimicrobial activity against Escherichia coli ATCC 25922 after 16 to 22 hrs by broth microdilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2 | Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae. |
| AID545925 | Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID603986 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing erm gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID509004 | Antimicrobial activity against Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. |
| AID559050 | Antibacterial activity against Staphylococcus hominis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID534860 | Antibacterial activity against quinolone-resistant Salmonella enterica serovar stanley s2280 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID1475190 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate after 18 to 24 hrs | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12 | Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC. |
| AID520024 | Antimicrobial activity against Enterococcus faecalis A5962 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1666869 | Inhibition of swarming motility of Salmonella enterica clinical isolates incubated for 16 to 20 hrs | 2020 | Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5 | Optimized plant compound with potent anti-biofilm activity across gram-negative species. |
| AID416238 | Drug level in Cftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse serum at 500 mg/kg, po after 1 hr | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID208467 | The compound has been evaluated for the antibacterial activity against Streptococcus pneumoniae EryRc 030PW23c strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID499561 | Antibacterial activity against Haemophilus influenzae B0529 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID499556 | Antibacterial activity against erythromycin A-resistant Streptococcus pyogenes B0542 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID207637 | Compound was evaluated for antibacterial activity against Staphylococcus aureus (MB2865) sensitive strain | 1998 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. |
| AID559510 | Antibacterial activity against Lancefield Streptococcus sp. 'group C' assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID416243 | Antimicrobial activity against Pseudomonas aeruginosa NH57388A mucoid isolate assessed as reduction of viable count in stationary phase at 16 ug/mL after 8 hrs | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID425615 | Cmax in patient with Crohn's disease at 500 mg administered orally | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID1326849 | Antibacterial activity against Streptococcus pneumoniae CL2883 by broth microdilution technique | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | A Gestalt approach to Gram-negative entry. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1549365 | Bactericidal activity against erythromycin-susceptible Streptococcus pneumoniae ATCC49619 pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID425406 | Antibacterial activity against mucosa-associated Escherichia coli isolate HM454 isolated from patient with irritable bowel syndrome or sporadic polyps after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID1860923 | Bactericidal activity against Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial density at 150 ug/ml incubated for 6 hrs by colony-counting method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Glycosylation increases the anti-QS as well as anti-biofilm and anti-adhesion ability of the cyclo (L-Trp-L-Ser) against Pseudomonas aeruginosa. |
| AID558083 | Antimicrobial activity against Mycoplasma pneumoniae isolated from human by two fold serial dilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. |
| AID144014 | Compound was evaluated for in vitro anti-mycobacterial activity against Mycobacterium fortuitum | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. |
| AID1549378 | Selectivity ratio of MBC to MIC for MLS-resistant Streptococcus pyogenes 01-968 expressing inducible ermB gene | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID520403 | Antimicrobial activity against macrolide-susceptible Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID524827 | Antibacterial activity against erythromycin susceptible Campylobacter sp. assessed as resistance breakpoint by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID508451 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 2132 after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID596006 | Apparent volume of distribution during terminal phase in Sprague-Dawley rat at 10 mg/kg, iv and 30 mg/kg, po | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID508376 | Antibacterial activity against quinolone-resistant Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID285509 | Antibacterial activity against Streptococcus viridans after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID565316 | Antibacterial activity against Mycoplasma genitalium UTMB-10G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID663047 | Oral bioavailability in CD1 mouse at 25 mg/kg | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID520406 | Antimicrobial activity against quinolone-resistant Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID422658 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 49 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID619450 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by the broth microdilution method | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10 | Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID431505 | Inhibition of Escherichia coli ribosome | 2009 | Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16 | Free and bound state structures of 6-O-methyl homoerythromycins and epitope mapping of their interactions with ribosomes. |
| AID422883 | Antimicrobial activity against 8 ug/ml colistin-subcultured Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis and bacteremia by broth microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex. |
| AID535340 | Antimicrobial activity against Streptococcus pneumoniae clinical isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID577688 | Antimicrobial activity against Neisseria gonorrhoeae isolate 252611 NG-MAST sequence type 470 harboring A2059G mutation in 23S rRNA V domain allele 1, allele 2, allele 3 and allele 4 selected after 0.5 to 8 mg/L of erythromycin by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID522650 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K7978 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID565229 | Antimicrobial activity against Mycobacterium chelonae ATCC 35752 harboring pZS01 carrying mspA gene by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID416430 | Antimicrobial activity in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene infected in ftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse lung assessed as scattered residues of alginate without bacteria at 500 | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID678722 | Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID565321 | Antibacterial activity against Mycoplasma genitalium M6257 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID531447 | Antibacterial activity against Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID278855 | Cytotoxicity against primary human osteoblasts at 200 ug/ml assessed as LDH release after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID66404 | Minimum inhibitory concentration against macrolide susceptible strain of Enterococcus faecium (MB5516) | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: I. 4", 11 and 12-OMe derivatives via direct methylation. |
| AID425986 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 41 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID206073 | In vitro inhibitory activity against Streptococci EryRi (98) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID577680 | Antimicrobial activity against Neisseria gonorrhoeae harboring C2611T mutation in 23S rRNA V domain allele 1, allele 2 and allele 4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID114194 | Effective dose in vivo, in mouse inoculated intraperitoneally with 5.09*10e7 CFU of erythromycin susceptible strain Staphylococcus aureus Smith | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID423260 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected inpatients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID322135 | Antimalarial activity against Plasmodium falciparum W2 as reduced [3H]hypoxanthine uptake after 72 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID704309 | Cellular uptake in human T lymphocytes assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID206551 | In Vivo evaluation for its effective dose against Staphylococcus aureus (011UC4). | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID509008 | Antimicrobial activity against Streptococcus pyogenes | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. |
| AID559058 | Antibacterial activity against levofloxacin-susceptible Streptococcus pneumoniae by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID520408 | Antimicrobial activity against trimethoprim-sulfamethoxazole-resistant Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID209749 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030SJ1 EryRc) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID425631 | Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as lowest drug level producing inhibition at 10'6 CFU of inoculum by agar counting method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID559063 | Antibacterial activity against Streptococcus constellatus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1754229 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID360367 | Antimalarial activity after 96 hrs against Plasmodium falciparum GCO3 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID678716 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID574706 | Enhancement of biofilm formation Staphylococcus epidermidis SW115 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID735599 | Antibacterial activity against erythromycin-resistant Streptococcus dysgalactiae A1 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID559043 | Antibacterial activity against vancomycin- resistant Enterococcus faecium by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1055345 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis ATCC 12228 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID522645 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Texas by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID565309 | Antibacterial activity against Mycoplasma genitalium by quantitative TaqMan PCR method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID576348 | Bactericidal activity against Chlamydia trachomatis serovar J infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID429064 | Antiplasmodial activity after 72 hrs against Plasmodium falciparum 3D7 as Malstat LDH activity | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. |
| AID279874 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM promazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID425337 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID556351 | Antimicrobial activity against Mycoplasma pneumoniae FH by microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. |
| AID574698 | Enhancement of biofilm formation Staphylococcus epidermidis SW015 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID559520 | Antibacterial activity against Streptococcus mitis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID283552 | Antimicrobial activity against Streptococcus pneumoniae PC13 isolate with erm(B) mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID531110 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa TNP090 mutant harboring las and rhl gene at 1 ug/ml after 5.5 hrs by Cat-2,3-diO reporter gene assay relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID539511 | Antibacterial activity against constitutive macrolide-lincosamide-streptogramin B-resistant Streptococcus pyogenes B0544 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID582683 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 assessed as concentration required to no apparent bacterial growth after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID206554 | In vivo antibacterial activity against Staphylococcus aureus strain 10649 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID19662 | Calculated partition coefficient (clogP) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID520226 | Antimicrobial activity against Streptococcus pneumoniae PU1071099 harboring 65WR66 deletion in ribosomal protein L4 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID573422 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA selected at 4 ug/ml of compound after 4 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID535342 | Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as susceptible isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID285522 | Antibacterial activity against Haemophilus influenzae after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID422463 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as decrease in biomass of biofilm at 0.125 ug/mL incubated for 2 days measured after day 4 using flow cell culture | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID574699 | Enhancement of biofilm formation Staphylococcus epidermidis SW021 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID510558 | Antimicrobial activity against Chlamydia trachomatis after 72 hrs by fluorescence assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. |
| AID559054 | Antibacterial activity against Streptococcus agalactiae by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID519205 | Antibacterial activity against Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
| AID683708 | Antimalarial activity against Plasmodium yoelii infected in CD-1 mouse assessed as efficacy at 160 mg/kg, ip | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Targeting the liver stage of malaria parasites: a yet unmet goal. |
| AID696115 | Antiinflammatory activity in BALB/cJ mouse assessed as decrease in LPS-induced total cell number in bronchoalveolar lavage fluid at 200 mg/kg, ip administered 2 hrs prior to LPS challenge measured after 24 hrs post LPS challenge | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID429068 | Antiplasmodial activity against Plasmodium falciparum 3D7 as early schizont maturation arrest at IC50 after 48-120 hrs by giemsa stain | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. |
| AID558251 | Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in intracellular bacterial cfu in peritoneum at 1 mg/kg, sc administered 2 hrs after infection measured after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID531626 | Antimicrobial activity against Mycoplasma genitalium by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas. |
| AID559046 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285519 | Antibacterial activity against Legionella pneumophila after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID279887 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM omeprazole | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID565317 | Antibacterial activity against Mycoplasma genitalium M2282 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID423099 | Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID534523 | Drug level in human THP1 cells at 10 mg/L after 2 hrs in presence 10 uM efflux pump inhibitor verapamil relative to control | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils. |
| AID573415 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB selected at 4 ug/ml of compound after 6 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID425336 | Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID573174 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm assessed as reduction in bacterial load at 0.5 ug/ml for 7 days measured on day 1 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1232317 | Volume of distribution in human | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15 | Volume of Distribution in Drug Design. |
| AID283573 | Reduction of TNFalpha mRNA level in cystic fibrosis 2CFSMEo cells at 8 ug after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID425569 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559061 | Antibacterial activity against Streptococcus anginosus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID422674 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 21 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID531625 | Antimicrobial activity against Mycoplasma pneumoniae by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas. |
| AID535569 | Antibacterial activity against Salmonella enterica serovar Typhimurium harboring G235A mutation in rlpD gene by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID559531 | Antibacterial activity against ciprofloxacin-susceptible Haemophilus influenzae assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID531630 | Antimicrobial activity against Ureaplasma urealyticum by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas. |
| AID510854 | Antibacterial activity against erythromycin-resistant Staphylococcus aureus PU-19 expressing erm(A) gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID279313 | Inhibition of Plasmodium falciparum in HRP2 ELISA | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. |
| AID422683 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID425396 | Antibacterial activity against Escherichia coli isolates isolated from patients with Crohn's disease at 15 ug/disk by susceptibility testing disk method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID559049 | Antibacterial activity against Staphylococcus haemolyticus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID501281 | Antibacterial activity against macrolide, licosamide and streptogramin inducible-resistance Staphylococcus aureus 90256 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID1855563 | Inhibition of quorum sensing system in Pseudomonas aeruginosa assessed as downregulation of rhlR gene expression at sub-MIC by fluorescence real time PCR analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation. |
| AID573419 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB selected at 4 ug/ml of compound after 2 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID444053 | Renal clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1647109 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing ermB gene by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID209746 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030Cr29 EryRc) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1241206 | Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID483701 | Antimicrobial activity against macrolide-sensitive Staphylococcus aureus PK1 | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID1180563 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution/CLSI method | 2014 | Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14 | Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). |
| AID422479 | Antimicrobial activity against azithromycin-resistant nontypeable Haemophilus influenzae isolate S61 assessed as inhibition of biofilm formation at >64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID576351 | Antimicrobial activity against Chlamydia trachomatis Bour serovar E infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID585925 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b-c+ cell expression level in lung lavage fluid at 0.16 g/kg, po measured after 3 days by flow cytometry (Rvb = 47.01 +/- 33.74 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID588210 | Human drug-induced liver injury (DILI) modelling dataset from Ekins et al | 2010 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12 | A predictive ligand-based Bayesian model for human drug-induced liver injury. |
| AID571764 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID524825 | Antibacterial activity against erythromycin susceptible Campylobacter sp. by agar plate dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID379526 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 | 2006 | Journal of natural products, Nov, Volume: 69, Issue:11 | Acetylated flavanone glycosides from the rhizomes of Cyclosorus acuminatus. |
| AID573181 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm assessed as increase in viable cells at 4 ug/ml for 4 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID724507 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing erm and mef genes by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1853149 | Antibacterial activity against Macrolide resistant Streptococcus pneumoniae clinical isolate B0326 assessed as inhibition of bacterial growth incubated for 20 to 22 hrs by broth microdilution method | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling. |
| AID1241215 | Ratio of Kd for 5'-FAM-pre-miR-372 (unknown origin) in presence of 100-fold excess of 15-mer DNA to Kd for 5'-FAM-pre-miR-372 (unknown origin) | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID422650 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 38 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID320706 | Inhibition of PAD4 by ABPP-based assay | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2 | Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. |
| AID724177 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID279868 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM prochlorperazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID206084 | Antibacterial activity against Streptococci; More active | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | New directions in antibacterial research. |
| AID531459 | Antibacterial activity against Streptococcus pneumoniae serotype 15A assessed as percent resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID558616 | Antimicrobial activity against Streptococcus pneumoniae isolate 2880 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID529895 | Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 3 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID559504 | Antibacterial activity against Staphylococcus haemolyticus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1539175 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID666491 | Antibacterial activity against Streptococcus pyogenes isolate 3565 by broth microdilution method | 2012 | Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 | Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides. |
| AID559047 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID704308 | Cellular uptake in human NCI-H292 cells assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID524826 | Antibacterial activity against erythromycin resistant Campylobacter sp. assessed as resistance breakpoint by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID663048 | Fraction unbound in CD1 mouse plasma at 5 mg/kg, iv | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID425987 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 33 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID522649 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Colorado by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID423261 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected inpatients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID554659 | Antimicrobial activity against Ureaplasma parvum SV1 isolate UHWQ3 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID285517 | Antibacterial activity against Enterococcus faecium | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID725369 | Antibacterial activity against methicillin-susceptible, inducible MLS-resistant Staphylococcus epidermidis E 1 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID725377 | Antibacterial activity against erythromycin-resistant Streptococcus dysgalactiae A1 expressing efflux pump by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID278859 | Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID559082 | Antibacterial activity against Morganella morganii by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID558024 | Half life in human at 1000 mg, po | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID425984 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1853150 | Antibacterial activity against Macrolide sensitive Streptococcus pyogenes clinical isolate B0542 assessed as inhibition of bacterial growth incubated for 20 to 22 hrs by broth microdilution method | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling. |
| AID416414 | Antimicrobial activity against quorum sensing lasI-deficient isogenic Pseudomonas aeruginosa NH57388D mucoid isolate assessed as reduction of viable count at 12 ug/mL in presence of 2.5% human normal serum | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID576340 | Antimicrobial activity against Chlamydia trachomatis serovar J infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID571444 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 2 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID559057 | Antibacterial activity against Lancefield Streptococcus sp. 'group G' by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID322963 | Antimicrobial activity against macrolide-susceptible Mycobacterium avium by radiometric broth nanodilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. |
| AID573178 | Bactericidal activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMA biofilm assessed as reduction in bacterial load at => 4 ug/ml upto 7 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID520413 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID556348 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained from bronchial aspirations expressing 23S rRNA A2063G mutant gene and P1 RFLP type I gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. |
| AID425974 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID574689 | Enhancement of biofilm formation Staphylococcus epidermidis SW032 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID543818 | Bactericidal activity against Escherichia coli ATCC 25922 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID1691388 | Antibacterial activity against Erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID428894 | Bactericidal activity against Pseudomonas aeruginosa PT1332 rhlA mutant harboring vector pAK1900 at 2 to 18 ug/ml after 22 hrs by plating serial dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID558582 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID360365 | Antimalarial activity after 48 hrs against Plasmodium falciparum GCO3 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID279272 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 37 with GyrA S81Y, GyrB E474K and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID26362 | Ionization constant (pKa) | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. |
| AID559077 | Antibacterial activity against non-ciprofloxacin-susceptible Haemophilus influenzae by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID369228 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae assessed as percent resistant isolates by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain. |
| AID596081 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 10 uM treated for 48 hrs after 6 hrs infection followed by reinoculate | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID279880 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM promazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID520001 | Antimicrobial activity against Haemophilus influenzae | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID540233 | Dose normalised AUC in human after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
| AID547519 | Antimicrobial activity against Streptococcus anginosus obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on brain heart infusion agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID372548 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID550370 | Antimicrobial activity against macrolide-resistant erythromycin-Streptococcus pneumoniae after 16 to 22 hrs by broth microdilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2 | Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae. |
| AID531423 | Antibacterial activity against Streptococcus pneumoniae serotype 15A by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID279889 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM omeprazole | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID283575 | Reduction of TNFalpha protein level in cystic fibrosis 16HBE14oAS3 cells at 8 ug after 24 hrs by ELISA relative to control | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID531417 | Antibacterial activity against Streptococcus pneumoniae serotype 19A by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID512011 | Antibacterial activity against ampicillin-resistant Haemophilus influenzae 3300 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID483702 | Antimicrobial activity against inducible macrolide-resistant Streptococcus pyogenes Finland 3 | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID558088 | Antimicrobial activity against Ureaplasma urealyticum isolated from human by two fold serial dilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. |
| AID573179 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm assessed as increase in viable cells at 4 ug/ml for 4 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID547536 | Antimicrobial activity against invasive Streptococcus anginosus obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of 5 | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID499560 | Antibacterial activity against Moraxella catarrhalis B0324 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID571926 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-N623S-Q624S mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID574688 | Enhancement of biofilm formation Staphylococcus epidermidis SW029 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID206484 | The compound was tested in vitro for antibacterial activity against erythromycin susceptible Staphylococcus aureus 011UC4 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID644452 | Antibacterial activity against methicillin-resistant, coagulase-negative, constitutive MLS-resistant Staphylococcus haemolyticus PU 19 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID416253 | Inhibition of quorum sensing-regulated chitinase production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 8 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID203429 | In vitro inhibitory activity against Staphylococci EryRc (23);ND=not determined | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID675201 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 1104 expressing ermB ribosomal methylase by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID1180564 | Antimicrobial activity against Enterococcus faecalis by broth microdilution/CLSI method | 2014 | Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14 | Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). |
| AID520000 | Antimicrobial activity against Moraxella catarrhalis | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID559056 | Antibacterial activity against Lancefield Streptococcus sp. group F by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID585929 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as up-regulation of CD80 in CD11+ Gr1- cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID666487 | Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay | 2012 | Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 | Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides. |
| AID550373 | Antimicrobial activity against Moraxella catarrhalis ATCC 23246 after 16 to 22 hrs by broth microdilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2 | Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae. |
| AID608733 | Antibacterial activity against erythromycin-sensitive Staphylococcus aureus ATCC 13709 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID577192 | Decrease in shiga toxin production in Escherichia coli C600::H19B encoding Stx-1 gene at 0.5 X MIC by luciferase assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID529303 | Antimicrobial activity against Acinetobacter genospecies 3 isolate Ac057 expressing beta-lactamase Oxa-58 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. |
| AID1498152 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 incubated for 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID423266 | Antibacterial activity against azithromycin-resistant 0.01 MOI Chlamydia psittaci 6BC BCRBAZ2 harboring A2058C mutation in bacterial 23S rRNA gene infected in mouse L2 cells treated 2 hrs after infection measured on day 7 by plaque assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID704311 | Cellular uptake in normal human lung fibroblasts assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID279257 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID423097 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID483694 | Antimicrobial activity against macrolide-resistant Streptococcus pneumoniae Ci137 | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID571435 | Ratio of the MIC for Escherichia coli ATCC 25992 in the absence of NAB7061 to MIC for Escherichia coli ATCC 25992 in the presence of 4 ug/ml of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID423251 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients within 2 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID423274 | Antibacterial activity against azithromycin-tolerant 0.01 MOI Chlamydia trachomatis L2AZM#31 harboring mutation in bacterial ribosomal protein L4 infected in mouse L2 cells treated 2 hrs after infection measured on day 7 by plaque assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID279883 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM omeprazole | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID425979 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 49 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID543792 | Antimicrobial activity against Acinetobacter baumannii VT 126 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID522656 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis 17T5 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID657726 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 after 20 to 22 hrs by broth microdilution method | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10 | An efficient and convenient microwave-assisted chemical synthesis of (thio)xanthones with additional in vitro and in silico characterization. |
| AID323660 | Antibacterial activity against Peptostreptococcus stomatis | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources. |
| AID725367 | Antibacterial activity against methicillin-resistant, inducible MLS-resistant, coagulase-deficient Staphylococcus hominis E 3 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID508379 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring erm(B) and mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID565810 | Antimicrobial activity against Neisseria meningitidis by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. |
| AID559060 | Antibacterial activity against Streptococcus pyogenes by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID596053 | Blood clearance in Sprague-Dawley rat at 10 mg/kg, iv and 30 mg/kg, po | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID545936 | Ratio of MIC for Escherichia coli IH3080 to MIC for Escherichia coli IH3080 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID522664 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis BA1024 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID1488452 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 harboring erm gene after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID596005 | Half life in mouse liver microsomes at 1 uM by LCMS analysis | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID422648 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID567473 | Antimicrobial activity against gBLPAR-TEM1 Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID550372 | Antimicrobial activity against macrolide-resistant erythromycin-Streptococcus pyogenes after 16 to 22 hrs by broth microdilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2 | Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae. |
| AID520029 | Antimicrobial activity against Enterococcus faecium A6348 harboring G2576U mutation in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1053268 | Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching. |
| AID422482 | Antimicrobial activity against azithromycin-resistant nontypeable Haemophilus influenzae isolate S53 assessed as inhibition of biofilm formation at 16 ug/mL after 7 hrs using crystal violet | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID576353 | Antimicrobial activity against Chlamydia trachomatis UW-36 serovar J infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID596015 | Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 10 uM treated for 48 hrs immediately after infection followed by reinoculated into fresh HFF monolayers | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID279252 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 2527 after 20 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID545929 | Antimicrobial activity against Enterobacter cloacae ATCC 23355 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID573185 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm assessed as increase in viable cells at 16 ug/ml | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID416403 | Inhibition of quorum sensing-regulated alginate production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 2 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID1502709 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID1238048 | Antibacterial activity against Staphylococcus aureus by broth dilution assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Gageopeptins A and B, new inhibitors of zoospore motility of the phytopathogen Phytophthora capsici from a marine-derived bacterium Bacillus sp. 109GGC020. |
| AID416252 | Inhibition of quorum sensing-regulated chitinase production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 4 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID416127 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives. |
| AID85951 | In Vivo evaluation for its effective dose against Haemophilus influenzae (351RD7 AmpR beta (+)) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID416250 | Inhibition of quorum sensing-regulated elastase production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 8 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID577681 | Antimicrobial activity against Neisseria gonorrhoeae harboring A2059G mutation in 23S rRNA V domain allele 1, allele 2, allele 3 and allele 4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID644446 | Antibacterial activity against constitutive MLS-resistant Streptococcus pyogenes A 2 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID479977 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus PU19 encoded by erm(A) gene | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID644454 | Antibacterial activity against methicillin-resistant, constitutive MLS-resistant Staphylococcus epidermidis E2 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID724189 | Antibacterial activity against Staphylococcus aureus ATCC 13709 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID520020 | Antimicrobial activity against Enterococcus faecalis ATCC 29212 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID501669 | Antimicrobial activity against macrolide, licosamide streptogramin-resistant Staphylococcus aureus 90265/97 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID508443 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2686 harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID373650 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus by agar dilution CLSI method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. |
| AID559048 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID558627 | Antimicrobial activity against Streptococcus pneumoniae isolate 3587 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID425564 | Antibacterial activity against quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 5048 expressing mefA after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID502239 | Antibacterial activity against inducible resistance to macrolide, licosamide and streptogramin Streptococcus pyogenes 11 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and properties of macrolones characterized by two ether bonds in the linker. |
| AID1055337 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 09-3 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID422478 | Antimicrobial activity against azithromycin-resistant nontypeable Haemophilus influenzae isolate S44 assessed as inhibition of biofilm formation at >64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID534854 | Antibacterial activity against quinolone-resistant Salmonella enterica serovar stanley s2086 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID596055 | Oral bioavailability in Sprague-Dawley rat at 30 mg/kg | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID522667 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K8091 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID279872 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM prochlorperazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID483700 | Antimicrobial activity against inducible macrolide and constitutive lincosamide, streptogramin-resistant Streptococcus pyogenes 166 GR-micro | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID144294 | Compound was evaluated for in vitro anti-mycobacterial activity against Mycobacterium malmoense | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. |
| AID1647110 | Antibacterial activity against erythromycin resistant Streptococcus pyogenes R1 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID423264 | Biodistribution in healthy human epithelial lining fluid assessed as drug accumulation at 500 mg | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID559065 | Antibacterial activity against Streptococcus mitis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID244984 | Minimum inhibitory concentration of compound against Ery-R Streptococcus pyogenes 13029 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID428896 | Antimicrobial activity against exponential-phase Pseudomonas aeruginosa PT1323 cultures harboring mutation in bacterial rhlA protein and expressing rhamnosyltransferase rhlAB gene at 1 mg/ml after 18 hrs by susceptibility assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID508476 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 237 harboring mutation in L4 ribosomal protein after 50 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID437308 | Antibacterial activity against erythromycin-resistant Staphylococcus pneumoniae A22072 encoded by mef gene | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin. |
| AID1666868 | Inhibition of swarming motility of Burkholderia cepacia clinical isolates incubated for 16 to 20 hrs | 2020 | Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5 | Optimized plant compound with potent anti-biofilm activity across gram-negative species. |
| AID550371 | Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes after 16 to 22 hrs by broth microdilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2 | Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae. |
| AID545939 | Ratio of MIC for Acinetobacter baumannii ATCC 19606 to MIC for Acinetobacter baumannii ATCC 19606 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID416418 | Antimicrobial activity against quorum sensing lasI-deficient isogenic Pseudomonas aeruginosa NH57388E nonmucoid isolate assessed as reduction of viable count at 12 ug/mL in absence of 2.5% human normal serum | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID519998 | Antimicrobial activity against Streptococcus pyogenes | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID501286 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID642856 | Antibacterial activity against efflux mediated macrolide resistant Staphylococcus aureus by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID425341 | Antibacterial activity against quinolone-resistant Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1498151 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID279261 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3665 with GyrA S81Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID576344 | Bactericidal activity against Chlamydia trachomatis serovar F infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID582688 | Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD assessed as decrease of CFU after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID117677 | Protected dose at which the test compound protects 50% of challenged mice from death owing to the Pasteurella multocida infection | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Repromicin derivatives with potent antibacterial activity against Pasteurella multocida. |
| AID520013 | Antimicrobial activity against Staphylococcus aureus A8761 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID499552 | Antibacterial activity against efflux-resistant Staphylococcus aureus B0331 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID422690 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 30 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID425820 | Antituberculosis activity against Mycobacterium paratuberculosis UCF-4 isolated from Crohn's disease patient assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID279886 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM omeprazole | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID1180566 | Antimicrobial activity against Enterococcus faecium by broth microdilution/CLSI method | 2014 | Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14 | Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). |
| AID1055327 | Antibacterial activity against beta-lactamase producing Escherichia coli 09-20 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID423248 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 6 to 14 years of age after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID1539173 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID1691389 | Bactericidal activity against Erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID571203 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID559051 | Antibacterial activity against Staphylococcus lugdunensis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID132634 | The compound was tested in vivo for antibacterial activity against inducibly erythromycin resistant Staphylococcus aureus 011GO3 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID555114 | AUC (0 to infinity) in healthy human at 500 mg, po administered as single dose | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. |
| AID582674 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 at pH 5.5 to 7.4 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID596001 | Cytotoxicity against human THP1 cells after 1 to 4 hrs by MTS assay | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID663057 | Antimalarial activity against Plasmodium berghei KBG173 infected in mouse assessed as decrease in parasitemia at 10 mg/kg, iv BID administered on day 3, 4 and 5 post infection measured on day 31 relative to control | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID423238 | Antibacterial activity against beta lactamase-negative Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID132631 | The compound was tested in vivo for antibacterial activity against erythromycin susceptible Staphylococcus aureus 011UC4 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID1459141 | Protein binding in mouse plasma at 1 ug/ml by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID279270 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 24 with GyrA S81Y, GyrB P413S and ParC S79F mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID423255 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients more than 65 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID1459114 | Antibacterial activity against erythromycin susceptible Staphylococcus aureus by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID559073 | Antibacterial activity against Citrobacter koseri by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID508373 | Antibacterial activity against Streptococcus pneumoniae harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID508387 | Antibacterial activity against macrolide-resistant Streptococcus pyogenes harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID571447 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID508421 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2686 harboring mutation in L4 ribosomal protein after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID543796 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID574695 | Enhancement of biofilm formation Staphylococcus epidermidis SW098 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID595946 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF at 5 to 50 uM treated immediately after infection measured after 48 hrs followed by reinoculated into fresh HFF monolayers measured a | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID372471 | Antimalarial activity as arrested schizont maturation in chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 48 hrs at 100 nM dosed 96 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID425995 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID206079 | In vitro inhibitory activity against Streptococci EryR (27) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID422943 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae harboring A2063G transition in domain V of 23S rRNA isolated from pediatric patients with community-acquired pneumonia after 10 to 14 days by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. |
| AID209866 | In vivo antibacterial activity against Streptococcus pneumoniae strain 6303 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID520235 | Antimicrobial activity against Staphylococcus aureus A7820 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID508464 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 22 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1180520 | Antimicrobial activity against Haemophilus influenzae by broth microdilution/CLSI method | 2014 | Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14 | Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID508411 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after 32 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID429063 | Antiplasmodial activity after 48 hrs against Plasmodium falciparum 3D7 as Malstat LDH activity | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. |
| AID568333 | Antimicrobial activity against multidrug-resistant Pseudomonas aeruginosa by broth dilution assay | 2011 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4 | Design and synthesis of potent Gram-negative specific LpxC inhibitors. |
| AID285507 | Antibacterial activity against methicillin-resistant Staphylococcus aureus after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID644817 | Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum W2 infected in human A-positive erythrocytes assessed as inhibition of [3H]-hypoxanthine incorporation after 48 hrs by semi-automated microdilution technique | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. |
| AID85968 | Compound was tested for antibacterial activity against Haemophilus influenzae 351HT3 using standard broth microdilution assay. | 1998 | Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18 | Synthesis of 6-O-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime. |
| AID522363 | Antimicrobial activity against azithromycin resistant Neisseria gonorrhoeae isolate harboring C2599T mutation in peptidyltransferase loop in domain V of 23S rRNA alleles and T insertion in mtrR gene promoter region | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. |
| AID550369 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae after 16 to 22 hrs by broth microdilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2 | Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae. |
| AID416423 | Antimicrobial activity against Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene infected in ftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse lungs assessed as reduction in GFP signal at 250 mg/kg, iv administ | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID1666867 | Inhibition of swarming motility of Escherichia coli clinical isolates incubated for 16 to 20 hrs | 2020 | Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5 | Optimized plant compound with potent anti-biofilm activity across gram-negative species. |
| AID372504 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 96hrs at 100 nM dosed 24-36 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID416426 | Antimicrobial activity in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene infected in ftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse lungs assessed as median alginate content in lungs at 500 mg/kg, po admi | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID724771 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID585778 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c+ cell expression level in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry (Rvb = 1.51 +/- 1.53 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID201405 | In vitro minimum inhibitory concentration for antibacterial activity against erythromycin susceptible strain Staphylococcus aureus Smith | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1824779 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of biofilm formation for 24 hrs by crystal violet staining based assay | 2022 | Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1 | New |
| AID416416 | Antimicrobial activity against quorum sensing lasI-deficient isogenic Pseudomonas aeruginosa NH57388D mucoid isolate assessed as reduction of viable count at 12 ug/mL in absence of 2.5% human normal serum | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID535570 | Antibacterial activity against Salmonella enterica serovar montevideo harboring rlpD GC379T and rlpV G25A mutant gene by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID737042 | Antimalarial activity against Plasmodium berghei infected in mouse assessed as reduction of parasitemia at 8 mg/dose, ip on days 4 to 7 relative to untreated control | 2013 | Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6 | Antimalarial activities of 6-iodouridine and its prodrugs and potential for combination therapy. |
| AID608739 | Antibacterial activity against inducible macrolide-lincosamide-streptogramin B resistant Staphylococcus aureus 90256 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID1539178 | Antibacterial activity against penicillin-resistant Staphylococcus aureus ATCC 31007 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID559083 | Antibacterial activity against Neisseria meningitidis by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID508372 | Antibacterial activity against Streptococcus pneumoniae harboring erm(B) and mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID425407 | Antibacterial activity against mucosa-associated Escherichia coli isolate HM456 isolated from patient with irritable bowel syndrome or sporadic polyps after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID585756 | Antibacterial activity against Pseudomonas aeruginosa M57-15 infected in C57BL/6 mouse assessed as effect on host weight loss at 0.16 g/kg, po measured up to 14 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID595948 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF at 5 to 50 uM treated 6 hrs after infection measured after 48 hrs followed by reinoculated into fresh HFF monolayers measured after 4 | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID245061 | Minimum inhibitory concentration of compound against Ery-S Haemophilus influenzae ATCC 49247 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID283585 | Cell viability of 16HBE14o-AS3 cells at 8 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID596019 | Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 0.1 uM treated for 48 hrs immediately after infection followed by reinoculated into fresh HFF monolayer | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID520227 | Antimicrobial activity against methicillin resistant Staphylococcus aureus 67-0 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID423100 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID1055324 | Antibacterial activity against beta-lactamase producing Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1169034 | Antibacterial activity against efflux-resistant Streptococcus pyogenes by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID416239 | Elimination half life in healthy mouse | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID559067 | Antibacterial activity against Streptococcus salivarius by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425581 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring I460V mutation in QRDR of ParE gene after 41 passages with gemifloxacin measured after 10 daily antibiotic-free s | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID501670 | Antimicrobial activity against Staphylococcus aureus ATCC 13709 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID1515020 | Antibacterial activity against Enterococcus faecium isolate 569 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID573171 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA planktonic cells by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID585931 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as up-regulation of CCR7 expression in CD11+ Gr1- cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1238007 | Inhibition of ribosome nascent peptide exit tunnel in Escherichia coli S30 extract assessed as inhibition of prokaryotic translation in presence of amino acids incubated for 20 mins by luciferase reporter gene assay | 2015 | Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16 | Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel. |
| AID1427915 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mefA gene by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID678717 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID539509 | Antibacterial activity against inducible macrolide-lincosamide-streptogramin B-resistant Staphylococcus aureus B0538 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID508449 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 2132 after 28 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID725372 | Antibacterial activity against methicillin-resistant, constitutive MLS-resistant Staphylococcus aureus PU 20 expressing ermC gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID422644 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 44 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID558609 | Antimicrobial activity against Streptococcus pneumoniae isolate 1397 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID724186 | Antibacterial activity against efflux mediated macrolide-resistant Staphylococcus aureus PK1 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID559517 | Antibacterial activity against Streptococcus bovis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID569035 | Antimicrobial activity against penicillin-susceptible Staphylococcus aureus P1 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID279903 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM chlorpromazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID502234 | Antibacterial activity against constitutive MLS resistance Streptococcus pyogenes 166 GR-Micro by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and properties of macrolones characterized by two ether bonds in the linker. |
| AID671693 | Antibacterial activity against Haemophilus influenzae 551 infected in immunocompetent Sprague-Dawley rat assessed as reduction in lung CFU per gram of tissue at 50 mg/kg, po administered 5, 24 and 48 hrs post infection measured after 72 hrs | 2012 | Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2 | Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. |
| AID567471 | Antimicrobial activity against gLow-BLNAR Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID724770 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing erm gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID1550822 | Antimicrobial activity against inducibly erythromycin-resistant Staphylococcus aureus PU32 expressing i-ermA incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID508419 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 24 harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID502241 | Antibacterial activity against inducible resistance to macrolide, licosamide, and streptogramin Staphylococcus aureus 90265/97 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and properties of macrolones characterized by two ether bonds in the linker. |
| AID724502 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes RE clinical isolate by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID547524 | Antimicrobial activity against Streptococcus constellatus obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of 5% def | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID663053 | Antimalarial activity against Plasmodium berghei KBG173 infected in mouse assessed as mouse survival time at 15 mg/kg, iv BID administered on day 3, 4 and 5 post infection | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID596084 | Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs after 6 hrs infection followed by reinoculated into fresh HFF monolayers measur | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID508365 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID510855 | Antibacterial activity against erythromycin-resistant Staphylococcus aureus PU-32 expressing erm(A) gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID278858 | Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID1544293 | Selectivity index, ratio of CC50 for African green monkey Vero cells to MIC for multi drug resistant Enterococcus faecium NCTC 7171 | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Synthesis and biological evaluation of solithromycin analogs against multidrug resistant pathogens. |
| AID571766 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-N616 mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID510557 | Antimicrobial activity against Chlamydophila pneumoniae infected in human Hep2 cells after 72 hrs by twofold serial dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. |
| AID1169031 | Antibacterial activity against efflux-resistant Streptococcus pneumoniae by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID508388 | Antibacterial activity against macrolide-resistant Streptococcus pyogenes harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1754234 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC9372 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID508453 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2368 harboring erm(B) gene after 8 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID543798 | Antimicrobial activity against Streptococcus pyogenes VT 59 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID666488 | Selectivity ratio of IC50 for human HepG2 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7A | 2012 | Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 | Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides. |
| AID360380 | Antimalarial activity after 96 hrs against azithromycin-resistant Plasmodium falciparum Dd2 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID533861 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium septicum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID576352 | Antimicrobial activity against Chlamydia trachomatis 580 serovar H infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID322133 | In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID535568 | Antibacterial activity against Salmonella enterica subsp. enterica serovar Saintpaul harboring G235A mutation in rlpD gene by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID423234 | Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID567470 | Antimicrobial activity against gBLNAS Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID728909 | Antibacterial activity against levofloxacin-intermediate and levofloxacin-resistant Streptococcus pneumoniae after 18 hrs by microbroth dilution method | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5 | Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens. |
| AID575170 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
| AID244994 | Minimum inhibitory concentration of compound against Ery-S Streptococcus pneumoniae 3773 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID529900 | Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 9 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID1853148 | Antibacterial activity against Macrolide sensitive Streptococcus pneumoniae clinical isolate B0652 assessed as inhibition of bacterial growth incubated for 20 to 22 hrs by broth microdilution method | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling. |
| AID663050 | Antimalarial activity against Plasmodium berghei KBG173 infected in mouse assessed as cured mouse at 5 mg/kg, iv BID administered on day 3, 4 and 5 post infection measured up to day 31 | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID569033 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing the erm and mef gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID283553 | Antimicrobial activity against Streptococcus pneumoniae PC13 isolate with L4 mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID1766093 | Antibacterial activity against penicillin-resistant Staphylococcus aureus by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID425824 | Antituberculosis activity against Mycobacterium paratuberculosis UCF-7 isolated from Crohn's disease patient assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID582690 | Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD infected in human THP1 cells assessed as decrease of CFU after 24 hrs relative to initial inoculum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID501287 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID696111 | Antiinflammatory activity in mouse splenocytes assessed as inhibition of LPS-induced IL-6 production in mouse splenocytes at 25 uM preincubated for 2 hrs prior to LPS challenge by sandwich ELISA | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID422464 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as decrease in maximal thickness of biofilm at 0.125 ug/mL incubated for 2 days measured after days 4 using flow cell cu | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID635187 | Antibacterial activity against constitutive macrolide, licosamide and streptogramin-resistant Streptococcus pyogenes 166 GR-Micro by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID1548185 | Anti-Chlamydial activity against Chlamydia trachomatis Serovar LGV-L2 infected in Hep2 cells assessed as reduction in size and number of chlamydial inclusion at 4 ug/ml treated at 8 hrs post-infection and 24 hrs later re-infecting fresh Hep2 cells monolay | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8 | Synthesis and Antichlamydial Activity of Molecules Based on Dysregulators of Cylindrical Proteases. |
| AID1055330 | Antibacterial activity against vancomycin-sensitive Enterococcus faecium 09-10 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID559509 | Antibacterial activity against Streptococcus agalactiae assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID547518 | Antimicrobial activity against Streptococcus anginosus obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of 5% defrib | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID573413 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB selected at 4 ug/ml of compound after 5 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1539181 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing the ermB and mefA incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID323659 | Antibacterial activity against Peptostreptococcus anaerobius | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources. |
| AID543809 | Bactericidal activity against Escherichia coli ATCC 25922 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs by serial dilution | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID1459112 | Antibacterial activity against erythromycin susceptible Streptococcus pyogenes by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID559522 | Antibacterial activity against Streptococcus salivarius assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID428889 | Bactericidal activity against stationary-phase Pseudomonas aeruginosa PT1300 culture harboring vector pEX1.8 after 20 to 22 hrs by plating serial dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID529894 | Antimicrobial activity against Leptospira interrogans serovar Grippotyphosa isolate 2 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID283574 | Reduction of TNFalpha protein level in cystic fibrosis IB3-1 cells at 8 ug after 24 hrs by ELISA relative to control | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID1646209 | Maximum serum concentration in human at 500 mg, po measured within 2 hrs | 2020 | Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12 | Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics. |
| AID416404 | Inhibition of quorum sensing-regulated alginate production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 4 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID283551 | Antimicrobial activity against Streptococcus pneumoniae PC13 transformants | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID206486 | The compound was tested in vitro for antibacterial activity against inducibly erythromycin resistant Staphylococcus aureus 011GO25i | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID499554 | Antibacterial activity against constitutive macrolide-lincosamide-streptogramin B-resistant Streptococcus pneumoniae B0627 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID558621 | Antimicrobial activity against Streptococcus pneumoniae isolate 3346 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID644816 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7A infected in human A-positive erythrocytes assessed as inhibition of [3H]-hypoxanthine incorporation after 48 hrs by semi-automated microdilution technique | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. |
| AID372501 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 96hrs at 100 nM dosed 12-24 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID559052 | Antibacterial activity against Staphylococcus saprophyticus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID422476 | Antimicrobial activity against azithromycin-resistant nontypeable Haemophilus influenzae isolate S34 assessed as inhibition of biofilm formation at >64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID559059 | Antibacterial activity against non-levofloxacin susceptible Streptococcus pneumoniae by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1241211 | Binding affinity to 5'-FAM-pre-miR-373 (unknown origin) after 4 hrs by fluorescence assay | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID1257223 | Antibacterial activity against Haemophilus influenzae ATCC 49247 after overnight incubation by broth microdilution method | 2015 | Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23 | 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity. |
| AID279879 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM promazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID582611 | Drug uptake in human THP1 cells after 24 hrs in presence of gemfibrozil | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID1515014 | Antibacterial activity against Staphylococcus epidermidis isolate 533 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID209616 | In vitro inhibitory activity against Streptococcus pyogenes (02A1UC1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID573173 | Bactericidal activity against Pseudomonas aeruginosa PAO1 biofilm assessed as reduction in bacterial load at 256 ug/ml for 7 days measured on day 1 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID522361 | Antimicrobial activity against high-level azithromycin resistant Neisseria gonorrhoeae isolate 1782 harboring A2143G mutation in peptidyltransferase loop in domain V of 23S rRNA alleles | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. |
| AID425551 | Antibacterial activity against penicillin-, macrolide- and quinolone-susceptible Streptococcus pneumoniae HMC 63 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID423098 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID132633 | The compound was tested in vivo for antibacterial activity against erythromycin susceptible Streptococcus pyogenes 02A1UC1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID425561 | Antibacterial activity against penicillin-, quinolone-resistant Streptococcus pneumoniae HMC 1541 harboring mutation in L4 protein by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID508385 | Antibacterial activity against Streptococcus pyogenes harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID595943 | Antiparasitic activity against yellow fluorescent protein expressing Toxoplasma gondii 2F-1 infected in HFF treated 6 hrs after infection measured after 48 hrs | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID23733 | Calculated partition coefficient (clogP) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID704317 | Cellular uptake in normal human lung fibroblast at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID582609 | Drug uptake in human THP1 cells after 2 hrs in presence of monensin | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID479819 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae PU13 encoded by erm and mef gene | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID724182 | Antibacterial activity against efflux mediated macrolide-resistant Streptococcus pneumoniae Ci137 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID203437 | The compound was tested in vitro for antibacterial activity against 66 strains of inducibly erythromycin resistant Staphylococci; Value is 40/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID501680 | Antimicrobial activity against macrolide-resistant Streptococcus pneumoniae Ci137 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID423245 | Antibacterial activity against Moraxella catarrhalis isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID543817 | Bactericidal activity against Klebsiella pneumoniae VT 1367 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID642865 | Antibacterial activity against Moraxella catarrhalis by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID608746 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID279869 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM prochlorperazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID557793 | Antimicrobial activity against Streptococcus pyogenes clinical isolate expressing mef(A) gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005. |
| AID508438 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3009 harboring mutation in 23S rRNA after 25 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID283587 | Cell viability of 2CFSMEo cells at 8 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID519995 | Antimicrobial activity against Streptococcus pneumoniae harboring erm(B) and mef(A) gene | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID577195 | Decrease in shiga toxin production in Escherichia coli C600::933W encoding Stx-2 gene at 0.5 X MIC by luciferase assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID595941 | Antiparasitic activity against yellow fluorescent protein expressing Toxoplasma gondii 2F-1 infected in HFF treated immediately after infection measured after 48 hrs | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID85811 | The compound was tested in vitro for antibacterial activity against 39 strains of Haemophilus influenza AmpR; Value is 1.2/10 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID278394 | Antimicrobial activity against Naegleria fowleri Lee (M67) in presence of azithromycin at 1:3 ratio on day 3 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID279875 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM promazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID278386 | Antimicrobial activity against Naegleria fowleri Lee (M67) at day 2 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID577210 | Antimicrobial activity against Escherichia coli C600::933W in stationary phase encoding Stx-2 gene by broth macrodilution assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID501293 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID1055342 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID425652 | Total body clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID535558 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar blockley s2608 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID584097 | Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 19606R harboring pAL840 plasmid encoding intact lpxA gene by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. |
| AID585766 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c- cell expression level in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry (Rvb = 17.07 +/- 4.84 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1417287 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing ermB gene after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID416425 | Antimicrobial activity in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene infected in ftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse lungs assessed as median bacterial density per lung at 500 mg/kg, po adm | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID519204 | Antibacterial activity against Streptococcus pneumoniae assessed as resistant isolates by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
| AID1238049 | Antibacterial activity against Bacillus subtilis by broth dilution assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Gageopeptins A and B, new inhibitors of zoospore motility of the phytopathogen Phytophthora capsici from a marine-derived bacterium Bacillus sp. 109GGC020. |
| AID1487246 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing ermB gene | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID221227 | The compound has been evaluated for the in vivo efficacy that protect 50% of mice from lethal infection of Streptococcus Pneumonia EryS 032UC1 strain after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID1502710 | Antimycobacterial activity against Mycobacterium avium isolate MAV1 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID512005 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID596054 | Half life in Sprague-Dawley rat at 10 mg/kg, iv and 30 mg/kg, po | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID519987 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus nosocomial isolate | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID557792 | Antimicrobial activity against Streptococcus pyogenes clinical isolate expressing mosaic variant of mef gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1691432 | Antibacterial activity against Escherichia coli JW5503-1 depletion of toIC efflux gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID245013 | Minimum inhibitory concentration of compound against Ery-S Staphylococcus aureus ATCC 23029 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID596083 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs after 6 hrs infection followed by reinoculated | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID425567 | Antibacterial activity against Streptococcus pneumoniae HMC 3041 after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID577208 | Antimicrobial activity against Escherichia coli C600::H19B in logarithmic phase encoding Stx-1 gene by broth macrodilution assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID574934 | Enhancement of biofilm formation Staphylococcus epidermidis ATCC 35984 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID221226 | The compound has been evaluated for the in vivo efficacy that protect 50% of mice from lethal infection of Staphylococcus aureus EryS 011HT17 strains after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID533852 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium abscessus after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID565324 | Antibacterial activity against Mycoplasma genitalium M6286 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1733674 | Inhibition of mitochondrial respiration in human GFP-labelled MDA-MB-231 cells assessed as reduction in oxygen consumption rate at 30 uM pretreated for 88 hrs under low oxygen condition followed measured for 60 mins with sequential addition of OLI, FCCP a | 2021 | ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4 | Impact of Mitochondrial Targeting Antibiotics on Mitochondrial Function and Proliferation of Cancer Cells. |
| AID423249 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 15 to 64 years of age after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID558086 | Antimicrobial activity against Mycoplasma hominis isolated from human by two fold serial dilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. |
| AID470195 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID565817 | Antimicrobial activity against Neisseria gonorrhoeae isolates by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. |
| AID567474 | Antimicrobial activity against gBLPACR-1 Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID1855562 | Inhibition of quorum sensing system in Pseudomonas aeruginosa assessed as downregulation of lasR gene expression at sub-MIC by fluorescence real time PCR analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation. |
| AID1169030 | Antibacterial activity against macrolide lincosamide- streptogramin B inducibly-resistant Streptococcus pneumoniae by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID279865 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM prochlorperazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID637553 | Antibacterial activity against Streptococcus pneumoniae 994 expressing mef gene by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID1349195 | Antichlamydial activity against Chlamydia trachomatis serovar D 454/Bu infected in human HeLa 299 cells assessed as reduction in number of inclusion bodies measured after 44 to 48 hrs by DAPI staining-based HCS assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. |
| AID573416 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA selected at 4 ug/ml of compound after 1 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID619453 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing erm and mef gene by the broth microdilution method | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10 | Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID573411 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB selected at 4 ug/ml of compound after 4 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID547531 | Antimicrobial activity against Streptococcus intermedius obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on brain heart infusion agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID425630 | Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as lowest drug level producing inhibition at 10'6 CFU of inoculum by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID372547 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID522659 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis 003BS by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID278401 | Effect on mortality in Naegleria fowleri Lee (M67) infected CD1 mouse at 25 mg/kg/day, ip | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID559513 | Antibacterial activity against levofloxacin susceptible Streptococcus pneumoniae assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1691394 | Antibacterial activity against MLSB-resistant Streptococcus pneumoniae 07P390 harboring ermB gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID558087 | Antimicrobial activity against Ureaplasma parvum isolated from human by two fold serial dilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. |
| AID535346 | Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as susceptible isolates by PK/PD technique | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID1180567 | Antimicrobial activity against vancomycin-resistant Enterococcus faecium by broth microdilution/CLSI method | 2014 | Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14 | Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). |
| AID533862 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium wolinskyi after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID285506 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID533855 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium fortuitum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID1459151 | Metabolic stability in human liver microsomes assessed as parent compound remaining at 1 uM after 60 mins in presence of NADP by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID519990 | Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis nosocomial isolate | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID422652 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID531425 | Antibacterial activity against Streptococcus pneumoniae serotype 22 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID520410 | Antimicrobial activity against macrolide-resistant Streptococcus sp. 'group A' by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID573184 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm assessed as increase in viable cells relative to mutS::lox-deficient Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID425580 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene and I460V, D435N mutation in QRDR of ParE g | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559512 | Antibacterial activity against Lancefield Streptococcus sp. 'group G' assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID7783 | Unbound fraction (plasma) | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. |
| AID571433 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of 2 ug/ml NAB7062 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID425340 | Antibacterial activity against quinolone-susceptible Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID539506 | Antibacterial activity against erythromycin A-susceptible Streptococcus pneumoniae B0541 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID221229 | The compound has been evaluated for the in vivo efficacy that protect 50% of mice from lethal infection of Streptococcus Pneumoniae EryRi 030SJ5i strains after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID1459143 | Protein binding in human plasma at 1 ug/ml by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID558619 | Antimicrobial activity against Streptococcus pneumoniae isolate 3275 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID425578 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1766091 | Antibacterial activity against clinical isolate erythromycin-resistant Enterococcus faecium by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID279884 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM omeprazole | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID554655 | Antimicrobial activity against Ureaplasma parvum SV14 isolate HPA32 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID202097 | In vitro minimum inhibitory concentration for antibacterial activity against Streptococcus pneumoniae 210 (efflux-resistant strain encoded by the mef(A) gene) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID416249 | Inhibition of quorum sensing-regulated elastase production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 4 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID637556 | Antibacterial activity against Moraxella catarrhalis 8176 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID529896 | Antimicrobial activity against Leptospira interrogans serovar Pomona isolate 4 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID508454 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2368 harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID510853 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID512007 | Antibacterial activity against erythromycin, methicillin-resistant Staphylococcus aureus A333 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID508413 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID508375 | Antibacterial activity against quinolone-susceptible Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID666492 | Antibacterial activity against Staphylococcus aureus ATCC 13709 by broth microdilution method | 2012 | Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 | Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides. |
| AID657727 | Antibacterial activity against Haemophilus influenzae ATCC 49247 after 20 to 22 hrs by broth microdilution method | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10 | An efficient and convenient microwave-assisted chemical synthesis of (thio)xanthones with additional in vitro and in silico characterization. |
| AID585943 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as decrease of IFN-gamma production in in CD11b+ cells in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID508434 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 43 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1238009 | Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as inhibition of bacterial growth after 18 hrs by liquid microdilution method | 2015 | Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16 | Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel. |
| AID588220 | Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset | 2008 | Toxicology mechanisms and methods, , Volume: 18, Issue:2-3 | Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. |
| AID519986 | Antimicrobial activity against Streptococcus pneumoniae nosocomial isolate | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID642854 | Antibacterial activity against Staphylococcus aureus with inducible resistance to MLS by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID444051 | Total clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID206078 | The compound was tested in vitro for antibacterial activity against 31 strains of erythromycin resistant Streptococci; Value is 10/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID508377 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID565319 | Antibacterial activity against Mycoplasma genitalium M2321 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID501671 | Antimicrobial activity against Streptococcus pneumoniae SP030 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID437306 | Antibacterial activity against erythromycin-susceptible Staphylococcus pneumoniae ATCC 49619 | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin. |
| AID585936 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of CD80 expression in CD11b+ Gr1+ cells in alveolar space at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID285525 | Antibacterial activity against Neisseria meningitidis after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID429066 | Antiplasmodial activity after 120 hrs against Plasmodium falciparum 3D7 as Malstat LDH activity | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. |
| AID422461 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as decrease in biomass of biofilm in 2 days established biofilm at 0.125 ug/mL after 4 days using flow cell culture | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID422942 | Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae isolated from pediatric patients with community-acquired pneumonia after 10 to 14 days by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. |
| AID558250 | Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in bacterial cfu in peritoneum at 1 mg/kg, sc administered 2 hrs after infection measured after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID244965 | Minimum inhibitory concentration of compound against Ery-R Streptococcus pyogenes 3262 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID558592 | Antimicrobial activity against Streptococcus pneumoniae 4 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID582680 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of intracellular CFU at 4 mg/liter | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID533854 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium peregrinum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID1646207 | Antibacterial activity against Haemophilus influenzae | 2020 | Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12 | Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics. |
| AID508409 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1076 harboring erm(B) and mef(A) gene after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID422680 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID86128 | In vitro inhibitory activity against Haemophilus influenzae (351HT3) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID423240 | Antibacterial activity against beta lactamase-positive Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID557794 | Antimicrobial activity against Streptococcus pyogenes clinical isolate expressing mef(E) gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005. |
| AID559045 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID209865 | In vivo antibacterial activity against Streptococcus pneumoniae strain 5649 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID520407 | Antimicrobial activity against trimethoprim-sulfamethoxazole-susceptible Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID577679 | Antimicrobial activity against Neisseria gonorrhoeae harboring C2611T mutation in 23S rRNA V domain allele 1, allele 2, allele 3 and allele 4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID724184 | Antibacterial activity against constitutive-resistant to macrolide, licosamide and streptogramin Streptococcus pneumoniae 58 Spain by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID155757 | Antibacterial activity against Pasteurella multocida; More active | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | New directions in antibacterial research. |
| AID470190 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID559578 | Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Vero cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID735602 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae PU09 harboring mef gene by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID279888 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM omeprazole | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID509007 | Antimicrobial activity against methicillin susceptible Staphylococcus aureus | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. |
| AID534853 | Antibacterial activity against quinolone-resistant Salmonella enterica serovar stanley s2085 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID1488449 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 harboring harboring mef and erm gene after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID520028 | Antimicrobial activity against Enterococcus faecium A6345 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1515018 | Antibacterial activity against Staphylococcus aureus isolate 1025 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID531446 | Antibacterial activity against Streptococcus pneumoniae serotype 3 assessed as percent susceptible isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID696112 | Antiinflammatory activity in mouse splenocytes assessed as inhibition of LPS-induced IL-6 production at 12 uM preincubated for 2 hrs prior to LPS challenge by sandwich ELISA | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID585755 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of CD80 expression in CD11b+ Gr1+ cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID596013 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as decrease in density of parasitophorous vacuoles at 10 uM treated 6 hrs after infection measured after 24 hrs by microscop | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID434128 | Antibacterial activity against Enterococcus faecalis ATCC 29212 after 16 to 22 hrs by broth dilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID1549390 | Antibacterial activity against erythromycin-susceptible Moraxella catarrhalis 13L332 assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID423265 | Antibacterial activity against 0.01 MOI wild type Chlamydia psittaci 6BC BCRB infected in mouse L2 cells treated 2 hrs after infection measured on day 7 by plaque assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID543806 | Bactericidal activity against Acinetobacter baumannii VT 126 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs by serial dilution | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID585771 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b-c+ cell expression level in lung digest at 0.16 g/kg, po measured after 3 days by flow cytometry (Rvb = 19.71 +/- 3.89 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID444055 | Fraction absorbed in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID724174 | Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID470192 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID1720811 | Inhibition of quorum sensing system in Chromobacterium violaceum ATCC 31532 assessed as reduction in violacein production at 400 uM relative to control | 2020 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16 | Chloroquine fumardiamides as novel quorum sensing inhibitors. |
| AID558629 | Antimicrobial activity against Streptococcus pneumoniae isolate 3791 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID483699 | Antimicrobial activity against inducible macrolide and constitutive lincosamide, streptogramin-resistant Streptococcus pneumoniae 58 Spain | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID585930 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as up-regulation of CD23 expression in CD11+ Gr1- cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1515037 | Half life in human serum | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID519989 | Antimicrobial activity against coagulase-negative Staphylococcus nosocomial isolate | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID543811 | Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs by serial dilution | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID644812 | Antibacterial activity against clinical isolate Streptococcus pneumoniae SP030 | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. |
| AID372481 | Tmax in human at 1000 mg, po once daily for 3 days | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID696129 | Cmax in cystic fibrosis patient plasma at 500 mg | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID1766092 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC43300 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID423233 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID1691390 | Ratio of MBC to MIC against Erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID1409611 | AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay. | 2020 | Nature, 07, Volume: 583, Issue:7816 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID543808 | Bactericidal activity against Klebsiella pneumoniae VT 1367 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs by serial dilution | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID1427907 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID704320 | Cellular uptake in human PMNC at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID519991 | Antimicrobial activity against vancomycin-resistant Enterococcus faecalis nosocomial isolate | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID531629 | Antimicrobial activity against Ureaplasma parvum by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas. |
| AID1549367 | Selectivity ratio of MBC to MIC for erythromycin-susceptible Streptococcus pneumoniae ATCC49619 | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID279256 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81F and ParC D83N mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID502235 | Antibacterial activity against constitutive MLS resistance Streptococcus pneumoniae 58 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and properties of macrolones characterized by two ether bonds in the linker. |
| AID285524 | Antibacterial activity against Neisseria gonorrhoeae after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID1754230 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID520404 | Antimicrobial activity against macrolide-resistant Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID423101 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID725376 | Antibacterial activity against constitutive MLS-resistant Streptococcus pyogenes A2 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID1860914 | Anti-adhesion activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of adhesion ability at 50 ug/ml incubated for 3 hrs using glass as substrate by SEM analysis | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Glycosylation increases the anti-QS as well as anti-biofilm and anti-adhesion ability of the cyclo (L-Trp-L-Ser) against Pseudomonas aeruginosa. |
| AID571440 | Ratio of the MIC for Escherichia coli IH3080 in the absence of NAB7061 to MIC for Escherichia coli IH3080 in the presence of 4 ug/ml of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID208604 | The compound was tested in vitro for antibacterial activity against inducibly erythromycin resistant Streptococcus pneumoniae 030J5i | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID531418 | Antibacterial activity against Streptococcus pneumoniae serotype 6A/C by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID132625 | The compound was tested in vivo for antibacterial activity against AmpR beta(-) Haemophilus influenza 351TO19 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID596016 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs immediately after infection followed by reinoc | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID1539176 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID558611 | Antimicrobial activity against Streptococcus pneumoniae isolate 1564 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1855556 | Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition of bacterial growth incubated for 24 hrs by CLSI broth microdilution method | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation. |
| AID429065 | Antiplasmodial activity after 96 hrs against Plasmodium falciparum 3D7 as Malstat LDH activity | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. |
| AID554650 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA12 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID425653 | Renal clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID1427917 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes R1 clinical isolate by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID501296 | Antibacterial activity against efflux-mediated macrolide-resistance Streptococcus pneumoniae Ci137 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID422477 | Antimicrobial activity against azithromycin-resistant nontypeable Haemophilus influenzae isolate S43 assessed as inhibition of biofilm formation at >64 ug/mL | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID558623 | Antimicrobial activity against Streptococcus pneumoniae isolate 3412 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID428893 | Bactericidal activity against Pseudomonas aeruginosa PT1323 harboring rhlAB-encoding pAKRHL at 2 to 18 ug/ml after 22 hrs by plating serial dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID425762 | Antibacterial activity against penicillin-, macrolide-susceptible and quinolone-resistant Streptococcus pneumoniae HMC 1074 harboring S81F, E85K mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID658059 | Antibacterial activity against Haemophilus influenzae ATCC 49247 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID425832 | Antituberculosis activity against Mycobacterium avium ATCC 35712 isolated from chicken assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID144302 | Compound was evaluated for in vitro anti-mycobacterial activity against Mycobacterium simiae | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. |
| AID210049 | Compound was evaluated for antibacterial activity against Streptococcus pneumoniae (MB3957) sensitive strain | 1998 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID1053269 | Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching. |
| AID206083 | In vitro inhibitory activity against Streptococci EryRi (98) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID144563 | Minimum inhibitory concentration against macrolide susceptible strains of Mycobacterium smegmatis (MC2155) | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: I. 4", 11 and 12-OMe derivatives via direct methylation. |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID642855 | Antibacterial activity against constitutive MLS resistant Staphylococcus aureus by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID574709 | Antimicrobial activity against Staphylococcus epidermidis SW036 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID522643 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Sterne by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID520010 | Antimicrobial activity against Staphylococcus aureus A8833 harboring U2500A mutation in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1720813 | Inhibition of quorum sensing in violacein-negative Chromobacterium violaceum CV026 mini-Tn5 mutant assessed as quorum quenching by measuring violacein production at 400 uM in presence of C6-HSL relative to control | 2020 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16 | Chloroquine fumardiamides as novel quorum sensing inhibitors. |
| AID559507 | Antibacterial activity against Staphylococcus saprophyticus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1169033 | Antibacterial activity against macrolide lincosamide- streptogramin B inducibly-resistant Streptococcus pyogenes by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID425579 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I46 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID633418 | Antibacterial activity against efflux-mediated macrolide-resistant Streptococcus pyogenes Finland 2 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID559053 | Antibacterial activity against Staphylococcus warneri by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID565290 | Antimicrobial activity against Mycoplasma pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis. |
| AID1853144 | Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated assessed as inhibition of bacterial growth for 20 to 22 hrs by broth microdilution method | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling. |
| AID206550 | In Vivo evaluation for its effective dose against Staphylococcus aureus (011GO25 EryRi. | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID565314 | Antibacterial activity against Mycoplasma genitalium TW10-6G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID522665 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis BA0018 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID425559 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1427911 | Antibacterial activity against erythromycin/penicillin-susceptible Bacillus subtilis ATCC 9372 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID416415 | Antimicrobial activity against Pseudomonas aeruginosa NH57388A mucoid isolate expressing quorum sensing lasI assessed as reduction of viable count at 12 ug/mL in absence of 2.5% human normal serum | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID1691392 | Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae PU09 harboring mef gene | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID571448 | Antibacterial activity against Enterobacter cloacae ATCC 23355 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID422687 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID501280 | Antibacterial activity against efflux-mediated macrolide resistance Streptococcus pyogenes 2 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID132635 | The compound was tested in vivo for antibacterial activity against inducibly erythromycin resistant Streptococcus pneumoniae 030RO1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID558587 | Antimicrobial activity against Streptococcus pneumoniae 19A by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID244993 | Minimum inhibitory concentration of compound against Ery-R Streptococcus pneumoniae 5032 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID508384 | Antibacterial activity against Streptococcus pyogenes harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID519997 | Antimicrobial activity against Streptococcus pneumoniae ribosomal mutant | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID663051 | Antimalarial activity against Plasmodium berghei KBG173 infected in mouse assessed as cured mouse at 15 mg/kg, iv BID administered on day 3, 4 and 5 post infection measured up to day 31 | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID508456 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2368 harboring erm(B) gene after 6 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID638883 | Antibacterial activity against Streptococcus pneumoniae 49619 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID535561 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar saintpaul s2829 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID565820 | Antimicrobial activity against Chlamydia trachomatis isolates | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. |
| AID596058 | Antiplasmodial activity against Plasmodium berghei KBG-173 infected in mouse assessed as mouse without parasitemia at 240 mg/kg, sc bid for 3 days measured on day 31 | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID1515027 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID1550824 | Antimicrobial activity against inducibly erythromycin resistant Staphylococcus aureus PU64 expressing i-ermA incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID508396 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 15 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID585765 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c- cell expression level in lung digest at 0.16 g/kg, po measured after 3 days by flow cytometry (Rvb = 25.42 +/- 10.57 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID244962 | Minimum inhibitory concentration of compound against Ery-R Streptococcus pyogenes 1721 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID283557 | Antimicrobial activity against Streptococcus pneumoniae R6 with L4 69GTG71 to TPS mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID535356 | Antimicrobial activity against Streptococcus pyogenes clinical isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID425632 | Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as minimum drug level resulting in no detectable growth at 10'6 CFU of inoculum after 56 days by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID596017 | Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs immediately after infection followed by reinoculated into fresh HFF monolayers | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID595940 | Cytotoxicity against HFF after 48 hrs by MTS assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID205551 | Minimum inhibitory concentration against Staphylococcus aureus | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and SAR of azalide 3,6-ketal aromatic derivatives as potent Gram-positive and Gram-negative antibacterial agents. |
| AID279898 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM chlorpromazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID1417286 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mefA gene after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID547758 | Antimicrobial activity against invasive Streptococcus intermedius obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on brain heart infusion agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID203430 | In vitro inhibitory activity against Staphylococci EryRi (65) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID582689 | Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD assessed as concentration required to no apparent bacterial growth after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID425628 | Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as effect on average time to detection of growth at >10'2 CFU of inoculum by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID558610 | Antimicrobial activity against Streptococcus pneumoniae isolate 1424 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID360366 | Antimalarial activity after 96hrs against Plasmodium falciparum 7G8 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID585767 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c- cell expression level in lung digest at 0.16 g/kg, po measured after 14 days by flow cytometry (Rvb = 21.97 +/- 3.51 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1691431 | Antibacterial activity against Escherichia coli BW25113 depletion of toIC efflux gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID608734 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae SP030 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID425596 | Antibacterial activity against extracellular Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease at 0.01 to 10 ug/ml after 3 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID531108 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa TNP090 mutant harboring las and rhl gene at 1 ug/ml after 9.5 hrs by Cat-2,3-diO reporter gene assay relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID567472 | Antimicrobial activity against gBLNAR Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID416429 | Antimicrobial activity in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene infected in ftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse lung assessed as fibrous spongy-like material surrounding polymorphonucl | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID582201 | Drug concentration in Epithelial lining fluid of healthy human at 500 mg, po administered as single dose after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study. |
| AID1417285 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 2 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID571436 | Antibacterial activity against Escherichia coli IH3080 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID724188 | Antibacterial activity against inducible-resistant to macrolide, licosamide and streptogramin Staphylococcus aureus 90265/97 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID278856 | Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID582612 | Antibacterial activity against Listeria monocytogenes EGD after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID426376 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae 07H252 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID644811 | Antibacterial activity against Staphylococcus aureus ATCC 13709 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. |
| AID635189 | Antibacterial activity against efflux-mediated macrolide-resistant Streptococcus pneumoniae Ci137 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID559521 | Antibacterial activity against Streptococcus oralis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1550816 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID422480 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as inhibition of biofilm formation at 0.25 ug/ml after 7 hrs using crystal violet | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID283583 | Cell viability of IB3-1 cells at 8 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID1238011 | Ratio of MIC50 for Staphylococcus aureus ATCC 29213 in absence of 50% bovine serum to MIC50 for Staphylococcus aureus ATCC29213 in presence of 50% bovine serum | 2015 | Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16 | Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel. |
| AID143699 | Compound was evaluated for in vitro anti-mycobacterial activity against MAC 101 | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. |
| AID372506 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 96hrs at 100 nM dosed 36-48 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID423235 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID508426 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 16 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID571768 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-I626M mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID565816 | Antimicrobial activity against Neisseria gonorrhoeae assessed as resistant isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. |
| AID619452 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mef gene by the broth microdilution method | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10 | Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID1241212 | Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay in presence of 100-fold excess of Escherichia coli tRNA | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID483704 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing erm gene by broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives. |
| AID1550825 | Antimicrobial activity against Staphylococcus epidermidis E1 incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID1498155 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 harboring ermB gene after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID577675 | Antimicrobial activity against Neisseria gonorrhoeae expressing wild type 23S rRNA by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID483695 | Antimicrobial activity against inducible macrolide, lincosamide, streptogramin-resistant Streptococcus pyogenes Finland 11 | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID559532 | Antibacterial activity against non-ciprofloxacin-susceptible Haemophilus influenzae assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425583 | Antibacterial activity against Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID595998 | Antimalarial activity against multidrug-resistant Plasmodium falciparum TM91C235 after 48 hrs by [3H]hypoxanthine incorporation assay | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID642863 | Antibacterial activity against efflux mediated macrolide resistant Streptococcus pyogenes by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID278871 | Increase in lactate production in MG63 cells at 400 ug/ml by ELISA relative to control | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID1488454 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC 9372 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID285518 | Antibacterial activity against Streptococcus pyogenes | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID577676 | Antimicrobial activity against Neisseria gonorrhoeae harboring A2059G mutation in 23S rRNA domain V allele 4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID416408 | Inhibition of alginate synthesis in Pseudomonas aeruginosa NH57388A mucoid isolate supernatant assessed as uronic acid fraction out of the dialysis bag of total amount of uronic acids after equilibrium dialysis at 12 ug/mL after 24 hrs by carbazole-borate | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID434127 | Antibacterial activity against Haemophilus influenzae ATCC 49247 after 16 to 22 hrs by broth dilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID571443 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 1 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID582679 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 assessed as decrease of CFU at 4 mg/liter | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID422452 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as maximal doubling time at 0.125 ug/mL using flow cell culture after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID434122 | Antibacterial activity against constitutive macrolide-lincosamide-streptogramin-resistant Streptococcus pneumoniae after 16 to 22 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID704314 | Cellular uptake in human T NCI-H292 cells at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID1691391 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae PU09 harboring mef gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID577686 | Antimicrobial activity against Neisseria gonorrhoeae isolate 352521 NG-MAST sequence type 1443 harboring A2059G mutation in 23S rRNA V domain allele 1, allele 2, allele 3 and allele 4 selected after 0.5 to 8 mg/L of erythromycin by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID132632 | The compound was tested in vivo for antibacterial activity against erythromycin susceptible Streptococcus pneumoniae 032UC1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID360369 | Antimalarial activity after 96 hrs against Plasmodium falciparum 7G8 T76K1 mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID519988 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus nosocomial isolate | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID416236 | Drug level in Cftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse serum at 500 mg/kg, po after 4 hrs | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID508471 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2011 harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID558252 | Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in extracellular bacterial cfu in peritoneum at 1 mg/kg, sc administered 2 hrs after infection measured after 4 hrs | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID279905 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM chlorpromazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID644455 | Antibacterial activity against methicillin-resistant, coagulase-negative, inducible MLS-resistant Staphylococcus hominis E3 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID520414 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID550374 | Antimicrobial activity against Haemophilus influenzae ATCC 49247 after 16 to 22 hrs by broth microdilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2 | Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae. |
| AID1691399 | Ratio of MBC to MIC against MLSB/methicillin/ciprofloxacin-resistant Staphylococcus aureus PU32 harboring ermA gene | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID531106 | Inhibition of MexAB-OprM efflux pump expression in las1 deficient Pseudomonas aeruginosa TNP091 at 1 ug/ml after 9 hrs by Cat-2,3-diO reporter gene assay | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID19403 | Calculated partition coefficient (logD) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID1766090 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC9372 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID1691393 | Ratio of MBC to MIC against penicillin-susceptible Streptococcus pneumoniae PU09 | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID422465 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as decrease in biofilm formation at 0.125 ug/mL treated for 4 days measured on day 2 to 4 using flow cell culture | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID696131 | Cmax in lung cancer patient serum at 2 gram, po qd | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID519993 | Antimicrobial activity against vancomycin-resistant Enterococcus faecium nosocomial isolate | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1241205 | Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID577205 | Antimicrobial activity against Escherichia coli O157:H7 PT-32 in logarithmic phase encoding Stx-1 and Stx-2 gene by broth macrodilution assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID508440 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3665 harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1698705 | Antibacterial activity against genotype penicillin-resistant Streptococcus pneumoniae by CLSI method | 2020 | Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22 | Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors. |
| AID585762 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as reduction of CD11b- and Gr-1+ cells infiltration in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID576342 | Bactericidal activity against Chlamydia trachomatis serovar D infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1409608 | AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells). | 2020 | Nature, 07, Volume: 583, Issue:7816 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID543795 | Antimicrobial activity against Escherichia coli ATCC 25922 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID604044 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID556349 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae ATCC 15531 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. |
| AID326091 | Antimicrobial activity against Streptococcus pneumoniae NMU112 infected in po dosed CBA/J mouse assessed as delaying in development of bacteremia relative to roxithromycin | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID569036 | Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes S2 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID132622 | The compound was tested in vitro for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030SJ6. | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID1487243 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID206548 | Effective dose required to inhibit Staphylococcus aureus intraperitoneal (IP) infection model | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and SAR of azalide 3,6-ketal aromatic derivatives as potent Gram-positive and Gram-negative antibacterial agents. |
| AID574704 | Enhancement of biofilm formation Staphylococcus epidermidis SW088 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID575169 | Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. |
| AID425985 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 20 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID209880 | Cell free inhibiting activity against Streptococcus pneumoniae 5635(Wild type ribosomes for transcription/translation assay) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID425994 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID279885 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM omeprazole | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID543814 | Bactericidal activity against Streptococcus pyogenes VT 59 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID1666866 | Inhibition of swarming motility of Pseudomonas aeruginosa clinical isolates incubated for 16 to 20 hrs | 2020 | Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5 | Optimized plant compound with potent anti-biofilm activity across gram-negative species. |
| AID283589 | Cell viability of C38 cells at 16 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID508442 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID508475 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 237 harboring mutation in L4 ribosomal protein after 43 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID283590 | Cell viability of 16HBE14o-AS3 cells at 16 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID85952 | In Vivo evaluation for its effective dose against Haemophilus influenzae (351GR1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID425556 | Antibacterial activity against quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 441 expressing ermB by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID585772 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b-c+ cell expression level in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry (Rvb = 29.15 +/- 3.98 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID326069 | Reduction of pneumolysin production in Streptococcus pneumoniae NMU112 lysates at 5 ug/mL after 12 hrs by Western blot relative to control | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID558242 | Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 9 mg/liter after 24 hrs by time-kill study | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID279204 | Antibacterial activity against Streptococcus pneumoniae 1077 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID285508 | Antibacterial activity against Streptococcus pneumoniae by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID1498150 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 incubated for 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID508432 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 38 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID283584 | Cell viability of C38 cells at 8 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID426378 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae 05Z006 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID531453 | Antibacterial activity against Streptococcus pneumoniae serotype 19A assessed as percent resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID596085 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 0.1 uM treated for 48 hrs after 6 hrs infection followed by reinoculat | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID209097 | In Vivo evaluation for its effective dose against Streptococcus pyogenes (02A1UC1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID559062 | Antibacterial activity against Streptococcus bovis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425982 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID499555 | Antibacterial activity against efflux-resistant Streptococcus pneumoniae B0326 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID326074 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae NMU112 infected CBA/J mouse assessed as median survival time at 5 mg/kg, po relative to control | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID522662 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K7038 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID531424 | Antibacterial activity against Streptococcus pneumoniae serotype 33 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID423262 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected outpatients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID559581 | Antimicrobial activity against Chlamydophila pneumoniae infected in Vero cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID202098 | In vitro minimum inhibitory concentration for antibacterial activity against Streptococcus pneumoniae 211 (MLSb-resistant strain encoded by the erm(B) gene) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1720815 | Inhibition of quorum sensing in Chromobacterium violaceum ATCC 31532 assessed as reduction in violacein production at 40 uM relative to control | 2020 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16 | Chloroquine fumardiamides as novel quorum sensing inhibitors. |
| AID539514 | Antibacterial activity against Haemophilus influenzae B0529 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID1055328 | Antibacterial activity against extended spectrum beta-lactamase producing Escherichia coli 09-1 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID550368 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 16 to 22 hrs by broth microdilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2 | Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae. |
| AID596086 | Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 0.1 uM treated for 48 hrs after 6 hrs infection followed by reinoculated into fresh HFF monolayers meas | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID1487248 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB/mefA gene | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID1502706 | Antimycobacterial activity against Mycobacterium avium 104 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID508369 | Antibacterial activity against Streptococcus pneumoniae harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID520019 | Antimicrobial activity against Staphylococcus aureus pLXM1 harboring cfr gene | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID416248 | Inhibition of quorum sensing-regulated elastase production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 2 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID520234 | Antimicrobial activity against Haemophilus influenzae A1950 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1754232 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID565230 | Antimicrobial activity against Mycobacterium chelonae 9917 by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID585776 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c- cell expression level in lung lavage fluid at 0.16 g/kg, po measured after 14 days by flow cytometry (Rvb = 1.15 +/- 0.62 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID483705 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mef gene by broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives. |
| AID360372 | Antimalarial activity after 96 hrs against Plasmodium falciparum GCO3 C6 mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID508380 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID543793 | Antimicrobial activity against Haemophilus influenzae VT450-2006 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID529893 | Antimicrobial activity against Leptospira interrogans serovar Bataviae isolate 1 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID372555 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene assessed as susceptibility rate by broth microdilution metho | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID558617 | Antimicrobial activity against Streptococcus pneumoniae isolate 3260 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID559508 | Antibacterial activity against Staphylococcus warneri assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1487249 | Antibacterial activity against Escherichia coli ATCC 25922 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID1055336 | Antibacterial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID531101 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa TNP090 mutant harboring las and rhl gene at 0.5 ug/ml by Cat-2,3-diO reporter gene assay relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID508466 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 34 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1417279 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID422665 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID428887 | Inhibition of swarming motility of Pseudomonas aeruginosa PT1300 harboring vector pEX1.8 at 2 ug/ml after 18 hrs | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID423272 | Antibacterial activity against 0.01 MOI wild type Chlamydia trachomatis L2/LGV/434/Bu infected in mouse L2 cells treated 2 hrs after infection measured on day 7 by plaque assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID529902 | Antimicrobial activity against Leptospira interrogans serovar Pomona isolate 12 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID245037 | Minimum inhibitory concentration of compound against Ery-S Streptococcus pyogenes ATCC 19615 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID518970 | Induction of erm(C) expression in Escherichia coli JM109 harboring Staphylococcus aureus erm(C)-containing pERMZdelta2-4 mutant leader peptide cistrons reporter plasmid at 25 mg/ml after 36 hrs at 37 degC by disc-based beta-galactosidase reporter gene ass | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of erm(C) expression by noninducing antibiotics. |
| AID520023 | Antimicrobial activity against Enterococcus faecalis A6343 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID696100 | Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID416244 | Antimicrobial activity against Pseudomonas aeruginosa NH57388A mucoid isolate assessed as reduction of viable count in exponential phase at 64 ug/mL after 8 hrs | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID558245 | Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 20 mg/liter after 24 hrs by time-kill study | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID604043 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing erm and mef gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID558589 | Antimicrobial activity against Streptococcus pneumoniae 1 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID283579 | Reduction of NF-kappaB binding to DNA in cystic fibrosis 2CFSMEo cells at 8 ug after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID360360 | Antimalarial activity after 96 hrs against Plasmodium falciparum 7G8 C1 mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID423247 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 3 to 5 years of age after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID425833 | Antituberculosis activity against Mycobacterium avium ATCC 35712 isolated from chicken assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID209629 | In vivo antibacterial activity against Streptococcus pyogenes strain C203 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID372505 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 96hrs at 100 nM dosed 24-48 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID501283 | Antibacterial activity against macrolide, licosamide and streptogramin inducible-resistance Streptococcus pyogenes 11 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID524824 | Antibacterial activity against erythromycin resistant Campylobacter sp. by agar plate dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID520224 | Antimicrobial activity against Enterococcus faecium A9621 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID501284 | Antibacterial activity against constitutive MLS-resistance Streptococcus pneumoniae 58 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID208145 | In vivo antibacterial activity against Streptococcus pneumoniae strain 6396 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID1691395 | Bactericidal activity against MLSB-resistant Streptococcus pneumoniae 07P390 harboring ermB gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID322130 | In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID508370 | Antibacterial activity against Streptococcus pneumoniae harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID369230 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae assessed as percent sensitive isolates by CLSI breakpoint method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain. |
| AID638882 | Antibacterial activity against Streptococcus pneumoniae 6303 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID425826 | Antituberculosis activity against Mycobacterium paratuberculosis B213 isolated from bovine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID534511 | Drug level in human THP1 cells at 10 mg/L at pH =< 6.5 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils. |
| AID558583 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID558246 | Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 0.5 mg/liter after 24 hrs by time-kill study | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID444054 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1733670 | Inhibition of mitochondrial COX1 expression in human GFP-labelled MDA-MB-231 cells at 30 uM incubated for 72 hrs under low oxygen condition by Western blot analysis | 2021 | ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4 | Impact of Mitochondrial Targeting Antibiotics on Mitochondrial Function and Proliferation of Cancer Cells. |
| AID725378 | Antibacterial activity against penicillin-susceptible, constitutive MLS-resistant Streptococcus pneumoniae PU 27 expressing erm gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID279255 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID1625272 | Antimalarial activity against Plasmodium falciparum 3D7 after 48 hrs | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12 | Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action. |
| AID416254 | Inhibition of quorum sensing-regulated pyocyanin production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 2 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID735603 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID518975 | Induction of erm(C) expression in Escherichia coli ZK796 harboring Staphylococcus aureus erm(C)-containing pERMCT plasmid assessed as increase in A2058 dimethylation in 23S rRNA at 25% MIC after 4 hrs by primer extension assay | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of erm(C) expression by noninducing antibiotics. |
| AID422459 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as decrease biomass of biofilm at 0.125 ug/mL after 2 days using flow cell culture relative to control | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID585753 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as decrease of TNFalpha production in in CD11b+ cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID582202 | Drug concentration in Alveolar macrophage of healthy human at 500 mg, po administered as single dose after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study. |
| AID510849 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID1549379 | Bactericidal activity against MLS/methicillin-resistant Staphylococcus aureus PU 32 expressing inducible ermA gene pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID633421 | Antibacterial activity against inducible macrolide-lincosamide-streptogramin B resistant Streptococcus pyogenes Finland 11 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID114196 | Effective dose in vivo, in mouse inoculated intraperitoneally with 7.05*10e2 CFU of erythromycin susceptible strain Streptococcus pneumoniae IID553 | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID573414 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA selected at 4 ug/ml of compound after 6 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID510850 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae PU-11 expressing erm and mef gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID279863 | Antimicrobial activity against Burkholderia pseudomallei KHW | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID675202 | Antibacterial activity against Haemophilus influenzae ATCC 43095 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID1691403 | Antibacterial activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID422944 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae harboring A2064G transition in domain V of 23S rRNA isolated from pediatric patients with community-acquired pneumonia after 10 to 14 days by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. |
| AID283580 | Reduction of Sp1 binding to DNA in cystic fibrosis IB3-1 cells at 8 ug after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID1055341 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 09-13 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID577206 | Antimicrobial activity against Escherichia coli O157:H7 PT-32 in stationary phase encoding Stx-1 and Stx-2 gene by broth macrodilution assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID704321 | Cellular uptake in human NHBE assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID498876 | Antimicrobial activity against Neisseria meningitidis M7tolC::Kan mtr::Spc by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli. |
| AID577685 | Antimicrobial activity against Neisseria gonorrhoeae isolate 352521 NG-MAST sequence type 1443 harboring A2059G mutation in 23S rRNA V domain allele 4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID479978 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus PU32 encoded by erm(A) gene | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID1515022 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID535562 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar stanley s2868 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID642852 | Antibacterial activity against ciprofloxacin-resistant Staphylococcus aureus by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID540232 | Dose normalised AUC in monkey after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
| AID522660 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis BA1086 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID577684 | Antimicrobial activity against Neisseria gonorrhoeae isolate 136 NG-MAST sequence type 1704 harboring A2059G mutation in 23S rRNA V domain allele 1, allele 2, allele 3 and allele 4 selected after 0.5 to 8 mg/L of erythromycin by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID428895 | Inhibition of rhamnolipid production in Pseudomonas aeruginosa PT1323 harboring pAKRHL expressing rhlAB gene up to 50 ug/ml incubated for 24 hrs at 37 deg C further 24 hrs at 25 deg C | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID1754227 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID322128 | In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs by SYBR green fluorescence assay | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID534424 | Antibacterial activity against Mycobacterium bovis BCG-Pasteur | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID1515019 | Antibacterial activity against Enterococcus faecium isolate 568 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID322126 | In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID520233 | Antimicrobial activity against Haemophilus influenzae 54A1100 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID520011 | Antimicrobial activity against Staphylococcus aureus A8831 harboring U2500A mutation in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID724178 | Antibacterial activity against efflux mediated macrolide-resistant Streptococcus pyogenes Finland 2 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID520405 | Antimicrobial activity against quinolone-susceptible Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID221231 | The compound has been evaluated for the in vivo efficacy that protect 50%of mice from lethal infection of Haemophilus influenzae AmpR 351RD7 after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID642861 | Antibacterial activity against Streptococcus pyogenes with inducible resistance to MLS by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID425971 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 20 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID278861 | Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID416409 | Inhibition of alginate synthesis in Pseudomonas aeruginosa NH57388A mucoid isolate supernatant assessed as uronic acid concentration in dialysis bag before exhaustive dialysis at 12 ug/mL after 24 hrs by carbazole-borate assay | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID571767 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-M626I mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID207076 | In vitro inhibitory activity against Staphylococcus aureus (EryRc 011CB20) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID666490 | Antibacterial activity against Streptococcus pneumoniae isolate SP030 by broth microdilution method | 2012 | Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 | Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides. |
| AID279268 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81F mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID322127 | In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID416420 | Antimicrobial activity against Pseudomonas aeruginosa NH57388C nonmucoid isolate expressing quorum sensing lasI assessed as reduction of viable count at 12 ug/mL in presence of 2.5% human normal serum | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID66555 | In vitro inhibitory activity against enterococci EryRi (19) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID416422 | Elimination half life in human | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID416237 | Drug level in Cftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse serum at 500 mg/kg, po after 0.5 hrs | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID208469 | The compound has been evaluated for the antibacterial activity against Streptococcus pneumoniae EryS 032UC1 strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID373649 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by agar dilution CLSI method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. |
| AID1241209 | Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID582606 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID208468 | The compound has been evaluated for the antibacterial activity against Streptococcus pneumoniae EryRc 030SJ1 strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID577691 | Antimicrobial activity against Neisseria gonorrhoeae isolate 254921 NG-MAST sequence type 649 selected after 2 to 8 mg/L of compound by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID569030 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID531449 | Antibacterial activity against Streptococcus pneumoniae serotype 23A assessed as percent susceptible isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID584096 | Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 19606R harboring empty plasmid pWH1266 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. |
| AID585939 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as decrease of TNFalpha production in in CD11b+ cells in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID423256 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected male patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID644818 | Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. |
| AID596008 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as parasite doubling time at 5 to 50 uM treated immediately after infection measured after 48 hrs | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID633424 | Antibacterial activity against constitutive macrolide, lincosamide, streptogramin-resistant Staphylococcus aureus PK2 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID619456 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 by the broth microdilution method | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10 | Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation. |
| AID582676 | Antibacterial activity against Legionella pneumophila ATCC 33153 at pH 6.5 to 7.4 after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID735597 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes A3 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID425821 | Antituberculosis activity against Mycobacterium paratuberculosis UCF-4 isolated from Crohn's disease patient assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID360370 | Antimalarial activity after 96hrs against Plasmodium falciparum GCO3 C2 mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID534851 | Antibacterial activity against quinolone-resistant Salmonella enterica serovar stanley s2018 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID619454 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by the broth microdilution method | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10 | Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation. |
| AID379524 | Antibacterial activity against Staphylococcus aureus ATCC 25923 | 2006 | Journal of natural products, Nov, Volume: 69, Issue:11 | Acetylated flavanone glycosides from the rhizomes of Cyclosorus acuminatus. |
| AID479817 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID633413 | Antibacterial activity against erythromycin-sensitive Staphylococcus aureus ATCC 13709 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID483703 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives. |
| AID559064 | Antibacterial activity against Streptococcus intermedius by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID508383 | Antibacterial activity against Streptococcus pyogenes harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID548257 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID498873 | Antimicrobial activity against Neisseria meningitidis M7 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli. |
| AID508423 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2686 harboring mutation in L4 ribosomal protein after 25 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID539502 | Antibacterial activity against inducible macrolide-lincosamide-streptogramin B-resistant Streptococcus pyogenes B0543 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID635180 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae SP030 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID21901 | Calculated partition coefficient (clogP) | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and SAR of azalide 3,6-ketal aromatic derivatives as potent Gram-positive and Gram-negative antibacterial agents. |
| AID244963 | Minimum inhibitory concentration of compound against Ery-R Streptococcus pyogenes 1850 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID279271 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 2527 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID559498 | Antibacterial activity against vancomycin- resistant Enterococcus faecium assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID558084 | Antimicrobial activity against Mycoplasma genitalium isolated from human by two fold serial dilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. |
| AID1625277 | Half life in human | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12 | Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action. |
| AID501677 | Antimicrobial activity against Haemophilus influenzae ATCC 49247 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID117681 | Protective dose at which 50% of infected, treated mice survive | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID131359 | Effective dose against Streptococcus pneumoniae 6303 (erythromycin susceptible strain) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID558600 | Antimicrobial activity against Streptococcus pneumoniae 12 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID428294 | Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by E test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. |
| AID1549372 | Bactericidal activity against Streptococcus pneumoniae 07P390 expressing constitutive ermB gene pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID508460 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 5 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID8002 | Observed volume of distribution | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. |
| AID1409613 | Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay. | 2020 | Nature, 07, Volume: 583, Issue:7816 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID132629 | The compound was tested in vivo for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030SJ1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID426381 | Antimicrobial activity against erythromycin-resistant Streptococcus pyogenes 07Z011 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID573426 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA selected at 4 ug/ml of compound after 6 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID501295 | Antibacterial activity against efflux-mediated macrolide-resistance Staphylococcus aureus PK1 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID558581 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID522663 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis SPS 0053 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID278065 | Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from deployed military patient | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. |
| AID548253 | Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID426383 | Antimicrobial activity against erythromycin-resistant Streptococcus pyogenes 07Z016 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID279871 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM prochlorperazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID283581 | Reduction of Sp1 binding to DNA in cystic fibrosis 16HBE14o-AS3 cells at 8 ug after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID724181 | Antibacterial activity against erythromycin susceptible Streptococcus pyogenes 3565 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID559523 | Antibacterial activity against Streptococcus sanguinis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID206352 | The compound has been evaluated for the antibacterial activity against Staphylococcus aureus EryRc 011CB20 strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID206729 | Colony forming units of Staphylococcus aureus intramammary infection (IMI) model was determined at a dose of 15 mg/kg | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and SAR of azalide 3,6-ketal aromatic derivatives as potent Gram-positive and Gram-negative antibacterial agents. |
| AID1257218 | Antibacterial activity against Staphylococcus aureus ATCC 29213 after overnight incubation by broth microdilution method | 2015 | Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23 | 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity. |
| AID666484 | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in type A rhesus-positive human erythrocytes assessed as [3H]hypoxanthine incorporation after 48 hrs by scintillation counting | 2012 | Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 | Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides. |
| AID422662 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 29 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1417284 | Antibacterial activity against penicillin-resistant Staphylococcus aureus ATCC 31007 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID562271 | Antimalarial activity against Plasmodium falciparum isolates assessed as parasite growth inhibition after 72 hrs by ELISA based histidine-rich protein 2 in vitro drug susceptibility assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Antimalarial activity of tigecycline, a novel glycylcycline antibiotic. |
| AID548256 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID678714 | Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID483692 | Antimicrobial activity against macrolide-sensitive Streptococcus pneumoniae SPO 30 | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID508403 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3665 harboring mef(A) gene after 50 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID543803 | Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 assessed as eradication of pre-formed biofilm at 1 to 10 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID678721 | Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID1409609 | Cytotoxicity of compound against Vero E6 cells by MTT assay. | 2020 | Nature, 07, Volume: 583, Issue:7816 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID206070 | In vitro inhibitory activity against Streptococci EryR (27) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID571449 | Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of 1 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID360378 | Antimalarial activity after 96 hrs against Plasmodium falciparum 3BA6 SND mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID508378 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID483706 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB1-1 expressing erm and mef gene by broth microdilution method | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives. |
| AID558624 | Antimicrobial activity against Streptococcus pneumoniae isolate 3455 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID574694 | Enhancement of biofilm formation Staphylococcus epidermidis SW085 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID568332 | Antimicrobial activity against wild type Pseudomonas aeruginosa by broth dilution assay | 2011 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4 | Design and synthesis of potent Gram-negative specific LpxC inhibitors. |
| AID520412 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Antistreptococcal activity of AR-709 compared to that of other agents. |
| AID1326853 | Antibacterial activity against Haemophilus influenzae MB5363 by broth microdilution technique | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | A Gestalt approach to Gram-negative entry. |
| AID278387 | Antimicrobial activity against Naegleria fowleri Lee (M67) at day 3 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID1515024 | Antibacterial activity against Streptococcus agalactiae isolate 52 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID425988 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 29 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID423254 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 15 to 64 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID554648 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA3 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID683709 | Antimalarial activity against Plasmodium yoelii infected in CD-1 mouse assessed as efficacy at 40 mg/kg, ip | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Targeting the liver stage of malaria parasites: a yet unmet goal. |
| AID558605 | Antimicrobial activity against Streptococcus pneumoniae isolate 1146 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID425398 | Antibacterial activity against Escherichia coli isolate HM154 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID520008 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1853147 | Antibacterial activity against hypersensitive AcrAB deficient Escherichia coli assessed as inhibition of bacterial growth incubated for 20 to 22 hrs by broth microdilution method | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling. |
| AID543810 | Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs by serial dilution | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID696133 | Antiinflammatory activity in BALB/cJ mouse assessed as decrease in LPS-induced neutrophil number in bronchoalveolar lavage fluid at 200 mg/kg, ip administered 2 hrs prior to LPS challenge measured after 24 hrs post LPS challenge | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID565228 | Antimicrobial activity against Mycobacterium chelonae ATCC 35752 by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID372476 | Antimalarial activity as segregation of apicoplast in chloroquine-sensitive Plasmodium falciparum 3D7 progeny infected human erythrocytes at 100 nM dosed 96 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID1417278 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes 1 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID1488451 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 harboring mef gene after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID565327 | Antibacterial activity against Mycoplasma genitalium M6151 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID519992 | Antimicrobial activity against vancomycin-susceptible Enterococcus faecium nosocomial isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID360371 | Antimalarial activity after 96 hrs against Plasmodium falciparum GCO3 C4 mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID519994 | Antimicrobial activity against Streptococcus pneumoniae harboring erm(B) gene by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID278388 | Antimicrobial activity against Naegleria fowleri Lee (M67) in presence of azithromycin at 1:3 ratio on day 2 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID425966 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 50 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID360368 | Antimalarial activity after 96 hrs against Plasmodium falciparum Dd2 T76K1 mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID559076 | Antibacterial activity against ciprofloxacin-susceptible Haemophilus influenzae by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID501674 | Antimicrobial activity against Streptococcus pyogenes Finland 2 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID543797 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID1417283 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID608735 | Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 3565 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID369227 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain. |
| AID518963 | Induction of erm(C) expression in Escherichia coli JM109 harboring Staphylococcus aureus erm(C)-containing pERMZalpha reporter plasmid after 36 hrs at 25 mg/ml 37 degC by disc-based beta-galactosidase reporter gene assay | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of erm(C) expression by noninducing antibiotics. |
| AID559068 | Antibacterial activity against Streptococcus sanguinis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID558622 | Antimicrobial activity against Streptococcus pneumoniae isolate 3374 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID209863 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (032UC1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID425819 | Antituberculosis activity against Mycobacterium paratuberculosis JTC303 isolated from bovine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID596002 | Cytotoxicity against human HepG2 cells after 1 to 4 hrs by MTS assay | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID66411 | In vitro inhibitory activity against enterococci EryRi (19) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID585777 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c+ cell expression level in lung lavage fluid at 0.16 g/kg, po measured after 3 days by flow cytometry (Rvb = 2.38 +/- 0.75 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID678715 | Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID522661 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K1938 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID573168 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 planktonic cells by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID573406 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA selected at 4 ug/ml of compound after 2 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID531421 | Antibacterial activity against Streptococcus pneumoniae serotype 35B by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID558598 | Antimicrobial activity against Streptococcus pneumoniae 10 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID523012 | Ratio of Kcat to Km for macrolide 2'-phosphotransferase 1 by PK/LDH-coupled assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Nucleotide selectivity of antibiotic kinases. |
| AID558593 | Antimicrobial activity against Streptococcus pneumoniae 5 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID704319 | Cellular uptake in human NHBE at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID767507 | Antibacterial activity against Escherichia coli 236 by standard dilution assay | 2013 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18 | Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents. |
| AID574696 | Enhancement of biofilm formation Staphylococcus epidermidis SW104 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID279899 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM chlorpromazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID531107 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa TNP090 mutant harboring las and rhl gene at 1 ug/ml after 11.5 hrs by Cat-2,3-diO reporter gene assay relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID1487242 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID573421 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB selected at 4 ug/ml of compound after 3 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID534862 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar Typhimurium s2391 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID633416 | Antibacterial activity against efflux-mediated macrolide-resistant Staphylococcus aureus PK1 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID1691426 | Antibacterial activity against MLSB/methicillin-resistant Staphylococcus aureus 15B196 assessed as reduction in microbial growth relative to ciprofloxacin | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID279873 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM promazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID434119 | Antibacterial activity against Staphylococcus aureus ATCC 29213 after 16 to 22 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID559536 | Antibacterial activity against Moraxella catarrhalis assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID608745 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID279259 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID558590 | Antimicrobial activity against Streptococcus pneumoniae 2 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID547537 | Antimicrobial activity against invasive Streptococcus anginosus obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on brain heart infusion agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID558606 | Antimicrobial activity against Streptococcus pneumoniae isolate 1147 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID425825 | Antituberculosis activity against Mycobacterium paratuberculosis UCF-7 isolated from Crohn's disease patient assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID379525 | Antibacterial activity against Escherichia coli ATCC 25922 | 2006 | Journal of natural products, Nov, Volume: 69, Issue:11 | Acetylated flavanone glycosides from the rhizomes of Cyclosorus acuminatus. |
| AID279901 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM chlorpromazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID519996 | Antimicrobial activity against Streptococcus pneumoniae harboring mef(A) gene | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID657724 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 20 to 22 hrs by broth microdilution method | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10 | An efficient and convenient microwave-assisted chemical synthesis of (thio)xanthones with additional in vitro and in silico characterization. |
| AID579589 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 assessed as inhibition of [3H]hypoxanthine incorporation after 96 hrs by microtiter plate scintillation counting | 2011 | Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5 | An automated, polymer-assisted strategy for the preparation of urea and thiourea derivatives of 15-membered azalides as potential antimalarial chemotherapeutics. |
| AID548472 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID577203 | Antimicrobial activity against Escherichia coli O157:H7 PT-40 in logarithmic phase encoding Stx-2 gene by broth macrodilution assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID559081 | Antibacterial activity against Moraxella catarrhalis by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID508398 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 49 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID425399 | Antibacterial activity against Escherichia coli isolate HM580 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID565328 | Antibacterial activity against Mycoplasma genitalium M6282 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1549370 | Bactericidal activity against penicillin-susceptible Streptococcus pneumoniae PU 09 expressing mef gene pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID322131 | In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID203447 | In vitro inhibitory activity against Staphylococci EryRi (65) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID208615 | The compound was tested in vitro for antibacterial activity against 32 strains of inducibly erythromycin resistant Streptococcus pneumoniae; Value is 40/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID416405 | Inhibition of quorum sensing-regulated alginate production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 8 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID520229 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus BK 11512 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID508374 | Antibacterial activity against Streptococcus pneumoniae harboring mutation in 23S rRNA after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID285516 | Antibacterial activity against Enterococcus faecalis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID278857 | Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID1326850 | Antibacterial activity against Staphylococcus aureus MB2865 by broth microdilution technique | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | A Gestalt approach to Gram-negative entry. |
| AID510555 | Antimicrobial activity against Chlamydia trachomatis after 72 hrs by twofold serial dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. |
| AID565325 | Antibacterial activity against Mycoplasma genitalium M6328 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID619455 | Antibacterial activity against penicillin-resistant Staphylococcus aureus by the broth microdilution method | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10 | Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation. |
| AID425822 | Antituberculosis activity against Mycobacterium paratuberculosis UCF-5 isolated from Crohn's disease patient assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID279254 | Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81Y and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID508368 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID585759 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of total cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID663046 | Half life in CD1 mouse at 5 mg/kg, iv | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID1691401 | Bactericidal activity against MLSB/methicillin-resistant Staphylococcus aureus 15B196 | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID558243 | Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 2 mg/liter after 24 hrs by time-kill study | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID577689 | Antimicrobial activity against Neisseria gonorrhoeae isolate 254921 NG-MAST sequence type 649 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID425562 | Antibacterial activity against penicillin- and quinolone-susceptible Streptococcus pneumoniae HMC 5055 expressing mefA after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID585773 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b-c+ cell expression level in lung digest at 0.16 g/kg, po measured after 14 days by flow cytometry (Rvb = 23.93 +/- 4.10 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID206464 | The compound has been evaluated for the antibacterial activity against Staphylococcus aureus EryRi 011GO25i strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID425404 | Antibacterial activity against Escherichia coli isolate HM95 isolated from ileal mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID531456 | Antibacterial activity against Streptococcus pneumoniae serotype 19F assessed as percent resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID539513 | Antibacterial activity against Moraxella catarrhalis B0324 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID416130 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing erm and mef genes by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives. |
| AID425828 | Antituberculosis activity against Mycobacterium paratuberculosis B236 isolated from bovine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID595944 | Antiparasitic activity against yellow fluorescent protein expressing Toxoplasma gondii 2F-1 treated 6 hrs after infection for 42 hrs followed by reinoculated into fresh HFF monolayers measured after 48 hrs | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID558628 | Antimicrobial activity against Streptococcus pneumoniae isolate 3681 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID573404 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA selected at 4 ug/ml of compound after 1 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID529867 | Antimicrobial activity against Streptococcus uberis UCN61 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene. |
| AID428891 | Bactericidal activity against stationary-phase Pseudomonas aeruginosa PT1300 culture harboring vector pEX1.8 at 1 to 16 ug/ml after 22 hrs by plating serial dilution method in presence of 1 mM Mg2+ | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID326071 | Inhibition of pneumococcal surface protein A production in Streptococcus pneumoniae NMU112 lysates at 5 ug/mL after 12 hrs by Western blot relative to control | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID416421 | Antimicrobial activity against quorum sensing lasI-deficient isogenic nonmucoid Pseudomonas aeruginosa NH57388E mutant assessed as reduction of viable count at 12 ug/mL in presence of 2.5% human normal serum | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID725368 | Antibacterial activity against methicillin-resistant, constitutive MLS-resistant Staphylococcus epidermidis E 2 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID283571 | Reduction of TNFalpha mRNA level in cystic fibrosis IB3-1 cells at 8 ug after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID585941 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as decrease of CCL2 production in in CD11b+ cells in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID522668 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis B126 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID531450 | Antibacterial activity against Streptococcus pneumoniae serotype 15A assessed as percent susceptible isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID1549369 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae PU 09 expressing mef gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID423102 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID658055 | Antibacterial activity against Staphylococcus aureus ATCC 13709 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID558238 | Bacteriostatic activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 0.5 mg/liter upto 8 hrs by time-kill study | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID633423 | Antibacterial activity against constitutive macrolide, lincosamide, streptogramin-resistant Streptococcus pyogenes 166 GR-Micro by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID279241 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 1077 with 23S rRNA A2058G mutation after 29 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID1549388 | Bactericidal activity against Streptococcus pyogenes 12-207 expressing mef gene pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID283572 | Reduction of TNFalpha mRNA level in cystic fibrosis 16HBE14o-AS3 cells at 8 ug after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID423246 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients within 2 years of age after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID657723 | Antibacterial activity against Staphylococcus aureus ATCC 29213 after 20 to 22 hrs by broth microdilution method | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10 | An efficient and convenient microwave-assisted chemical synthesis of (thio)xanthones with additional in vitro and in silico characterization. |
| AID372502 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes assessed after 96hrs at 100 nM dosed 12-36 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID499557 | Antibacterial activity against inducible macrolide-lincosamide-streptogramin B-resistant Streptococcus pyogenes B0543 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID502236 | Antibacterial activity against efflux-mediated macrolide-resistance Streptococcus pyogenes 2 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and properties of macrolones characterized by two ether bonds in the linker. |
| AID574700 | Enhancement of biofilm formation Staphylococcus epidermidis SW036 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID644441 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID558614 | Antimicrobial activity against Streptococcus pneumoniae isolate 2688 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID85953 | In Vivo evaluation for its effective dose against Haemophilus influenzae (351TO19 AmpR beta (-)) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID423236 | Antibacterial activity against Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID534524 | Drug level in human THP1 cells at 10 mg/L after 2 hrs in presence 250 uM efflux pump inhibitor gemfibrozil relative to control | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils. |
| AID1427910 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID425967 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID372462 | Antimalarial activity as 3rd generation ring-stage chloroquine-sensitive Plasmodium falciparum 3D7 after 48 hrs dose then 48 hrs drug-free | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID372497 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 96 hrs at 100 nM dosed 0-12 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID520231 | Antimicrobial activity against Streptococcus pneumoniae 02J1258 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID422481 | Antimicrobial activity against azithromycin-resistant nontypeable Haemophilus influenzae isolate S52 assessed as inhibition of biofilm formation at 8 ug/mL after 7 hrs using crystal violet | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID360375 | Antimalarial activity after 96 hrs against Plasmodium falciparum GCO3 CDY mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID508430 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 15 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID724497 | Antibacterial activity against Salmonella typhimurium TA102 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID208472 | The compound was tested in vitro for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030CR18c | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID545937 | Ratio of MIC for Klebsiella pneumoniae ATCC 13883 to MIC for Klebsiella pneumoniae ATCC 13883 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID1055331 | Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 700221 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID558015 | Antibacterial activity against Staphylococcus aureus E19977 by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID437309 | Antibacterial activity against erythromycin-resistant Staphylococcus pneumoniae AB11 encoded by erm and mef gene | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin. |
| AID422645 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID520027 | Antimicrobial activity against Enterococcus faecium A5960 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID543812 | Bactericidal activity against Streptococcus pyogenes VT 59 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs by serial dilution | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID278860 | Antiproliferative effect against HeLa cells after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID1720812 | Bactericidal activity against Chromobacterium violaceum ATCC 31532 at 400 uM by resazurin dye based assay relative to control | 2020 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16 | Chloroquine fumardiamides as novel quorum sensing inhibitors. |
| AID434129 | Antibacterial activity against Escherichia coli ATCC 25922 after 16 to 22 hrs by broth dilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID416251 | Inhibition of quorum sensing-regulated chitinase production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 2 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID501285 | Antibacterial activity against constitutive MLS resistance Streptococcus pyogenes 166 GR-Micro by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID635184 | Antibacterial activity against inducible macrolide, licosamide and streptogramin-resistant Streptococcus pyogenes Finland 11 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID425980 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID571439 | Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of 4 ug/ml NAB7064 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID559580 | Antimicrobial activity against Chlamydia trachomatis infected in Vero cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID635179 | Antibacterial activity against erythromycin-sensitive Staphylococcus aureus ATCC 13709 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID245062 | Minimum inhibitory concentration of compound against Ery-S Streptococcus pneumoniae ATCC 49619 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID571453 | Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1544292 | Antibacterial activity against multi drug resistant Enterococcus faecium NCTC 7171 incubated for 24 hrs by broth dilution method | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Synthesis and biological evaluation of solithromycin analogs against multidrug resistant pathogens. |
| AID582687 | Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD assessed as decrease of CFU after 24 hrs relative to initial inoculum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID85784 | In vitro inhibitory activity against Haemophilus AmpR (37) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID571432 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of 1 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID596056 | Antiplasmodial activity against Plasmodium berghei KBG-173 infected in sc dosed mouse administered bid for 3 days | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID683710 | Antimalarial activity against Plasmodium yoelii infected in CD-1 mouse assessed as efficacy at 160 mg/kg, po after 2 hrs | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Targeting the liver stage of malaria parasites: a yet unmet goal. |
| AID425550 | Antibacterial activity against penicillin-susceptible, quinolone-resistant Streptococcus pneumoniae 1072 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460V muta | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID704316 | Cellular uptake in human MDM at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID696106 | Cytotoxicity against human THP1 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID85785 | In vitro inhibitory activity against Haemophilus AmpS (43) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID635183 | Antibacterial activity against inducible macrolide-resistant, constitutive licosamide and streptogramin-resistant Streptococcus pneumoniae 134 GR-Micro by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID675198 | Antibacterial activity against eryhtromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID574708 | Antimicrobial activity against Staphylococcus epidermidis SW029 expressing icaA gene | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID559519 | Antibacterial activity against Streptococcus intermedius assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573425 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB selected at 4 ug/ml of compound after 5 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1502713 | Antimycobacterial activity against Mycobacterium avium isolate MAV4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID574692 | Enhancement of biofilm formation Staphylococcus epidermidis SW061 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID554657 | Antimicrobial activity against Ureaplasma parvum SV1 isolate UHWO10 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID559538 | Antibacterial activity against Neisseria meningitidis assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1419576 | Drug accumulation in human NCI-H292 cells at 3 to 10 uM incubated for 3 hrs by LC-MS analysis relative to azithromycin | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Around the macrolide - Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation. |
| AID565231 | Antimicrobial activity against Mycobacterium chelonae 9917 harboring pZS01 carrying mspA gene by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID642864 | Antibacterial activity against Haemophilus influenzae B0529 by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID283578 | Reduction of NF-kappaB binding to DNA in cystic fibrosis 16HBE14o-AS3 cells at 8 ug after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID279263 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3676 with GyrA E85G, GyrB S478I and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID279314 | Inhibition of Plasmodium falciparum AZ10011003 isolate in HRP2 ELISA | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. |
| AID326073 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae NMU112 infected CBA/J mouse assessed as median survival time at 10 mg/kg, po relative to control | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID1853146 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 assessed as inhibition of bacterial growth incubated for 20 to 22 hrs by broth microdilution method | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling. |
| AID499553 | Antibacterial activity against erythromycin A-resistant Streptococcus pneumoniae B0541 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID588208 | Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset | 2010 | Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5 | Predicting phospholipidosis using machine learning. |
| AID520230 | Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 03B1069 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID565323 | Antibacterial activity against Mycoplasma genitalium M6285 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID278404 | Effect on mean time to death in Naegleria fowleri Lee (M67) infected CD1 mouse at 25 mg/kg/day, ip | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID1238051 | Antibacterial activity against Pseudomonas aeruginosa by broth dilution assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Gageopeptins A and B, new inhibitors of zoospore motility of the phytopathogen Phytophthora capsici from a marine-derived bacterium Bacillus sp. 109GGC020. |
| AID523010 | Activity at macrolide 2'-phosphotransferase 1 by PK/LDH-coupled assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Nucleotide selectivity of antibiotic kinases. |
| AID558601 | Antimicrobial activity against Streptococcus pneumoniae isolate 24 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID279890 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM omeprazole | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID683715 | Antimalarial activity against Plasmodium vivax assessed as effect on cure rate after 28 days | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Targeting the liver stage of malaria parasites: a yet unmet goal. |
| AID1459117 | Ratio of MIC for inducibly macrolide/lincosamide/streptogramin B-resistant Staphylococcus aureus to MIC for erythromycin susceptible Staphylococcus aureus | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID535358 | Antimicrobial activity against Streptococcus pyogenes clinical isolates assessed as susceptible isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID1232318 | Half life in human | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15 | Volume of Distribution in Drug Design. |
| AID565318 | Antibacterial activity against Mycoplasma genitalium M2300 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1238050 | Antibacterial activity against Salmonella typhi by broth dilution assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Gageopeptins A and B, new inhibitors of zoospore motility of the phytopathogen Phytophthora capsici from a marine-derived bacterium Bacillus sp. 109GGC020. |
| AID595945 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF at 5 to 50 uM treated immediately after infection measured after 48 hrs | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID642858 | Antibacterial activity against constitutive MLS resistant Streptococcus pneumoniae by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID529866 | Antimicrobial activity against Streptococcus uberis UCN60 expressing mph(B) and rdmC-like genes by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene. |
| AID360362 | Antimalarial activity after 48 hrs against Plasmodium falciparum 7G8 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID1549381 | Antibacterial activity against MLS-resistant Staphylococcus aureus PU 20 expressing constitutive ermC gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID360376 | Antimalarial activity after 96 hrs against Plasmodium falciparum 3BA6 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID565811 | Antimicrobial activity against Neisseria meningitidis assessed as susceptible isolate by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. |
| AID571765 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID501299 | Antibacterial activity against inducible resistance to macrolide and constitutive resistance to lincosamide Streptococcus pneumoniae 134 GR M by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID444057 | Fraction escaping hepatic elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID283577 | Reduction of NF-kappaB binding to DNA in cystic fibrosis IB3-1 cells at 8 ug after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID574703 | Enhancement of biofilm formation Staphylococcus epidermidis SW082 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID483691 | Antimicrobial activity against macrolide-sensitive Staphylococcus aureus ATCC 13709 | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID573428 | Antimicrobial activity against nfxB gene-deficient Pseudomonas aeruginosa PAONB assessed as increase in viable cells at 0.5 to 4 ug/ml after 24 hrs relative to wild-type | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID423267 | Antibacterial activity against azithromycin-resistant 0.01 MOI Chlamydia psittaci 6BC BCRBAZ5 harboring A2059C mutation in bacterial 23S rRNA gene infected in mouse L2 cells treated 2 hrs after infection measured on day 7 by plaque assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID372499 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 96hrs at 100 nM dosed 0-36 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID633420 | Antibacterial activity against inducible macrolide-resistant, constitutive lincosamide and streptogramin-resistant Streptococcus pneumoniae 134 GR M by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID522658 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis V770-NP1-R by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID372559 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene assessed as resistance rate by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID422882 | Antimicrobial activity against Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis by broth microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex. |
| AID1180562 | Antimicrobial activity against Staphylococcus aureus by broth microdilution/CLSI method | 2014 | Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14 | Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). |
| AID644443 | Antibacterial activity against efflux,penicillin-susceptible Streptococcus pneumoniae PU 09 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID372561 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene assessed as resistance rate by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID725371 | Antibacterial activity against methicillin-sensitive, inducible MLS-resistant Staphylococcus aureus PU 64 expressing ermA gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID372500 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 96 hrs at 100 nM dosed 0-48 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID574933 | Antimicrobial activity against Staphylococcus epidermidis SW027 expressing icaA gene assessed as enhancement of biofilm formation at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID1488450 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes R1 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID534861 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar Typhimurium s2389 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID585770 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c+ cell expression level in lung digest at 0.16 g/kg, po measured after 14 days by flow cytometry (Rvb = 6.6 +/- 1.86 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID372463 | Antimalarial activity as 2nd generation ring-stage chloroquine-resistant Plasmodium falciparum W2 after 48 hrs by flow cytometry | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID573170 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS planktonic cells by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID704318 | Cellular uptake in human BSMC at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID279316 | Inhibition of Plasmodium falciparum AZ10011017 isolate in HRP2 ELISA | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. |
| AID132628 | The compound was tested in vivo for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030MV2 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID696120 | Inhibition of AP1-mediated mediated IL-1beta production in LPS-induced mouse pulmonary neutrophila model | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID1487241 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID725381 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID520009 | Antimicrobial activity against Staphylococcus aureus A7819 harboring G2576U mutation in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID633419 | Antibacterial activity against inducible macrolide, lincosamide and streptogramin B-resistant Staphylococcus aureus 90256/97 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID565813 | Antimicrobial activity against Neisseria gonorrhoeae assessed as susceptible isolates by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. |
| AID531330 | Antibacterial activity against Pseudomonas aeruginosa TNP090 harboring chromosomal mexB::xylE fusion construct by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID521966 | Antibacterial activity against Campylobacter jejuni assessed as resistant isolates by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID543799 | Bactericidal activity against Acinetobacter baumannii VT 126 assessed as eradication of pre-formed biofilm at 1 to 10 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID520022 | Antimicrobial activity against Enterococcus faecalis A6350 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID644449 | Antibacterial activity against methicillin-, inducible MLS-resistant erythromycin-susceptible Staphylococcus aureus PU 32 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID422657 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID416411 | Inhibition of alginate synthesis in Pseudomonas aeruginosa NH57388A mucoid isolate supernatant assessed as uronic acid fraction out of the dialysis bag of total amount of uronic acids after exhaustive dialysis at 12 ug/mL after 24 hrs by carbazole-borate | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID533857 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium mageritense after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID21658 | Calculated partition coefficient (clogP) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID425991 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 33 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID425823 | Antituberculosis activity against Mycobacterium paratuberculosis UCF-5 isolated from Crohn's disease patient assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID1653059 | Antibacterial activity against Pseudomonas aeruginosa | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Isatin derivatives and their anti-bacterial activities. |
| AID1169028 | Antibacterial activity against macrolide lincosamide- streptogramin B-resistant Staphylococcus aureus by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID571446 | Ratio of the MIC for Klebsiella pneumoniae ATCC 13883 in the absence of NAB7061 to MIC for Klebsiella pneumoniae ATCC 13883 in the presence of 4 ug/ml of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID416410 | Inhibition of alginate synthesis in Pseudomonas aeruginosa NH57388A mucoid isolate supernatant assessed as uronic acid concentration in dialysis bag after exhaustive dialysis at 12 ug/mL after 24 hrs by carbazole-borate assay | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID558613 | Antimicrobial activity against Streptococcus pneumoniae isolate 2686 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1459142 | Protein binding in rat plasma at 1 ug/ml by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID555118 | Distribution half life in healthy human at 500 mg, po administered as single dose | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. |
| AID422686 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID585769 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c+ cell expression level in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry (Rvb = 5.16 +/- 1.09 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1241207 | Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID522651 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K5926 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID1502707 | Antimycobacterial activity against Mycobacterium avium 104 mc'2 3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID205647 | Compound was tested for antibacterial activity against Staphylococcus aureus 011UC4 using standard broth microdilution assay. | 1998 | Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18 | Synthesis of 6-O-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime. |
| AID608738 | Antibacterial activity against efflux-mediated macrolide-resistance Streptococcus pyogenes 2 Finland by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID571434 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of 4 ug/ml NAB7064 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID202104 | In vitro minimum inhibitory concentration for antibacterial activity against erythromycin susceptible strain Streptococcus pneumoniae IID553 | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1549392 | Selectivity ratio of MBC to MIC for erythromycin-susceptible Moraxella catarrhalis 13L332 | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID644815 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. |
| AID696101 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by CLSI broth microdilution method | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID1691433 | Antibacterial activity against Escherichia coli JW5503-KanS depletion of toIC efflux gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID483693 | Antimicrobial activity against macrolide-sensitive Streptococcus pyogenes 3665 | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID571200 | Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID209924 | The compound was tested in vitro for antibacterial activity against erythromycin susceptible Streptococcus pyogenes 02A1UC1 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID675200 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 205 expressing ermB ribosomal methylase by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID573409 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB selected at 4 ug/ml of compound after 3 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID520026 | Antimicrobial activity against Enterococcus faecium A5959 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID585763 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of CD4+ T cell in lung lavage fluid at 0.16 g/kg, po measured after 7 to 14 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1498149 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID483697 | Antimicrobial activity against Haemophilus influenzae ATCC 49247 | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID508458 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 43 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID425629 | Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as effect on average time to detection of growth at 10'5 CFU of inoculum by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID508459 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 5 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID520015 | Antimicrobial activity against Staphylococcus hominis A7828 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID205876 | In vitro inhibitory activity against Staphylococcus epidermidis (EryRi 012GO11i) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1515015 | Antibacterial activity against Staphylococcus aureus isolate 10 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID559579 | Antimicrobial activity against Parachlamydia acanthamoebae infected in Acanthamoeba castellanii amoeba cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID658058 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID143873 | Compound was evaluated for in vitro anti-mycobacterial activity against Mycobacterium avium complex (MAC) ATCC 49601 | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. |
| AID534858 | Antibacterial activity against quinolone-resistant Salmonella enterica serovar stanley s2236 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID203434 | The compound was tested in vitro for antibacterial activity against 23 strains of constitutively erythromycin resistant Staphylococci; Not determined | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID1550819 | Antimicrobial activity against constitutively erythromycin resistant Streptococcus pyogenes A2 expressing c-erm incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID644442 | Antibacterial activity against penicillin-, constitutive MLS-resistant Streptococcus pneumoniae PU 11 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID508428 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 29 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1055335 | Antibacterial activity against vancomycin-sensitive Enterococcus faecalis 09-8 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID696130 | Cmax in cystic fibrosis patient blood at 500 mg | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID559535 | Antibacterial activity against Legionella pneumophila assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID66403 | Minimum inhibitory concentration against macrolide susceptible strain of Enterococcus faecalis (MB5407) | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: I. 4", 11 and 12-OMe derivatives via direct methylation. |
| AID535571 | Antibacterial activity against quinolone-resistant Salmonella enterica | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID633422 | Antibacterial activity against constitutive macrolide, lincosamide, streptogramin-resistant Streptococcus pneumoniae 58 spain by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID522669 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis B133 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID1055325 | Antibacterial activity against New Delhi metallo-beta-lactamase 1 producing Klebsiella pneumoniae ATCC BAA-2146 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID279876 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM promazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID522648 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Africa 33 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID208478 | The compound was tested in vitro for antibacterial activity against erythromycin susceptible Streptococcus pneumoniae 032UC1 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID508392 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 29 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID508400 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 24 harboring erm(B) gene after 14 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID608740 | Antibacterial activity against inducible macrolide-resistant, constitutive lincosamide, streptogramin-resistant Streptococcus pneumoniae 134 GR M by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID658057 | Antibacterial activity against Streptococcus pyogenes ATCC 700294 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID1459110 | Antibacterial activity against inducibly macrolide/lincosamide/streptogramin B-resistant Staphylococcus aureus by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID1855558 | Inhibition of quorum sensing system in Pseudomonas aeruginosa assessed as inhibition of pyocyanin production at sub-MIC by absorbance based analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation. |
| AID595939 | Antibacterial activity against Bacillus subtilis | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID567091 | Drug absorption in human assessed as human intestinal absorption rate | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Prediction of drug intestinal absorption by new linear and non-linear QSPR. |
| AID279864 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM prochlorperazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID422485 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as viability at 0.125 ug/mL incubated for 2 days measured on day 4 using flow cell culture | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID508470 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2011 harboring mef(A) gene after 35 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID559511 | Antibacterial activity against Lancefield Streptococcus sp. group F assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID428883 | Inhibition of rhamnolipid production in azithromycin-hypersusceptible Pseudomonas aeruginosa 11B harboring mexX deletion mutant incubated for 24 hrs at 37 degC further 24 hrs at 25 degC | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID283554 | Antimicrobial activity against Streptococcus pneumoniae PC13 isolate with L4 69GTG71 to TPS mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID558603 | Antimicrobial activity against Streptococcus pneumoniae isolate 37 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID422672 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 19 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID508393 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after 29 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1550818 | Antimicrobial activity against constitutively erythromycin resistant Streptococcus pneumoniae PU27 expressing c-erm incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID1459107 | Antibacterial activity against constitutively macrolide/lincosamide/streptogramin B-resistant Streptococcus pyogenes by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID283582 | Reduction of Sp1 binding to DNA in cystic fibrosis 2CFSMEo cells at 8 ug after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID522657 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis V770 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID426377 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae 07Z001 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID595653 | Inhibition of quorum sensing activity in Pseudomonas aeruginosa ATCC 27853 assessed as N-acylhomoserin lactones production at 5 ug/ml after 24 hrs by measuring beta-galactosidase activity by spectrophotometry | 2011 | Journal of natural products, Apr-25, Volume: 74, Issue:4 | Bioactive sesqui- and diterpenoids from the Argentine liverwort Porella chilensis. |
| AID1647105 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID425335 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID508382 | Antibacterial activity against Streptococcus pyogenes harboring erm(B) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID426382 | Antimicrobial activity against erythromycin-resistant Streptococcus pyogenes 07Z014 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID582610 | Drug uptake in human THP1 cells after 24 hrs in presence of verapamil | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID244992 | Minimum inhibitory concentration of compound against Ery-R Staphylococcus aureus 96:11480 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID425972 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1549384 | Antibacterial activity against MLS-resistant Streptococcus pyogenes 12-206 expressing constitutive ermA gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID531458 | Antibacterial activity against Streptococcus pneumoniae serotype 23A assessed as percent resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID704312 | Cellular uptake in human BSMC assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID531103 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa TNP090 mutant harboring las and rhl gene at 0.125 ug/ml by Cat-2,3-diO reporter gene assay relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID1349196 | Antichlamydial activity against Chlamydia trachomatis serovar A 454/Bu infected in human HeLa 299 cells assessed as reduction in number of inclusion bodies measured after 44 to 48 hrs by DAPI staining-based HCS assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. |
| AID372560 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene assessed as resistance rate by broth microdilut | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID582682 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 assessed as decrease of CFU after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID1653047 | Antibacterial activity against Staphylococcus aureus | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Isatin derivatives and their anti-bacterial activities. |
| AID573424 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA selected at 4 ug/ml of compound after 5 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID535566 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar enteritidis s3139 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID372478 | Antimalarial activity as parasitaemia against chloroquine-sensitive ACP1-GFP-labeled Plasmodium falciparum 3D7 trophozoite infected human erythrocytes at 2xIC50 dosed 96 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID423259 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected female patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID279269 | Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81Y and ParC D83Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID585935 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of MHC2 expression in CD11b+ Gr1+ cells in alveolar space at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID520017 | Antimicrobial activity against Staphylococcus capitis A8935 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1549391 | Bactericidal activity against erythromycin-susceptible Moraxella catarrhalis 13L332 pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID425968 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 14 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1549371 | Selectivity ratio of MBC to MIC for penicillin-susceptible Streptococcus pneumoniae PU 09 expressing mef gene | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID1329015 | Antibacterial activity against Streptococcus pneumoniae PBS1399 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. |
| AID425405 | Antibacterial activity against mucosa-associated Escherichia coli isolate HM428 isolated from patient with irritable bowel syndrome or sporadic polyps after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID428884 | Inhibition of rhamnolipid production in Pseudomonas aeruginosa 12B overexpressing mexXY incubated for 24 hrs at 37 degC further 24 hrs at 25 degC | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID416413 | Increase in sensitivity of hydrogen peroxide to quorum sensing lasI-deficient isogenic Pseudomonas aeruginosa NH57388A mucoid isolate mutant assessed as increase in zone of inhibition at 12 ug/mL after 48 hrs relative to untreated bacterial control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID1459111 | Antibacterial activity against constitutively macrolide/lincosamide/streptogramin B-resistant Staphylococcus aureus by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID642860 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID208474 | The compound was tested in vitro for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030PW23c | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID558594 | Antimicrobial activity against Streptococcus pneumoniae 6 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID535557 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar bredeney s2477 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID531445 | Antibacterial activity against Streptococcus pneumoniae serotype 6A/C assessed as percent susceptible isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID279870 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM prochlorperazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID576338 | Antimicrobial activity against Chlamydia trachomatis serovar H infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1487244 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes isolate S2 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID559533 | Antibacterial activity against Klebsiella oxytoca assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1427912 | Antibacterial activity against penicillin-resistant Staphylococcus epidermidis clinical isolate by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID559503 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID569031 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing the erm gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID132627 | The compound was tested in vivo for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030Cr29 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID372554 | Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene assessed as susceptibility rate by broth microd | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. |
| AID767512 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus MSSA-1 by standard dilution assay | 2013 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18 | Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents. |
| AID547757 | Antimicrobial activity against invasive Streptococcus intermedius obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID360373 | Antimalarial activity after 96 hrs against Plasmodium falciparum GCO3 SDD mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID535559 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar emek s2635 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID619451 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing erm gene by the broth microdilution method | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10 | Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation. |
| AID501676 | Antimicrobial activity against Streptococcus pyogenes 166 GR-Micro by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID209103 | In vivo antibacterial activity against Streptococcus pyogenes strain C203 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID574690 | Enhancement of biofilm formation Staphylococcus epidermidis SW045 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID425403 | Antibacterial activity Escherichia coli isolate HM419 isolated from ileo-colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID571931 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-S623N mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID767509 | Antibacterial activity against Streptococcus pneumoniae 746 by standard dilution assay | 2013 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18 | Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents. |
| AID426379 | Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes 07U084 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID283550 | Antimicrobial activity against Streptococcus pneumoniae BSF-11524 isolate with erm(B) and L4 mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID520018 | Antimicrobial activity against Staphylococcus aureus pL150 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1855557 | Inhibition of quorum sensing system in Pseudomonas aeruginosa assessed as inhibition of biofilm production at sub-MIC incubated for 24 hrs by crystal violet staining based analysis | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation. |
| AID534863 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar blockley s2439 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID1586841 | Induction of read through activity at cricket paralysis virus-internal ribosome entry site codon UGG assessed as increase in octapeptide formation from FKVRQ-tRNAGln at 30 to 600 uM measured after 20 mins in presence of Typ-tRNA, Leu-tRNA and [35S]-Met-tR | 2018 | ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12 | New |
| AID529892 | Antimicrobial activity against Leptospira interrogans isolate 7 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID571929 | Ratio of MIC for Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-M626I mutant gene to MIC for Escherichia coli K-12 3-AG300 | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID1498156 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 harboring mefA gene after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID535565 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar Typhimurium s3082 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID501277 | Antibacterial activity against erythromycin-sensitive Staphylococcus aureus ATCC 13709 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID680909 | TP_TRANSPORTER: cell accumulation of doxorubicin in the presence of Azithromycin at a concentration of 0.3uM and 1mM in K562/ADR cells | 2004 | European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3 | Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID608743 | Antibacterial activity against constitutive macrolide, lincosamide, streptogramin-resistant Streptococcus pneumoniae 58 spain by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID535359 | Antimicrobial activity against Streptococcus pyogenes clinical isolates assessed as resistant isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID425572 | Antibacterial activity against penicillin-, macrolide- and quinolone-susceptible Streptococcus pneumoniae HMC 63 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83Y mutation in QRDR of ParC gene and I460V mutation in QRDR | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1860921 | Bactericidal activity against Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial density at 150 ug/ml incubated for 1 hrs by colony-counting method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Glycosylation increases the anti-QS as well as anti-biofilm and anti-adhesion ability of the cyclo (L-Trp-L-Ser) against Pseudomonas aeruginosa. |
| AID520025 | Antimicrobial activity against Enterococcus faecalis A7789 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID483698 | Antimicrobial activity against inducible macrolide, lincosamide, streptogramin-resistant Streptococcus pneumoniae 134 GRM | 2010 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11 | Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity. |
| AID520228 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus BK 11118 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1241208 | Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID1691425 | Antibacterial activity against MLSB/methicillin/ciprofloxacin-resistant Staphylococcus aureus PU32 harboring ermA gene assessed as reduction in microbial growth relative to ciprofloxacin | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID543802 | Bactericidal activity against Escherichia coli ATCC 25922 assessed as eradication of pre-formed biofilm at 1 to 10 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID585937 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of mannose receptor expression in CD11b+ Gr1+ cells in alveolar space at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID558625 | Antimicrobial activity against Streptococcus pneumoniae isolate 3458 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1549389 | Selectivity ratio of MBC to MIC for Streptococcus pyogenes 12-207 expressing mef gene | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID571451 | Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of 4 ug/ml NAB7064 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID1055326 | Antibacterial activity against extended spectrum beta-lactamase producing Klebsiella pneumoniae ATCC 700603 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID573408 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA selected at 4 ug/ml of compound after 3 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID565320 | Antibacterial activity against Mycoplasma genitalium M2341 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1625276 | Antimalarial activity against Plasmodium falciparum FCR 3TC after 48 hrs | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12 | Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action. |
| AID725370 | Antibacterial activity against methicillin-resistant, constitutive MLS-resistant, coagulase-deficient Staphylococcus haemolyticus PU 19 expressing ermA gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID559501 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID422666 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 35 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID539512 | Antibacterial activity against efflux-resistant Streptococcus pyogenes B0545 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID569034 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID577687 | Antimicrobial activity against Neisseria gonorrhoeae isolate 252611 NG-MAST sequence type 470 harboring A2059G mutation in 23S rRNA V domain allele 2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID322129 | In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green fluorescence assay | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID535362 | Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as susceptible isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID529901 | Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 10 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID585760 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of total cells in lung digest at 0.16 g/kg, po measured after 14 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID423103 | Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID531444 | Antibacterial activity against Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID644450 | Antibacterial activity against methicillin-, constitutive MLS-resistant erythromycin-susceptible Staphylococcus aureus PU 20 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID644813 | Antibacterial activity against clinical isolate Streptococcus pyogenes 3565 | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. |
| AID585934 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of mannose receptor expression in CD11b+ Gr1+ cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID548254 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID1257219 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after overnight incubation by broth microdilution method | 2015 | Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23 | 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity. |
| AID535364 | Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as resistant isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID1766094 | Antibacterial activity against Klebsiella pneumoniae ATCC10031 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID565815 | Antimicrobial activity against Neisseria gonorrhoeae assessed as resistant isolates by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. |
| AID1055323 | Antibacterial activity against beta-lactamase producing Morganella morganii ATCC 25830 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID724498 | Antibacterial activity against Salmonella typhimurium TA98 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID155778 | Minimum inhibitory concentration against Pasteurella multocida | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID565814 | Antimicrobial activity against Neisseria gonorrhoeae assessed as susceptible isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. |
| AID372503 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 96hrs at 100 nM dosed 12-48 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID724504 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID428293 | Antimicrobial activity against Acinetobacter baumannii BM4651 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. |
| AID574705 | Enhancement of biofilm formation Staphylococcus epidermidis SW099 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID576337 | Antimicrobial activity against Chlamydia trachomatis serovar G infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID278390 | Antimicrobial activity against Naegleria fowleri Lee (M67) in presence of azithromycin at 3:1 ratio on day 2 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID1459109 | Antibacterial activity against erythromycin susceptible Streptococcus pneumoniae by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID425555 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 99 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1169026 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID1539177 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC 9372 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID520014 | Antimicrobial activity against Staphylococcus aureus A8727 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID498875 | Antimicrobial activity against Neisseria meningitidis M7mtrE::Spc by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli. |
| AID642853 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID423232 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID279877 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM promazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID1550823 | Antimicrobial activity against constitutively erythromycin resistant Staphylococcus aureus PU20 expressing c-ermC incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID1549374 | Bactericidal activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID508371 | Antibacterial activity against Streptococcus pneumoniae harboring erm(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1539179 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID326068 | Antimicrobial activity against Streptococcus pneumoniae NMU605 | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID1498154 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID585775 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c- cell expression level in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry (Rvb = 1.13 +/- 0.30 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID132624 | The compound was tested in vivo for antibacterial activity against AmpR beta(+) Haemophilus influenza 351RD7 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID437307 | Antibacterial activity against erythromycin-resistant Staphylococcus pneumoniae B1 encoded by erm gene | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin. |
| AID1754231 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes R1 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID529903 | Antimicrobial activity against Leptospira kirschneri serovar Grippotyphosa isolate 13 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID558016 | Cmax in human at 1000 mg, po | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID278407 | Protection against Naegleria fowleri Lee (M67) infection in CD1 mouse at 25 mg/kg/day, ip | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID573183 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm assessed as increase in viable cells at day 7 relative to wild-type | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1539174 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes 1 clinical isolate incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID416407 | Inhibition of alginate synthesis in Pseudomonas aeruginosa NH57388A mucoid isolate supernatant assessed as uronic acid concentration in outside of dialysis bag after equilibrium dialysis at 12 ug/mL after 24 hrs by carbazole-borate assay | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID416427 | Antimicrobial activity in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene infected in ftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse assessed as frequency of lung abscesses at 500 mg/kg, po administered 24 | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID608741 | Antibacterial activity against inducible macrolide-lincosamide-streptogramin B resistant Streptococcus pyogenes Finland 11 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID143437 | Compound was evaluated for in vitro anti-mycobacterial activity against Mycobacterium xenopi | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. |
| AID422649 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID558020 | Protein binding in human serum at 1000 mg, po | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID444050 | Fraction unbound in human plasma | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID520223 | Antimicrobial activity against Enterococcus faecium A8948 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID534852 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar rissen s2021 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID434123 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes after 16 to 22 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID558607 | Antimicrobial activity against Streptococcus pneumoniae isolate 1384 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID208144 | In vivo antibacterial activity against Streptococcus pneumoniae strain 6303 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID425560 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1691398 | Bactericidal activity against MLSB/methicillin/ciprofloxacin-resistant Staphylococcus aureus PU32 harboring ermA gene | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID499550 | Antibacterial activity against inducible macrolide-lincosamide-streptogramin B-resistant Staphylococcus aureus B0538 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID545917 | Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID545921 | Antimicrobial activity against Escherichia coli IH3080 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID210191 | Compound was tested for antibacterial activity against Streptococcus pneumoniae 030SJ1 EryRc using standard broth microdilution assay. | 1998 | Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18 | Synthesis of 6-O-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime. |
| AID603956 | In-vivo serum to lung partition coefficients of the compound, logP(lung) in rat | 2008 | European journal of medicinal chemistry, Mar, Volume: 43, Issue:3 | Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs. |
| AID1860912 | Anti-adhesion activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of adhesion ability at 50 ug/ml incubated for 3 hrs using glass as substrate by colony-counting method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Glycosylation increases the anti-QS as well as anti-biofilm and anti-adhesion ability of the cyclo (L-Trp-L-Ser) against Pseudomonas aeruginosa. |
| AID1515017 | Antibacterial activity against Staphylococcus aureus isolate 3798 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID508366 | Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID582613 | Antibacterial activity against Legionella pneumophila ATCC 33153 after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID429069 | Relative activity against Plasmodium falciparum 3D7 as IC50 ratio after 48 and 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. |
| AID663038 | Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID577207 | Antimicrobial activity against Escherichia coli C600::H19B in stationary phase encoding Stx-1 gene by broth macrodilution assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID416240 | Elimination half life in Cftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse model at 500 mg/kg, po | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID425818 | Antituberculosis activity against Mycobacterium paratuberculosis JTC303 isolated from bovine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID585754 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of MHC2 expression in CD11b+ Gr1+ cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID577193 | Decrease in shiga toxin production in Escherichia coli O157:H7 PT-32 encoding Stx-1 and Stx-2 gene at 0.5 X MIC by luciferase assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID565330 | Antibacterial activity against Mycoplasma genitalium M6284 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID283592 | Cell viability of 2CFSMEo cells at 16 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID279258 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID508450 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 2132 after 28 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID704315 | Cellular uptake in human T lymphocytes at 3 to 20 uM after 3 hrs by by LC-MS/MS analysis relative to azithromycin | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID425570 | Antibacterial activity against penicillin-susceptible, quinolone-resistant Streptococcus pneumoniae HMC 1072 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460V | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1550821 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 incubated in CAMHB medium for 20 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID582605 | Drug uptake in human THP1 cells at acidic pH after 30 mins | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID582685 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID416128 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing erm gene by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives. |
| AID428888 | Inhibition of swarming motility of Pseudomonas aeruginosa PT1308 expressing Clostridium perfringens 23S rRNA methylase ErmBP at 2 ug/ml after 18 hrs | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID508444 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID1349194 | Antichlamydial activity against Chlamydia trachomatis serovar L2 infected in human HeLa 299 cells assessed as reduction in number of inclusion bodies measured after 44 to 48 hrs by DAPI staining-based HCS assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. |
| AID422675 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 25 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID209919 | The compound has been evaluated for the antibacterial activity against Streptococcus pyogenes EryS 02A1UC1. | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID423253 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 6 to 14 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID1647104 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID522824 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis NH by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID1855559 | Inhibition of quorum sensing system in Pseudomonas aeruginosa assessed as inhibition of rhamnolipid production at sub-MIC by spectrophotometric method | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241 | Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation. |
| AID576349 | Bactericidal activity against Chlamydia trachomatis serovar K infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1691397 | Antibacterial activity against MLSB/methicillin/ciprofloxacin-resistant Staphylococcus aureus PU32 harboring ermA gene assessed as reduction in microbial growth | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID416129 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mef gene by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives. |
| AID508441 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1076 harboring erm(B) and mef(A) gene after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID558602 | Antimicrobial activity against Streptococcus pneumoniae isolate 33 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID633415 | Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 3565 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID577186 | Decrease in shiga toxin production in Escherichia coli O157:H7 185 encoding stx gene cocultured with Stx-phage susceptible Escherichia coli isolate CMUC-170 at 8 to 16 ug/ml by luciferase assay relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID596014 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 10 uM treated for 48 hrs immediately after infection followed by reino | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID479818 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae PU11 encoded by erm and mef gene | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID155774 | Minimum inhibitory concentration required to inhibit Pasteurella multocida 59A006 in vitro | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6 | Repromicin derivatives with potent antibacterial activity against Pasteurella multocida. |
| AID279267 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3243 with 23S rRNA A2059T mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID1427914 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing ermB gene by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID26832 | Dissociation constant (pKa) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID573180 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm assessed as increase in viable cells at 4 ug/ml for 7 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID548473 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID681153 | TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells | 2001 | Chemical research in toxicology, Dec, Volume: 14, Issue:12 | Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. |
| AID1238013 | Antibacterial activity against Escherichia coli ATCC 27856 assessed as inhibition of bacterial growth after 18 hrs by liquid microdilution method | 2015 | Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16 | Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel. |
| AID724179 | Antibacterial activity against constitutive-resistant to macrolide, licosamide and streptogramin Streptococcus pyogenes 166 GR-Micro by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID533859 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium smegmatis after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID576347 | Bactericidal activity against Chlamydia trachomatis serovar I infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID576350 | Antimicrobial activity against Chlamydia trachomatis Ic Cal-8 serovar D infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID1488455 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID539510 | Antibacterial activity against erythromycin A-susceptible Staphylococcus aureus B0329 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID1515026 | Antibacterial activity against Salmonella choleraesuis ATCC 14028 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID704313 | Cellular uptake in human PMNC assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID531451 | Antibacterial activity against Streptococcus pneumoniae serotype 33 assessed as percent susceptible isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID573405 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB selected at 4 ug/ml of compound after 1 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID197858 | Minimum inhibitory concentration against Staphylococcus aureus 10649 (erythromycin susceptible strain) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID422456 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID279317 | Inhibition of Plasmodium falciparum AZ10011022 isolate in HRP2 ELISA | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. |
| AID422454 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as growth inhibition at 0.125 ug/mL using static culture after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID244982 | Minimum inhibitory concentration of compound against Ery-R Streptococcus pneumoniae 163 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID428292 | Antimicrobial activity against Acinetobacter baumannii BM4579 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. |
| AID40789 | Minimum inhibitory concentration against macrolide susceptible strains of Bacillus subtilis (MB5586) | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: I. 4", 11 and 12-OMe derivatives via direct methylation. |
| AID425552 | Antibacterial activity against penicillin-, macrolide-susceptible and quinolone-resistant Streptococcus pneumoniae HMC 1074 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutat | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID725373 | Antibacterial activity against methicillin-resistant, inducible MLS-resistant Staphylococcus aureus PU 32 expressing ermA gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID595938 | Antiparasitic activity against Toxoplasma gondii 2F-1 expressing yellow fluorescent protein infected in HFF after 4 days | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1241213 | Ratio of Kd for 5'-FAM-pre-miR-372 (unknown origin) in presence of 100-fold excess of Escherichia coli tRNA to Kd for 5'-FAM-pre-miR-372 (unknown origin) | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID585933 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of arginase activity in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID444052 | Hepatic clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID531455 | Antibacterial activity against Streptococcus pneumoniae serotype 3 assessed as percent resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID633425 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID508415 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1635 harboring erm(A) gene after 49 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID559500 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID547530 | Antimicrobial activity against Streptococcus intermedius obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence of 5% defr | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID508407 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 1076 harboring erm(B) and mef(A) gene after 18 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID416241 | Antimicrobial activity against Pseudomonas aeruginosa NH57388A mucoid isolate assessed as reduction of viable count in stationary phase at 2 ug/mL after 8 hrs | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID508417 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2686 harboring mutation in L4 ribosomal protein after 22 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID69480 | Minimum inhibitory concentration against Escherichia coli | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and SAR of azalide 3,6-ketal aromatic derivatives as potent Gram-positive and Gram-negative antibacterial agents. |
| AID425574 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 harboring S81Y and S79Y mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively after 42 passages | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID279900 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM chlorpromazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID360377 | Antimalarial activity against Plasmodium falciparum 3BA6 SDD with CRT and MDR1 mutation after 96 hrs in [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID1549363 | Antibacterial activity against MLS-resistant Staphylococcus aureus PU 32 expressing inducible ermA gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID577191 | Antimicrobial activity against Escherichia coli O157:H7 185 cocultured with Stx-phage susceptible Escherichia coli isolate CMUC-170 relative to control | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID666483 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7A infected in type A rhesus-positive human erythrocytes assessed as [3H]hypoxanthine incorporation after 48 hrs by scintillation counting | 2012 | Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 | Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides. |
| AID535560 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar blockley s2768 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID642857 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID520222 | Antimicrobial activity against Enterococcus faecium A9650 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID1549377 | Bactericidal activity against MLS-resistant Streptococcus pyogenes 01-968 expressing inducible ermB gene pretreated followed by subculture in absence of compound measured after 24 hrs | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID422682 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID531448 | Antibacterial activity against Streptococcus pneumoniae serotype 35B assessed as percent susceptible isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID724176 | Antibacterial activity against Haemophilus influenzae ATTC 49247 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID360364 | Antimalarial activity after 48 hrs against Plasmodium falciparum Dd2 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID131225 | Mouse protection tests for effective dose against Staphylococcus aureus 10649 ((erythromycin susceptible strain)) infected mice | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID531104 | Inhibition of MexAB-OprM efflux pump expression in las1 and rhl1 deficient Pseudomonas aeruginosa TNP093 at 1 ug/ml after 9 hrs by Cat-2,3-diO reporter gene assay | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID283591 | Cell viability of 16HBE14o-S1 cells at 16 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID501282 | Antibacterial activity against inducible resistance to macrolide and constitutive resistance to lincosamide Streptococcus pneumoniae 134 GR M by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID596012 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as decrease in density of parasitophorous vacuoles at 10 uM treated immediately after infection measured after 24 hrs by mic | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID522641 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Ames by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID208476 | The compound was tested in vitro for antibacterial activity against constitutively erythromycin resistant Streptococcus pneumoniae 030SJ1 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID422659 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 29 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID575946 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae assessed as susceptible isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. |
| AID573423 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB selected at 4 ug/ml of compound after 4 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID279315 | Inhibition of Plasmodium falciparum AZ10011008 isolate in HRP2 ELISA | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. |
| AID608742 | Antibacterial activity against constitutive macrolide, lincosamide, streptogramin-resistant Staphylococcus aureus PK2 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID635192 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID644448 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID1169035 | Antibacterial activity against Haemophilus influenzae by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID724187 | Antibacterial activity against constitutive-resistant to macrolide, licosamide and streptogramin Staphylococcus aureus PK2 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID279265 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3243 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID1766089 | Antibacterial activity against vancomycin-susceptible Enterococcus faecalis ATCC29212 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID425563 | Antibacterial activity against penicillin-, macrolide- and quinolone-susceptible Streptococcus pneumoniae HMC 63 after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID425568 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1055334 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID1549380 | Selectivity ratio of MBC to MIC for MLS/methicillin-resistant Staphylococcus aureus PU 32 expressing inducible ermA gene | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID663052 | Antimalarial activity against Plasmodium berghei KBG173 infected in mouse assessed as mouse survival time at 5 mg/kg, iv BID administered on day 3, 4 and 5 post infection | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID638884 | Antibacterial activity against Streptococcus pneumoniae 3579 expressing erm gene by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID554654 | Antimicrobial activity against Ureaplasma parvum SV6 isolate HPA23 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID644453 | Antibacterial activity against methicillin-susceptible, inducible MLS-resistant Staphylococcus epidermidis E1 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID79582 | In vitro minimum inhibitory concentration for antibacterial activity against Haemophilus influenzae ATCC 43095 (ampicillin-susceptible strain that does not produce beta-lactamase) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID202105 | In vitro minimum inhibitory concentration for antibacterial activity against erythromycin-susceptible strain Streptococcus pneumoniae IID553 | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1515025 | Antibacterial activity against Escherichia coli ATCC 25922 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID531457 | Antibacterial activity against Streptococcus pneumoniae serotype 35B assessed as percent resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID1488457 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID499559 | Antibacterial activity against efflux-resistant Streptococcus pyogenes B0545 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID696102 | Antibacterial activity against Streptococcus pyogenes ATCC 700294 by CLSI broth microdilution method | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID558631 | Antimicrobial activity against Streptococcus pneumoniae isolate 4755 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID531102 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa TNP090 mutant harboring las and rhl gene at 0.25 ug/ml by Cat-2,3-diO reporter gene assay relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID573429 | Antimicrobial activity against mexD gene-deficient Pseudomonas aeruginosa PAOMxB assessed as increase in viable cells at 0.5 to 4 ug/ml after 24 hrs relative to wild-type | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1055329 | Antibacterial activity against apramycin-resistant Micrococcus luteus ATCC 10240 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID596057 | Antiplasmodial activity against Plasmodium berghei KBG-173 infected in mouse assessed as mouse without parasitemia at 960 mg/kg, sc bid for 3 days measured on day 31 | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID429072 | Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as multiple-nuclei schizont arrest at IC50 after 96 hrs by transmission electron microscopy | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. |
| AID603985 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID518962 | Induction of erm(C) expression in Escherichia coli JM109 harboring Staphylococcus aureus erm(C)-containing pERMZ7 lacking codons 2 to 4 with additional mutations leader peptide cistrons reporter plasmid at 25 mg/ml after 36 hrs at 37 degC by disc-based be | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of erm(C) expression by noninducing antibiotics. |
| AID533205 | Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as susceptible isolates by PK/PD technique | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID573407 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB selected at 4 ug/ml of compound after 2 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID428881 | Inhibition of rhamnolipid production in Pseudomonas aeruginosa PT1300 harboring vector pEX1.8 up to 50 ug/ml incubated for 24 hrs at 37 degC further 24 hrs at 25 degC | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID67085 | Compound was evaluated for antibacterial activity against Enterococcus faecalis (MB5407) sensitive strain | 1998 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. |
| AID683711 | Antimalarial activity against Plasmodium yoelii infected in CD-1 mouse assessed as efficacy at 40 mg/kg, po after 2 hrs | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Targeting the liver stage of malaria parasites: a yet unmet goal. |
| AID531420 | Antibacterial activity against Streptococcus pneumoniae serotype 19F by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID470193 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID735590 | Antibacterial activity against methicillin-resistant, MLS-resistant (constitutive) Staphylococcus epidermidis E2 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID704310 | Cellular uptake in human MDM assessed as compound retention at 3 to 20 uM incubated for 3 hrs followed by drug washout measured after 3 hrs by LC-MS/MS analysis relative to initial drug accumulation | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties. |
| AID423269 | Antibacterial activity against azithromycin-resistant 0.01 MOI Chlamydia psittaci 6BC BCRBAZ2 harboring A2058C mutation in bacterial 23S rRNA gene infected in mouse L2 cells assessed as growth of infectious particles at 200 ng/ml treated 2 hrs after infec | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID416412 | Increase in sensitivity of hydrogen peroxide to Pseudomonas aeruginosa NH57388A mucoid isolate expressing quorum sensing lasI assessed as increase in zone of inhibition at 12 ug/mL after 48 hrs relative to untreated bacterial control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID132626 | The compound was tested in vivo for antibacterial activity against Haemophilus influenza 351GR1 in mice after oral administration | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID696105 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by CLSI broth microdilution method | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID531452 | Antibacterial activity against Streptococcus pneumoniae serotype 22 assessed as percent susceptible isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID585940 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as decrease of IL-6 production in in CD11b+ cells in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID422458 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as decrease biofilm formation at 0.125 ug/mL after 2 days using flow cell culture relative to control | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID543794 | Antimicrobial activity against Klebsiella pneumoniae VT 1367 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID210193 | Compound was tested for antibacterial activity against Streptococcus pneumoniae 032UC1 using standard broth microdilution assay. | 1998 | Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18 | Synthesis of 6-O-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime. |
| AID423271 | Antibacterial activity against azithromycin-resistant 0.01 MOI Chlamydia psittaci 6BC BCRBAZ1 harboring A2059G mutation in bacterial 23S rRNA gene infected in mouse L2 cells assessed as growth of infectious particles at 200 ng/ml treated 2 hrs after infec | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID735589 | Antibacterial activity against methicillin-resistant, coagulase-negative, MLS-resistant (inducible) Staphylococcus epidermidis E3 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID422484 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as viability at 0.125 ug/mL after 2 days using flow cell culture | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID422670 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID423258 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected female patients after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID555112 | Cmax in healthy human at 500 mg, po administered as single dose | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. |
| AID635181 | Antibacterial activity against erythromycin-sensitive Streptococcus pyogenes 3565 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID635182 | Antibacterial activity against inducible macrolide, licosamide and streptogramin-resistant Staphylococcus aureus 90256/97 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID559577 | Antimicrobial activity against Waddlia chondrophila 2032/99 infected in Acanthamoeba castellanii amoeba cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID428885 | Inhibition of elastase production in Pseudomonas aeruginosa PT1300 harboring vector pEX1.8 after 18 hrs by elastin Congo red assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID596082 | Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 10 uM treated for 48 hrs after 6 hrs infection followed by reinoculated into fresh HFF monolayers measu | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID558244 | Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 1.5 mg/liter after 24 hrs by time-kill study | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. |
| AID595999 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 after 48 hrs by [3H]hypoxanthine incorporation assay | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID508473 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 237 harboring mutation in L4 ribosomal protein after 20 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID444058 | Volume of distribution at steady state in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1515023 | Antibacterial activity against Streptococcus gallinarum ATCC 35038 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID531100 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa TNP090 mutant harboring las and rhl gene at 1 ug/ml by Cat-2,3-diO reporter gene assay relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID565312 | Antibacterial activity against Mycoplasma genitalium R32 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID425401 | Antibacterial activity against Escherichia coli isolate HM615 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID508477 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 237 harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID585757 | Antibacterial activity against Pseudomonas aeruginosa M57-15 infected in C57BL/6 mouse assessed as increase of host survival time at 0.16 g/kg, po measured up to 14 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID283555 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID582681 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 assessed as decrease of CFU after 24 hrs relative to initial inoculum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID567475 | Antimicrobial activity against gBLPACR-2 Haemophilus influenzae by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. |
| AID576334 | Antimicrobial activity against Chlamydia trachomatis serovar D infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID558595 | Antimicrobial activity against Streptococcus pneumoniae 7 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID633417 | Antibacterial activity against efflux-mediated macrolide-resistant Streptococcus pneumoniae Ci137 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID208466 | The compound has been evaluated for the antibacterial activity against Streptococcus pneumoniae Ery Ri 030SJ 5i strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID279897 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM chlorpromazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID425969 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 20 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID278066 | Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from nondeployed military patient | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. |
| AID1419575 | Chromatographic hydrophobicity, logD of the compound at pH 7.4 by by fast-gradient RP-HPLC method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Around the macrolide - Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation. |
| AID279882 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM omeprazole | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID675199 | Antibacterial activity against Streptococcus pneumoniae 210 expressing mefA efflux pump by broth microdilution method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides. |
| AID161930 | In vitro inhibitory activity against Pneumococci EryRc (34) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID372477 | Antimalarial activity as abnormal apicoplast morphology in chloroquine-sensitive ACP1-GFP-labeled Plasmodium falciparum 3D7 trophozoite infected human erythrocytes at 2xIC50 dosed 96 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID585758 | Antibacterial activity against Pseudomonas aeruginosa M57-15 infected in C57BL/6 mouse assessed as effect on bacterial burden at 0.16 g/kg, po measured up to 14 days | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID510851 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae PU-09 expressing mef gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID534855 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar poona s2181 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID608737 | Antibacterial activity against efflux-mediated macrolide-resistant Streptococcus pneumoniae Ci137 by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID283586 | Cell viability of 16HBE14o-S1 cells at 8 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID543804 | Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as eradication of pre-formed biofilm at 1 to 10 times MIC after 24 hrs by serial dilution | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID425553 | Antibacterial activity against penicillin- and quinolone-susceptible Streptococcus pneumoniae HMC 5055 expressing mefA by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID735601 | Antibacterial activity against MLS-resistant (constitutive), penicillin-resistant Streptococcus pneumoniae PU11 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID558615 | Antimicrobial activity against Streptococcus pneumoniae isolate 2874 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1238012 | Antibacterial activity against Erm+ methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as inhibition of bacterial growth after 18 hrs by liquid microdilution method | 2015 | Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16 | Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel. |
| AID501279 | Antibacterial activity against efflux-mediated macrolide resistance Streptococcus pneumoniae Ci137 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID221228 | The compound has been evaluated for the in vivo efficacy that protect 50% of mice from lethal infection of Streptococcus Pneumoniae EryRc 030MV2 strains after oral administration | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID283588 | Cell viability of IB3-1 cells at 16 ug/ml after 24 hrs by trypan blue exclusion test | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID565326 | Antibacterial activity against Mycoplasma genitalium M6090 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID85808 | The compound was tested in vitro for antibacterial activity against Haemophilus influenza 351HT3 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID1459149 | Metabolic stability in mouse liver microsomes assessed as parent compound remaining at 1 uM after 60 mins in presence of NADP by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID585942 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as decrease of IL-10 production in in CD11b+ cells in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1459150 | Metabolic stability in rat liver microsomes assessed as parent compound remaining at 1 uM after 60 mins in presence of NADP by LC-MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID577187 | Decrease in shiga toxin production in Escherichia coli O157:H7 185 encoding stx gene cocultured with Stx-phage susceptible Escherichia coli isolate CMUC-170 at 4 ug/ml by luciferase assay relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID209747 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030MV2 EryRc) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID79581 | In vitro minimum inhibitory concentration for antibacterial activity against Haemophilus influenzae ATCC 33533 (ampicillin-resistant strain that produces beta-lactamase) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1549364 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC49619 assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID540231 | Dose normalised AUC in dog after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
| AID279867 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM prochlorperazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID565322 | Antibacterial activity against Mycoplasma genitalium M6280 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID502237 | Antibacterial activity against efflux-mediated macrolide-resistance Streptococcus pneumoniae Ci137 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and properties of macrolones characterized by two ether bonds in the linker. |
| AID522362 | Antimicrobial activity against azithromycin resistant Neisseria gonorrhoeae isolate 2498 harboring C2599T mutation in peptidyltransferase loop in domain V of 23S rRNA alleles | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. |
| AID577204 | Antimicrobial activity against Escherichia coli O157:H7 PT-40 in stationary phase encoding Stx-2 gene by broth macrodilution assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID372461 | Antimalarial activity as 2nd generation ring-stage chloroquine-sensitive Plasmodium falciparum 3D7 after 48 hrs by flow cytometry | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID372475 | Antimalarial activity as segregation of apicoplast in chloroquine-sensitive ACP1-GFP-labeled Plasmodium falciparum 3D7 schizont infected human erythrocytes at 100 nM dosed 96 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID425829 | Antituberculosis activity against Mycobacterium paratuberculosis B236 isolated from bovine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID501294 | Antibacterial activity against constitutive MLS resistance sStreptococcus pyogenes 166 GR-Micro by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID555120 | Terminal half life in healthy human at 500 mg, po administered as single dose | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. |
| AID576345 | Bactericidal activity against Chlamydia trachomatis serovar G infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1853145 | Antibacterial activity against Enterococcus faecalis ATCC29212 assessed as inhibition of bacterial growth incubated for 20 to 22 hrs by broth microdilution method | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling. |
| AID508445 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3009 harboring mutation in 23S rRNA after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID209301 | Compound was tested for antibacterial activity against Streptococcus pyogenes 02A1UC1 using standard broth microdilution assay. | 1998 | Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18 | Synthesis of 6-O-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime. |
| AID595654 | Inhibition of quorum sensing activity in Pseudomonas aeruginosa ATCC 27853 assessed as N-acylhomoserin lactones production at 5 ug/ml after 24 hrs by measuring beta-galactosidase activity by spectrophotometry relative to control | 2011 | Journal of natural products, Apr-25, Volume: 74, Issue:4 | Bioactive sesqui- and diterpenoids from the Argentine liverwort Porella chilensis. |
| AID1498157 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 harboring ermB and mefA genes after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID425978 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 by NCCLS M7-A7 method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID576335 | Antimicrobial activity against Chlamydia trachomatis serovar E infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID201246 | In vitro minimum inhibitory concentration for antibacterial activity against erythromycin-susceptible strain Staphylococcus aureus 209-JC | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID696110 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 by CLSI broth microdilution method | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID279206 | Antibacterial activity against Streptococcus pneumoniae 3243 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID577682 | Antimicrobial activity against Neisseria gonorrhoeae harboring A2059G mutation in 23S rRNA V domain allele 1, allele 3 and allele 4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID1241214 | Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay in presence of 100-fold excess of 15-mer DNA | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. |
| AID1691404 | Bactericidal activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID543807 | Bactericidal activity against Haemophilus influenzae VT450-2006 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs by serial dilution | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID571452 | Ratio of the MIC for Enterobacter cloacae ATCC 23355 in the absence of NAB7061 to MIC for Enterobacter cloacae ATCC 23355 ATCC 13883 in the presence of 4 ug/ml of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID508436 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3009 harboring mutation in 23S rRNA after 20 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID558604 | Antimicrobial activity against Streptococcus pneumoniae isolate 1055 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID369229 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae assessed as percent resistant isolates by CLSI breakpoint method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain. |
| AID1487250 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs. |
| AID52111 | Antibacterial activity against Chlamydia; More active | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | New directions in antibacterial research. |
| AID531461 | Antibacterial activity against Streptococcus pneumoniae serotype 22 assessed as percent resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID1515021 | Antibacterial activity against Enterococcus faecalis isolate 560 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID522666 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Texas 2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID425827 | Antituberculosis activity against Mycobacterium paratuberculosis B213 isolated from bovine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID559497 | Antibacterial activity against vancomycin- resistant Enterococcus faecalis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID209867 | In vivo antibacterial activity against Streptococcus pneumoniae strain 6396 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID26629 | Dissociation constant (pKa) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID596010 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH assessed as parasite doubling time at 5 to 50 uM treated immediately after infection for 48 hrs followed by reinoculated into fresh HFF monolayers me | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID558591 | Antimicrobial activity against Streptococcus pneumoniae 3 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID565315 | Antibacterial activity against Mycoplasma genitalium TW48-5G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID279262 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3665 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID360379 | Antimalarial activity after 96 hrs against Plasmodium falciparum 3BA6 CDY mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID1539180 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae B1 expressing the ermB incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID531111 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa TNP090 mutant harboring las and rhl gene at 1 ug/ml by Cat-2,3-diO reporter gene assay | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID559516 | Antibacterial activity against Streptococcus anginosus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID534419 | Antibacterial activity against Mycobacterium bovis BCG-Connaught | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID637555 | Antibacterial activity against Haemophilus influenzae 38 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID531105 | Inhibition of MexAB-OprM efflux pump expression in rhl1 deficient Pseudomonas aeruginosa TNP092 at 1 ug/ml after 9 hrs by Cat-2,3-diO reporter gene assay | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID209750 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030SJ6 EryRc) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID360381 | Antimalarial activity after 96 hrs against azithromycin-resistant Plasmodium falciparum 7G8 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID585924 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c+ cell expression level in lung lavage fluid at 0.16 g/kg, po measured after 14 days by flow cytometry (Rvb = 5.42 +/- 5.34 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID422483 | Antimicrobial activity against azithromycin-resistant nontypeable Haemophilus influenzae isolate S57 assessed as inhibition of biofilm formation at 64 ug/mL after 7 hrs using crystal violet | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID575948 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. |
| AID1720818 | Inhibition of quorum sensing in violacein-negative Chromobacterium violaceum CV026 mini-Tn5 mutant assessed as quorum quenching by measuring violacein production at 40 uM in presence of C6-HSL relative to control | 2020 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16 | Chloroquine fumardiamides as novel quorum sensing inhibitors. |
| AID279264 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3676 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID85790 | In vitro inhibitory activity against Haemophilus AmpR (37) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1754228 | Antibacterial activity against penicillin-resistant Staphylococcus aureus ATCC 31007 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 43 | Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. |
| AID1549387 | Antibacterial activity against Streptococcus pyogenes 12-207 expressing mef gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID372464 | Antimalarial activity as 3rd generation ring-stage chloroquine-resistant Plasmodium falciparum W2 after 48 hrs dose then 48 hrs drug-free | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID534859 | Antibacterial activity against quinolone-resistant Salmonella enterica serovar stanley s2265 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID520012 | Antimicrobial activity against Staphylococcus aureus A7817 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID425831 | Antituberculosis activity against Mycobacterium paratuberculosis B238 isolated from bovine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID522653 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K9724 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID585768 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c+ cell expression level in lung digest at 0.16 g/kg, po measured after 3 days by flow cytometry (Rvb = 8.63 +/- 0.53 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1515016 | Antibacterial activity against Staphylococcus aureus isolate 3797 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID425830 | Antituberculosis activity against Mycobacterium paratuberculosis B238 isolated from bovine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. |
| AID508427 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 7127 harboring S20N mutation in L4 ribosomal protein and A105V mutation in L22 ribosomal protein after 29 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID576341 | Antimicrobial activity against Chlamydia trachomatis serovar K infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID666489 | Selectivity ratio of IC50 for human HepG2 cells to IC50 for chloroquine-resistant Plasmodium falciparum W2 | 2012 | Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7 | Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides. |
| AID510554 | Antimicrobial activity against Chlamydophila pneumoniae infected in human Hep2 cells after 72 hrs by fluorescence assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. |
| AID40761 | Compound was evaluated for antibacterial activity against Bacillus subtilis (MB5586) sensitive strain | 1998 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. |
| AID644444 | Antibacterial activity against penicillin-susceptible, constitutive MLS-resistant Streptococcus pneumoniae PU 27 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID1427908 | Antibacterial activity against penicillin-susceptible Escherichia coli ATCC 25922 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID161932 | In vitro inhibitory activity against Pneumococci PenR (65) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID577678 | Antimicrobial activity against Neisseria gonorrhoeae C2611T mutation in 23S rRNA domain V allele 3 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID663049 | Unbound clearance in CD1 mouse at 5 mg/kg, iv | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID209879 | Cell free inhibiting activity against Streptococcus pneumoniae 1813 (methylated ribosomes for transcription/translation assay) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID425964 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 48 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID531454 | Antibacterial activity against Streptococcus pneumoniae serotype 6A/C assessed as percent resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID582691 | Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD infected in human THP1 cells assessed as decrease of CFU after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID635185 | Antibacterial activity against constitutive macrolide, licosamide and streptogramin-resistant Staphylococcus aureus PK2 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID725375 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes A3 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID434120 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae after 16 to 22 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID426380 | Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes 07U086 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID1853151 | Antibacterial activity against Macrolide resistant Streptococcus pyogenes clinical isolate B0545 assessed as inhibition of bacterial growth incubated for 20 to 22 hrs by broth microdilution method | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling. |
| AID512006 | Antibacterial activity against erythromycin-resistant, methicillin-susceptible Staphylococcus aureus A265 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID279247 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 3243 with L22 insertion 93SFRPRA94 mutation after 33 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID279881 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM promazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID554652 | Antimicrobial activity against Ureaplasma parvum SV1 isolate HPA18 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID479820 | Antimicrobial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives. |
| AID426375 | Antimicrobial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. |
| AID508389 | Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae 1077 after overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID512010 | Antibacterial activity against ampicillin-susceptible Haemophilus influenzae ATCC 49247 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID522652 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis 02AS-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID508462 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2094 harboring erm(A) gene after 6 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID425554 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1539182 | Antibacterial activity against erythromycin-resistant Streptococcus pyogenes 2 clinical isolate incubated for 24 hrs by broth dilution method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain. |
| AID423250 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients more than 65 years of age after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID68222 | Compound was evaluated for antibacterial activity against Enterococcus faecium (MB5516) sensitive strain | 1998 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. |
| AID588112 | Antimicrobial activity against Neisseria gonorrhoeae clinical isolates after 24 hrs by Etest | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. |
| AID569032 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing the mef gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID428295 | Antimicrobial activity against Acinetobacter baumannii BM4579 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. |
| AID85949 | Antibacterial activity against Haemophilus influenzae; Active | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | New directions in antibacterial research. |
| AID565329 | Antibacterial activity against Mycoplasma genitalium M6283 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID520225 | Antimicrobial activity against Enterococcus faecium A8767 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID444056 | Fraction escaping gut-wall elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID372480 | Cmax in human at 1000 mg, po once daily for 3 days | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID554651 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA17 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID635190 | Antibacterial activity against efflux-mediated macrolide-resistant Streptococcus pyogenes 3 Finland by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID1169027 | Antibacterial activity against macrolide lincosamide- streptogramin B inducibly-resistant Staphylococcus aureus by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID545935 | Ratio of MIC for Escherichia coli ATCC 25922 to MIC for Escherichia coli ATCC 25922 in presence of 4 ug/ml of NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID425765 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID585926 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b-c+ cell expression level in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry (Rvb = 72.59 +/- 16.30 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID1498153 | Antibacterial activity against erythromycin-susceptible Bacillus subtilis ATCC 9372 after 24 hrs by tube-dilution method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives. |
| AID548471 | Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID574702 | Enhancement of biofilm formation Staphylococcus epidermidis SW071 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID360374 | Antimalarial activity after 96 hrs against Plasmodium falciparum GCO3 SND mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID535563 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar hvittingfoss s2948 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID279878 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM promazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID1427916 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB/mefA genes by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID644451 | Antibacterial activity against methicillin-susceptible, inducible MLS-resistant Staphylococcus aureus PU 64 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID539505 | Antibacterial activity against constitutive macrolide-lincosamide-streptogramin B-resistant Streptococcus pneumoniae B0627 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID529899 | Antimicrobial activity against Leptospira weilii isolate 8 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. |
| AID604042 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mef gene by broth microdilution method | 2011 | European journal of medicinal chemistry, Jul, Volume: 46, Issue:7 | Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives. |
| AID425566 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID501673 | Antimicrobial activity against Streptococcus pneumoniae 134 GR-M by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID585764 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of CD4+ T cell in alveolar space at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID209758 | Minimum inhibitory concentration against macrolide susceptible strain of Streptococcus pyogenes (MB2874) | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: I. 4", 11 and 12-OMe derivatives via direct methylation. |
| AID522646 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Ohio by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID582675 | Antibacterial activity against Listeria monocytogenes EGD at pH 5.5 to 7.4 after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID574691 | Enhancement of biofilm formation Staphylococcus epidermidis SW058 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID596007 | Antimalarial activity against Plasmodium falciparum after 68 hrs | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID425577 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I460 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559518 | Antibacterial activity against Streptococcus constellatus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573410 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA selected at 4 ug/ml of compound after 4 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mutS::lox-deficient Pseudomonas aeruginosa PAOMS | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID571442 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID576346 | Bactericidal activity against Chlamydia trachomatis serovar H infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID416424 | Antimicrobial activity against Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene infected in ftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse assessed as mortality at 500 mg/kg, po administered 24 hrs postinfe | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID283576 | Reduction of TNFalpha protein level in cystic fibrosis 2CFSMEo cells at 8 ug after 24 hrs by ELISA relative to control | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. |
| AID161937 | In vitro inhibitory activity against Pneumococci EryRc (34) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID735595 | Antibacterial activity against methicillin-resistant, MLS-resistant (inducible) Staphylococcus aureus PU 32 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID512008 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID724175 | Antibacterial activity against Enterococcus faecalis ATCC 29213 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID558620 | Antimicrobial activity against Streptococcus pneumoniae isolate 3282 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID425975 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID569037 | Antimicrobial activity against erythromycin-resistant Streptococcus pyogenes R2 by broth microdilution method | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains. |
| AID633426 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID499549 | Antibacterial activity against erythromycin A-resistant Staphylococcus aureus B0329 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID1257220 | Antibacterial activity against Streptococcus pyogenes ATCC 700294 after overnight incubation by broth microdilution method | 2015 | Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23 | 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity. |
| AID208281 | Minimum inhibitory concentration against Streptococcus pneumoniae 6303 (erythromycin susceptible strain) | 2001 | Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24 | Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID531422 | Antibacterial activity against Streptococcus pneumoniae serotype 23A by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID1502711 | Antimycobacterial activity against Mycobacterium avium isolate MAV2 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID596003 | Ratio of compound IC50 to Azithromycin IC50 for Plasmodium falciparum | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID434121 | Antibacterial activity against efflux-mediated macrolide-resistant Streptococcus pneumoniae after 16 to 22 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID585774 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b+c- cell expression level in lung lavage fluid at 0.16 g/kg, po measured after 3 days by flow cytometry (Rvb = 1.20 +/- 0.41 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID644814 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. |
| AID207075 | In vitro inhibitory activity against Staphylococcus aureus (011UC4) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID635191 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1257221 | Antibacterial activity against Escherichia coli ATCC 25922 after overnight incubation by broth microdilution method | 2015 | Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23 | 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity. |
| AID210192 | Compound was tested for antibacterial activity against Streptococcus pneumoniae 030SJ5i EryRi using standard broth microdilution assay. | 1998 | Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18 | Synthesis of 6-O-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime. |
| AID534850 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar newport s2099 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID502240 | Antibacterial activity against inducible resistance to macrolide and constitutive resistance to lincosamide Streptococcus pneumoniae 134 GR M by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and properties of macrolones characterized by two ether bonds in the linker. |
| AID428882 | Inhibition of rhamnolipid production in Pseudomonas aeruginosa PT1308 expressing Clostridium perfringens 23S rRNA methylase ErmBP at 50 ug/ml incubated for 24 hrs at 37 degC further 24 hrs at 25 degC | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID585927 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as CD11b-c+ cell expression level in lung lavage fluid at 0.16 g/kg, po measured after 14 days by flow cytometry (Rvb = 72.38 +/- 13.69 %) | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID584100 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. |
| AID571763 | Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-F628F mutant gene | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID425585 | Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease in mouse J774A1 cells assessed as intracellular killing of bacteria at 0.4 ug/ml after 3 h | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID535344 | Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as resistant isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). |
| AID1549375 | Selectivity ratio of MBC to MIC for azithromycin-susceptible Haemophilus influenzae ATCC 49247 | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID244983 | Minimum inhibitory concentration of compound against Ery-R Streptococcus pneumoniae 303 was determined | 2005 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5 | Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. |
| AID1691427 | Antibacterial activity against azithromycin-susceptible Haemophilus influenzae ATCC 49247 assessed as reduction in microbial growth relative to ciprofloxacin | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID573182 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm assessed as increase in viable cells at 4 ug/ml for 7 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID522642 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Vollum 1B by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID568330 | Antimicrobial activity against multidrug-resistant Escherichia coli by broth dilution assay | 2011 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4 | Design and synthesis of potent Gram-negative specific LpxC inhibitors. |
| AID724183 | Antibacterial activity against inducible-resistant to macrolide, licosamide and streptogramin Streptococcus pneumoniae 134 GR-M by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID1902630 | Antibacterial activity against Methicillin-drug resistant Staphylococcus aureus C0621 incubated for 18 hrs by by disc diffusion method | 2022 | ACS medicinal chemistry letters, Feb-10, Volume: 13, Issue:2 | Antibacterial Activity of Metergoline Analogues: Revisiting the Ergot Alkaloid Scaffold for Antibiotic Discovery. |
| AID416402 | Inhibition of quorum sensing-regulated pyocyanin production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 8 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID571445 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 4 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID501278 | Antibacterial activity against efflux-mediated macrolide resistance Staphylococcus aureus PK1 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. |
| AID85791 | In vitro inhibitory activity against Haemophilus AmpS (43) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID520021 | Antimicrobial activity against Enterococcus faecalis ATCC 29212-P5 harboring G2576U mutation in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID416235 | Drug level in Cftr-tml-Unc-TgN(FABPCFTR) cystic fibrosis mouse serum at 500 mg/kg, po after 2 hrs | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID1502712 | Antimycobacterial activity against Mycobacterium avium isolate MAV3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID531329 | Inhibition of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa at 1.0 ug/ml | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID422667 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID533858 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium alvei after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID155776 | Minimum inhibitory concentration against Pasteurella multocida | 2002 | Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17 | Synthesis and SAR of azalide 3,6-ketal aromatic derivatives as potent Gram-positive and Gram-negative antibacterial agents. |
| AID501297 | Antibacterial activity against efflux-mediated macrolide-resistance Streptococcus pyogenes 2 Finland by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID543801 | Bactericidal activity against Klebsiella pneumoniae VT 1367 assessed as eradication of pre-formed biofilm at 1 to 10 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID554649 | Antimicrobial activity against Ureaplasma urealyticum isolate HPA6 after 48 hrs by modified broth microdilution technique | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. |
| AID1417282 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC 9372 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID1417281 | Antibacterial activity against penicillin-susceptible Pseudomonas aeruginosa ATCC 27853 after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID1427909 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes clinical isolate by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID1459113 | Antibacterial activity against Mef-mediated macrolide efflux resistant Streptococcus pneumoniae by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID121252 | Survival rate of mouse inoculated intraperitoneally with 5.05*10e7 CFU of erythromycin-susceptible strain Streptococcus pneumoniae IID553 after treatment with 0.3 mg of compound | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1055333 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis W4138 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID657725 | Antibacterial activity against Streptococcus pyogenes ATCC 700294 after 20 to 22 hrs by broth microdilution method | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10 | An efficient and convenient microwave-assisted chemical synthesis of (thio)xanthones with additional in vitro and in silico characterization. |
| AID360361 | Antimalarial activity after 96 hrs against Plasmodium falciparum Dd2 C1 mutant CRT/MDR1 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID678712 | Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID1647106 | Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC 9372 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID608744 | Antibacterial activity against macrolide, lincosamide, streptogramin-resistant Streptococcus pyogenes 166 GR-Micro by broth microdilution method | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. |
| AID534856 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar Typhimurium s2137 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID416245 | Antimicrobial activity against Pseudomonas aeruginosa NH57388A mucoid isolate assessed as reduction of viable count in exponential phase at 256 ug/mL after 8 hrs | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID725374 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID360363 | Antimalarial activity after 96 hrs against Plasmodium falciparum Dd2 by [3H]hypoxanthine uptake | 2007 | The Journal of biological chemistry, Jan-26, Volume: 282, Issue:4 | In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. |
| AID425766 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I46 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID573420 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA selected at 4 ug/ml of compound after 3 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID635188 | Antibacterial activity against efflux-mediated macrolide-resistant Staphylococcus aureus PK1 by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID696099 | Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID425400 | Antibacterial activity against Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID520031 | Antimicrobial activity against Enterococcus faecium A8130 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID724506 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID428291 | Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeABC adeIJK double mutant isolated from patient with urinary tract infection by E test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. |
| AID558626 | Antimicrobial activity against Streptococcus pneumoniae isolate 3481 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1515013 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by micro dilution method | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID423268 | Antibacterial activity against azithromycin-resistant 0.01 MOI Chlamydia psittaci 6BC BCRBAZ1 harboring A2059G mutation in bacterial 23S rRNA gene infected in mouse L2 cells treated 2 hrs after infection measured on day 7 by plaque assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID678713 | Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID70128 | The compound was tested in vitro for antibacterial activity against Escherichia coli 250 UCS | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID725380 | Antibacterial activity against penicillin-resistant, constitutive MLS-resistant Streptococcus pneumoniae PU 11 expressing erm and mef genes by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID422460 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as decrease maximal thickness of biofilm at 0.125 ug/mL after 2 days using flow cell culture relative to control | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID512009 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae 3469 by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides. |
| AID499558 | Antibacterial activity against constitutive macrolide-lincosamide-streptogramin B-resistant Streptococcus pyogenes B0544 by agar microdilution method | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides. |
| AID574701 | Enhancement of biofilm formation Staphylococcus epidermidis SW070 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID1488458 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 25923 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID422656 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 50 passages by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID1459115 | Antibacterial activity against Mef-mediated macrolide efflux resistant Streptococcus pyogenes by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID644445 | Antibacterial activity against efflux, erythromycin-resistant Streptococcus dysgalactiae A 1 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID423241 | Antibacterial activity against beta lactamase-negative Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID522655 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis BA1007 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID579590 | Antimalarial activity against chloroquine-,pyrimethamine-resistant Plasmodium falciparum W2 assessed as inhibition of [3H]hypoxanthine incorporation after 96 hrs by microtiter plate scintillation counting | 2011 | Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5 | An automated, polymer-assisted strategy for the preparation of urea and thiourea derivatives of 15-membered azalides as potential antimalarial chemotherapeutics. |
| AID502233 | Antibacterial activity against Haemophilus influenzae ATCC 49247 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | Synthesis and properties of macrolones characterized by two ether bonds in the linker. |
| AID501298 | Antibacterial activity against inducible resistance to macrolide, licosamide and streptogramin Staphylococcus aureus 90256 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID520232 | Antimicrobial activity against Streptococcus pneumoniae 02J1175 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID428290 | Antimicrobial activity against Acinetobacter baumannii BM4454 isolated from patient with urinary tract infection by E test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. |
| AID559582 | Antimicrobial activity against Chlamydophila psittaci infected in Vero cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID1647111 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID534857 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar virchow s2195 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID539503 | Antibacterial activity against erythromycin A-susceptible Streptococcus pyogenes B0542 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID372482 | Half life in human at 1000 mg, po once daily for 3 days | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID372498 | Antimalarial activity as 3rd generation parasitaemia against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 96hrs at 100 nM dosed 0-24 hrs post infection | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. |
| AID1055339 | Antibacterial activity against thiostrepton-resistant Staphylococcus aureus ATCC 6538P assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID1550820 | Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes A3 incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID501672 | Antimicrobial activity against Streptococcus pyogenes 3565 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID206482 | The compound was tested in vitro for antibacterial activity against constitutively erythromycin resistant Staphylococcus aureus 011CB20 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID1427913 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives. |
| AID423273 | Antibacterial activity against azithromycin-tolerant 0.01 MOI Chlamydia trachomatis L2AZM#23 harboring mutation in bacterial ribosomal protein L4 infected in mouse L2 cells treated 2 hrs after infection measured on day 7 by plaque assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID1515035 | Induction of translation arrest in tolC-deficient Escherichia coli harboring pRFPCER-TrpL2A assessed as increase in pRFPCER-TrpL2A reporter activity at 10 mg/ml after overnight incubation by dual fluorescent-reporter gene assay | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides. |
| AID576343 | Bactericidal activity against Chlamydia trachomatis serovar E infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID1180568 | Antimicrobial activity against amoxicillin-resistant Haemophilus influenzae by broth microdilution/CLSI method | 2014 | Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14 | Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). |
| AID1549368 | Antibacterial activity against Streptococcus pneumoniae 07P390 expressing constitutive ermB gene assessed as reduction in microbial growth by CLSI based two-fold broth dilution method | 2019 | European journal of medicinal chemistry, May-01, Volume: 169 | Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. |
| AID322132 | In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID434126 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 after 16 to 22 hrs by broth dilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID582608 | Drug uptake in human THP1 cells at pH 6 to 7 after 30 mins | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID522654 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K4539 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID724503 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID1625273 | Antimalarial activity against Plasmodium falciparum 3D7 after 96 hrs | 2016 | Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12 | Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action. |
| AID416406 | Inhibition of alginate synthesis in Pseudomonas aeruginosa NH57388A mucoid isolate supernatant assessed as uronic acid concentration in inside of dialysis bag after equilibrium dialysis at 12 ug/mL after 24 hrs by carbazole-borate assay | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID508405 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 3665 harboring mef(A) gene after 26 passages and 10 compound-free subculturing by retest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID558597 | Antimicrobial activity against Streptococcus pneumoniae 9 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID571930 | Ratio of MIC for Escherichia coli K-12 3-AG300 harboring AcrB-G616N mutant gene to MIC for Escherichia coli K-12 3-AG300 | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID558599 | Antimicrobial activity against Streptococcus pneumoniae 11 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID425558 | Antibacterial activity against penicillin-, quinolone-resistant and macrolide-susceptible Streptococcus pneumoniae HMC 1058 harboring S79F, K137N mutation in quinolone-resistant determining regions of ParC gene and 460V mutation in QRDR of ParE gene by br | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID416417 | Antimicrobial activity against Pseudomonas aeruginosa NH57388C nonmucoid isolate expressing quorum sensing lasI assessed as reduction of viable count at 12 ug/mL in absence of 2.5% human normal serum | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID565311 | Antibacterial activity against Mycoplasma genitalium M30 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID434124 | Antibacterial activity against inducible macrolide-lincosamide-streptogramin-resistant Streptococcus pyogenes 16 to 22 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID573175 | Bactericidal activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm assessed as reduction in bacterial load at 256 ug/ml for 7 days measured on day 1 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1329018 | Antibacterial activity against Streptococcus pneumoniae PBS1399 infected in mouse assessed as protection against bacterial infection by measuring mouse survival administered intravenously as single dose after 2 hrs of infection measured on day 7 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. |
| AID724505 | Antibacterial activity against penicillin-resistant Staphylococcus aureus clinical isolate by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID279266 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 3243 with L22 insertion 93SFRPRA94 mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID422651 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 26 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID161939 | In vitro inhibitory activity against Pneumococci PenR (65) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID434125 | Antibacterial activity against efflux-mediated macrolide-resistance Streptococcus pyogenes after 16 to 22 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Sep, Volume: 44, Issue:9 | Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. |
| AID521968 | Antibacterial activity against Campylobacter sp. assessed as resistance breakpoint by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID725379 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae PU 09 expressing mef gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. |
| AID696103 | Antibacterial activity against Staphylococcus aureus ATCC 13709 by CLSI broth microdilution method | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID278389 | Antimicrobial activity against Naegleria fowleri Lee (M67) in presence of azithromycin at 1:1 ratio on day 2 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID1488453 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 after 24 h by NCCLS broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16 | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. |
| AID209748 | In Vivo evaluation for its effective dose against Streptococcus pneumoniae (030RO1 EryRi) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID279260 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 1077 with 23S rRNA A2058G mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID428892 | Bactericidal activity against stationary-phase Pseudomonas aeruginosa PT1308 culture expressing Clostridium perfringens 23S rRNA methylase ErmBP at 1 to 16 ug/ml after 22 hrs by plating serial dilution method in presence of 1 mM Mg2+ | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID582692 | Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD infected in human THP1 cells assessed as concentration required to no apparent bacterial growth after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID425402 | Antibacterial activity Escherichia coli isolate HM413 isolated from ileo-colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID278396 | Antimicrobial activity against Naegleria fowleri Lee (M67) in presence of azithromycin at 3:1 ratio on day 3 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID637554 | Antibacterial activity against Streptococcus pyogenes 19615 by NCCLS method | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. |
| AID423257 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected male patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID70421 | Compound was tested for antibacterial activity against Escherichia coli 250 UC5 using standard broth microdilution assay. | 1998 | Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18 | Synthesis of 6-O-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime. |
| AID283556 | Antimicrobial activity against Streptococcus pneumoniae R6 with L4 mutation | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. |
| AID326066 | Antimicrobial activity against Streptococcus pneumoniae NMU112 | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. |
| AID68698 | In vitro inhibitory activity against Escherichia coli (250 UC5) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID206465 | The compound has been evaluated for the antibacterial activity against Staphylococcus aureus EryS 011UC4 strains | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17 | Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides. |
| AID635186 | Antibacterial activity against constitutive macrolide, licosamide and streptogramin-resistant Streptococcus pneumoniae 58 Spain by broth microdilution technique | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity. |
| AID1257222 | Antibacterial activity against Moraxella catarrhalis ATCC 23246 after overnight incubation by broth microdilution method | 2015 | Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23 | 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity. |
| AID767510 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by standard dilution assay | 2013 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18 | Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents. |
| AID1502708 | Antimycobacterial activity against Mycobacterium avium 104 mc'2 4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID543805 | Bactericidal activity against Streptococcus pyogenes VT 59 assessed as eradication of pre-formed biofilm at 1 to 10 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID576336 | Antimicrobial activity against Chlamydia trachomatis serovar F infected in pig LLC-MK2 cells monolayers assessed as reduction in number of microbial inclusions after 48 hrs | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. |
| AID735598 | Antibacterial activity against MLS-resistant (constitutive) Streptococcus pyogenes A2 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID208126 | In vitro inhibitory activity against Streptococcus pneumoniae (EryRc 030SJ1) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID559537 | Antibacterial activity against Morganella morganii assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1459108 | Antibacterial activity against constitutively macrolide/lincosamide/streptogramin B-resistant Streptococcus pneumoniae by agar microdilution method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity. |
| AID585938 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as decrease of IL-10 production in in CD11b+ cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID208143 | In vivo antibacterial activity against Streptococcus pneumoniae strain 5649 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID1691405 | Ratio of MBC to MIC against azithromycin-susceptible Haemophilus influenzae ATCC 49247 | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. |
| AID571927 | Ratio of MIC for Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene to MIC for Escherichia coli K-12 3-AG300 | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. |
| AID66408 | In vitro inhibitory activity against enterococci EryRc (13) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID545933 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 4 ug/ml NAB741 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. |
| AID531460 | Antibacterial activity against Streptococcus pneumoniae serotype 33 assessed as percent resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID573418 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA selected at 4 ug/ml of compound after 2 passages assessed as increase in survival rate at 4 ug/ml after 24hrs relative to mucA::lox, mutS::lox-deficient Pseudomona | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1169032 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID19425 | HPLC capacity factor (k) | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID574697 | Enhancement of biofilm formation Staphylococcus epidermidis SW126 expressing icaA gene at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID1544294 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTS/PMS assay | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Synthesis and biological evaluation of solithromycin analogs against multidrug resistant pathogens. |
| AID559505 | Antibacterial activity against Staphylococcus hominis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID207375 | In vivo antibacterial activity against Staphylococcus aureus strain 10649 | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. |
| AID585761 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as effect on CD11b+ cells infiltration in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID577692 | Antimicrobial activity against Neisseria gonorrhoeae harboring A2059G mutation in 23S rRNA V domain allele 1, allele 2 and allele 4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID278395 | Antimicrobial activity against Naegleria fowleri Lee (M67) in presence of azithromycin at 1:1 ratio on day 3 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. |
| AID558596 | Antimicrobial activity against Streptococcus pneumoniae 8 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID559514 | Antibacterial activity against non-levofloxacin susceptible Streptococcus pneumoniae assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID203446 | In vitro inhibitory activity against Staphylococci EryRc (23);ND=not determined | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID425612 | Cytotoxicity against mouse J774A1 cells assessed as release of adenylate kinase at 100 ug/ml after 3 hrs by total cell protein assay relative to control | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
| AID379527 | Antibacterial activity against Haemophilus influenzae ATCC 49247 | 2006 | Journal of natural products, Nov, Volume: 69, Issue:11 | Acetylated flavanone glycosides from the rhizomes of Cyclosorus acuminatus. |
| AID278854 | Cytotoxicity against primary human osteoblasts at 100 ug/ml assessed as LDH release after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID501300 | Antibacterial activity against inducible resistance to macrolide, licosamide and streptogramin Streptococcus pyogenes 2 Finland by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID577677 | Antimicrobial activity against Neisseria gonorrhoeae harboring A2059G mutation in 23S rRNA domain V allele 2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID582684 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs relative to initial inoculum | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID547542 | Antimicrobial activity against invasive Streptococcus constellatus obtained from non-cystic fibrosis patient assessed as non-susceptible isolates grown on mueller-Hinton blood agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method in presence o | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID767508 | Antibacterial activity against Streptococcus pyogenes 447 by standard dilution assay | 2013 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18 | Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents. |
| AID582686 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as concentration required to no apparent bacterial growth after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. |
| AID579588 | Antimalarial activity against multidrug-resistant Plasmodium falciparum TM91C235 assessed as inhibition of [3H]hypoxanthine incorporation after 96 hrs by microtiter plate scintillation counting | 2011 | Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5 | An automated, polymer-assisted strategy for the preparation of urea and thiourea derivatives of 15-membered azalides as potential antimalarial chemotherapeutics. |
| AID595947 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF at 5 to 50 uM treated 6 hrs after infection measured after 48 hrs | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID724180 | Antibacterial activity against inducible-resistant to macrolide, licosamide and streptogramin Streptococcus pyogenes Finland 11 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1 | Macrolactonolides: a novel class of anti-inflammatory compounds. |
| AID539507 | Antibacterial activity against efflux-resistant Staphylococcus aureus B0331 by agar microdilution method | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. |
| AID644447 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes A 3 by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities. |
| AID574707 | Enhancement of biofilm formation Staphylococcus epidermidis SW120 at subinhibitory concentration by microtiter plate assay | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. |
| AID558608 | Antimicrobial activity against Streptococcus pneumoniae isolate 1394 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID657728 | Antibacterial activity against Escherichia coli ATCC 25922 after 20 to 22 hrs by broth microdilution method | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10 | An efficient and convenient microwave-assisted chemical synthesis of (thio)xanthones with additional in vitro and in silico characterization. |
| AID571441 | Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID86127 | In vitro inhibitory activity against Haemophilus influenzae (351CB12) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID584099 | Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 19606R exhibiting complete loss of lipopolysaccharide production by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. |
| AID521967 | Antibacterial activity against Campylobacter coli assessed as resistant isolates by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID735592 | Antibacterial activity against methicillin-resistant, coagulase-negative, MLS-resistant (constitutive) Staphylococcus aureus PU 19 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID208621 | The compound was tested in vitro for antibacterial activity against 53 strains of Streptococcus pneumoniae PenR; Value is 2.5/40 | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. |
| AID522644 | Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis SK57 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. |
| AID423239 | Antibacterial activity against Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID322134 | Antimalarial activity against Plasmodium falciparum D6 as reduced [3H]hypoxanthine uptake after 72 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. |
| AID573177 | Bactericidal activity against Pseudomonas aeruginosa PAO1 biofilm assessed as reduction in bacterial load at => 4 ug/ml upto 7 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID565310 | Antibacterial activity against Mycoplasma genitalium G37 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID767511 | Antibacterial activity against methicillin-resistant Staphylococcus aureus MRSA-1 by standard dilution assay | 2013 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18 | Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents. |
| AID423252 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 3 to 5 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID543800 | Bactericidal activity against Haemophilus influenzae VT450-2006 assessed as eradication of pre-formed biofilm at 1 to 10 times MIC after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Effect of DNase and antibiotics on biofilm characteristics. |
| AID596004 | Half life in human liver microsomes at 1 uM by LCMS analysis | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID633414 | Antibacterial activity against erythromycin-sensitive Streptococcus pneumoniae SP 030 by broth microdilution method | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23 | Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4″-propenoyl-azithromycin. |
| AID1409607 | IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells). | 2020 | Nature, 07, Volume: 583, Issue:7816 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID423270 | Antibacterial activity against azithromycin-resistant 0.01 MOI Chlamydia psittaci 6BC BCRBAZ5 harboring A2059C mutation in bacterial 23S rRNA gene infected in mouse L2 cells assessed as growth of infectious particles at 200 ng/ml treated 2 hrs after infec | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. |
| AID585944 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as decrease of IL-12p70 production in in CD11b+ cells in lung lavage fluid at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID696104 | Antiinflammatory activity in mouse splenocytes assessed as inhibition of LPS-induced IL-6 production at 50 uM preincubated for 2 hrs prior to LPS challenge by sandwich ELISA | 2012 | Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13 | N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. |
| AID416242 | Antimicrobial activity against Pseudomonas aeruginosa NH57388A mucoid isolate after overnight incubation by E-test | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID548475 | Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. |
| AID663045 | Volume of distribution at steady state in CD1 mouse at 5 mg/kg, iv | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID596000 | Antimalarial activity against chloroquine/pyrimethamine-resistant Plasmodium falciparum W2 after 48 hrs by [3H]hypoxanthine incorporation assay | 2011 | Journal of medicinal chemistry, May-26, Volume: 54, Issue:10 | Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. |
| AID425576 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 harboring S79Y mutation in quinolone-resistant determining regions of ParC gene after 34 passages with gemifloxacin measured afte | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID558612 | Antimicrobial activity against Streptococcus pneumoniae isolate 2617 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1055338 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 09-9 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID571438 | Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of 2 ug/ml NAB7062 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID531419 | Antibacterial activity against Streptococcus pneumoniae serotype 3 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. |
| AID23096 | The negative logarithm of the fraction of neutral molecules | 1997 | Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9 | Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. |
| AID416246 | Inhibition of quorum sensing in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as suppression of GFP expression after 14 hrs by molecular technology | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID658056 | Antibacterial activity against Streptococcus pneumoniae ATCC 149619 after 24 hrs at 37 degC by CLSI protocol based microdilution method | 2012 | Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10 | Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity. |
| AID201267 | In vitro minimum inhibitory concentration for antibacterial activity against Staphylococcus aureus B1 (inducibly MLSb-resistant strain encoded by the erm(C) gene) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID663044 | Clearance at steady state in CD1 mouse at 5 mg/kg, iv | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. |
| AID1766088 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC25923 by broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 49 | Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains. |
| AID573176 | Bactericidal activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm assessed as reduction in bacterial load at 256 ug/ml for 7 days measured on day 1 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID501679 | Antimicrobial activity against efflux-mediated macrolide-resistant Staphylococcus aureus PK1 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID520030 | Antimicrobial activity against Enterococcus faecium A6349 harboring G2576U mutation in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. |
| AID416255 | Inhibition of quorum sensing-regulated pyocyanin production in Pseudomonas aeruginosa NH57388A mucoid isolate harboring GFP-fused avian sarcoma virus lasB gene assessed as enzyme activity per cell at 4 ug/mL after 24 hrs relative to control | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID559528 | Antibacterial activity against Citrobacter koseri assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1238008 | Binding affinity to ribosome nascent peptide exit tunnel in rabbit reticulocyte extract assessed as inhibition of eukaryotic translation in presence of amino acids incubated for 20 mins by luciferase reporter gene assay | 2015 | Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16 | Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel. |
| AID470191 | Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by standard dilution assay | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin. |
| AID201403 | In vitro minimum inhibitory concentration for antibacterial activity against Staphylococcus aureus SR138 (constitutively MLSb-resistant strain encoded by the erm(A) gene) | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives. |
| AID1653058 | Antibacterial activity against Escherichia coli | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Isatin derivatives and their anti-bacterial activities. |
| AID585928 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as increase of mannose receptor expression in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID595646 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition at 5 ug/ml by microplate assay | 2011 | Journal of natural products, Apr-25, Volume: 74, Issue:4 | Bioactive sesqui- and diterpenoids from the Argentine liverwort Porella chilensis. |
| AID540230 | Dose normalised AUC in rat after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
| AID585932 | Immunomodulatory activity in Pseudomonas aeruginosa M57-15 infected C57BL/6 mouse lung assessed as up-regulation of MHC2 expression in CD11+ Gr1- cells in lung digest at 0.16 g/kg, po measured after 7 days by flow cytometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. |
| AID559499 | Antibacterial activity against Listeria monocytogenes assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573169 | Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMA planktonic cells by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID425557 | Antibacterial activity against quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 5048 expressing mefA by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID565313 | Antibacterial activity against Mycoplasma genitalium TW10-5G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID422673 | Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 18 passages with levofloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID510852 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae PU-27 expressing erm gene by broth microdilution method | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues. |
| AID278853 | Cytotoxicity against primary human osteoblasts at 400 ug/ml assessed as LDH release after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID1169029 | Antibacterial activity against erythromycin-susceptible Streptococcus pneumoniae by agar microdilution method | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. |
| AID416419 | Antimicrobial activity against Pseudomonas aeruginosa NH57388A mucoid isolate expressing quorum sensing lasI assessed as reduction of viable count at 12 ug/mL in presence of 2.5% human normal serum | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. |
| AID425573 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 99 harboring S81Y and S79Y mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively after 41 passages | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID208298 | Minimum inhibitory concentration against macrolide susceptible strain of Streptococcus pneumoniae (MB3957) | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: I. 4", 11 and 12-OMe derivatives via direct methylation. |
| AID1550817 | Antimicrobial activity against mef-encoded erythromycin resistant Streptococcus pneumoniae PU09 incubated in CAMHB medium for 20 to 24 hrs by two-fold microbroth dilution method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH. |
| AID1532165 | Apparent permeability in human Caco2 cells | 2018 | Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24 | Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility. |
| AID1646210 | Terminal half life in human | 2020 | Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12 | Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics. |
| AID425575 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene after 22 passages with moxifloxacin measured afte | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559502 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1055332 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis R6512 assessed as growth inhibition after 18 hrs by agar dilution method | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening. |
| AID207077 | In vitro inhibitory activity against Staphylococcus aureus (EryRi 011GO25i) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID508469 | Antibacterial activity against macrolide-resistant Streptococcus pneumoniae 2011 harboring mef(A) gene after 35 passages following overnight incubation by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. |
| AID573172 | Bactericidal activity against Pseudomonas aeruginosa PAO1 biofilm assessed as reduction in bacterial load at 0.5 ug/ml for 7days measured on day 1 | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID501678 | Antimicrobial activity against macrolide-resistant Streptococcus pyogenes Finland 2 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile. |
| AID642862 | Antibacterial activity against constitutive MLS resistant Streptococcus pyogenes by agar microdilution method | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. |
| AID577683 | Antimicrobial activity against Neisseria gonorrhoeae isolate 136 NG-MAST sequence type 1704 harboring A2059G mutation in 23S rRNA V domain allele 4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. |
| AID535564 | Antibacterial activity against quinolone-susceptible Salmonella enterica serovar rissen s3141 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. |
| AID428886 | Inhibition of elastase production in Pseudomonas aeruginosa PT1308 expressing Clostridium perfringens 23S rRNA methylase ErmBP at 2 to 4 ug/ml after 18 hrs by elastin Congo red assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. |
| AID1417288 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB and mefA genes after 24 hrs by broth dilution assay | 2018 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20 | Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives. |
| AID596018 | Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 0.1 uM treated for 48 hrs immediately after infection followed by rein | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8 | Chemistry and biology of macrolide antiparasitic agents. |
| AID279902 | Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM chlorpromazine | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. |
| AID724769 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae A22072 expressing mef gene by broth microdilution method | 2013 | European journal of medicinal chemistry, Jan, Volume: 59 | Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. |
| AID577194 | Decrease in shiga toxin production in Escherichia coli O157:H7 PT-40 encoding Stx-2 gene at 0.5 X MIC by luciferase assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Different classes of antibiotics differentially influence shiga toxin production. |
| AID422466 | Antimicrobial activity against nontypeable Haemophilus influenzae isolate 2019 expressing GFP isolated from patient with COPD assessed as decrease in established biofilm formation at 0.125 ug/mL treated for 4 days measured on day 2 to 4 using flow cell cu | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. |
| AID558618 | Antimicrobial activity against Streptococcus pneumoniae isolate 3263 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID571437 | Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of 1 ug/ml NAB7061 | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. |
| AID559506 | Antibacterial activity against Staphylococcus lugdunensis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285520 | Antibacterial activity against Mycoplasma pneumoniae after 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. |
| AID533860 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium porcinum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID423263 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected outpatients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. |
| AID501301 | Antibacterial activity against constitutive MLS resistance Streptococcus pneumoniae 58 by broth microdilution method | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | 4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. |
| AID588209 | Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset | 2010 | Chemical research in toxicology, Jul-19, Volume: 23, Issue:7 | Developing structure-activity relationships for the prediction of hepatotoxicity. |
| AID66417 | In vitro inhibitory activity against enterococci EryRc (13) | 1998 | Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21 | Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. |
| AID1647108 | Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae AB11 expressing ermB and me/A genes by standard broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation. |
| AID43311 | Antibacterial activity against Brahmella species.; More active | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | New directions in antibacterial research. |
| AID767513 | Antibacterial activity against Streptococcus pneumoniae 943 by standard dilution assay | 2013 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18 | Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents. |
| AID425565 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 99 after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID547525 | Antimicrobial activity against Streptococcus constellatus obtained from patient with cystic fibrosis assessed as non-susceptible isolates grown on brain heart infusion agar at 15 ug/ml after 24 hrs at 37 degC by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. |
| AID1326854 | Antibacterial activity against Klebsiella pneumoniae MB4005 by broth microdilution technique | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | A Gestalt approach to Gram-negative entry. |
| AID735596 | Antibacterial activity against erythromycin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. |
| AID322964 | Antimicrobial activity against macrolide-resistant Mycobacterium avium radiometric broth nanodilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1745854 | NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1745855 | NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1346284 | Human motilin receptor (Motilin receptor) | 2013 | British journal of pharmacology, Apr, Volume: 168, Issue:8 | The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 25 (0.38) | 18.7374 |
| 1990's | 912 (13.85) | 18.2507 |
| 2000's | 1654 (25.12) | 29.6817 |
| 2010's | 2409 (36.58) | 24.3611 |
| 2020's | 1585 (24.07) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (116.86) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,263 (18.14%) | 5.53% |
| Reviews | 757 (10.87%) | 6.00% |
| Case Studies | 832 (11.95%) | 4.05% |
| Observational | 101 (1.45%) | 0.25% |
| Other | 4,011 (57.60%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||